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Abstract
Insulin drives the global anabolic response to nutrient ingestion, regulating both carbohydrate and lipid
metabolism. When insulin resistance occurs in Type 2 Diabetes Mellitus, dysregulation of both of these
processes ensues, resulting in hyperglycemia and lipid abnormalities. One of the most prevalent
morbidities associated with insulin resistance is the abnormal accumulation of triglycerides in the liver,
called hepatic steatosis, though the underlying pathogenesis of this accumulation remains unclear. There
is certainly an inappropriate increase in de novo lipogenesis in the livers of individuals with hepatic
steatosis, but the insulin signaling pathway involved in the control of normal, and therefore abnormal,
lipogenesis remain undefined. Previous studies have demonstrated that Akt2 is critical to insulin’s control
of glucose metabolism, but its role in lipid metabolism has remained controversial. Here we show that
Akt2 is required for hepatic lipid accumulation in obese, insulin-resistant states induced by either leptindeficiency or high fat diet feeding. Leptin-deficient ob/ob mice lacking hepatic Akt2 failed to amass
triglycerides in their livers, associated with and most likely due to a decrease in lipogenic gene expression
and de novo lipogenesis. However, Akt2 is also required for steatotic pathways unrelated to fatty acid
synthesis, as mice fed high fat diet had reduced liver triglycerides in the absence of hepatic Akt2 but did
not exhibit changes in lipogenesis. In addition, we show that Akt2 is a requisite component of the normal
insulin signaling pathway that controls de novo lipogenesis in lean non-steatotic livers. Following highcarbohydrate feeding, influx of glucose and secretion of insulin induce hepatic de novo lipogenesis in
normal animals. However, liver-specific Akt2 null mice failed to induce de novo lipogenesis in response to
high-carbohydrate feeding. These data demonstrate that Akt2 is required for the insulin-dependent
regulation of hepatic lipid metabolism both in normal livers and during insulin resistance. These studies
contribute to our understanding of insulin’s control of metabolism, and may potentially aid in the
development of therapeutics for diseases that are increasing in prevalence around the world.
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ABSTRACT

THE ROLE OF AKT2 IN HEPATIC LIPID METABOLISM
Karla Fitzgerald Leavens
Morris J. Birnbaum

Insulin drives the global anabolic response to nutrient ingestion, regulating
both carbohydrate and lipid metabolism. When insulin resistance occurs in Type
2 Diabetes Mellitus, dysregulation of both of these processes ensues, resulting in
hyperglycemia and lipid abnormalities. One of the most prevalent morbidities
associated with insulin resistance is the abnormal accumulation of triglycerides in
the liver, called hepatic steatosis, though the underlying pathogenesis of this
accumulation remains unclear. There is certainly an inappropriate increase in de
novo lipogenesis in the livers of individuals with hepatic steatosis, but the insulin
signaling pathway involved in the control of normal, and therefore abnormal,
lipogenesis remain undefined. Previous studies have demonstrated that Akt2 is
critical to insulin’s control of glucose metabolism, but its role in lipid metabolism
has remained controversial. Here we show that Akt2 is required for hepatic lipid
accumulation in obese, insulin-resistant states induced by either leptin-deficiency
or high fat diet feeding. Leptin-deficient ob/ob mice lacking hepatic Akt2 failed to
amass triglycerides in their livers, associated with and most likely due to a
decrease in lipogenic gene expression and de novo lipogenesis. However, Akt2
is also required for steatotic pathways unrelated to fatty acid synthesis, as mice
iv

fed high fat diet had reduced liver triglycerides in the absence of hepatic Akt2 but
did not exhibit changes in lipogenesis. In addition, we show that Akt2 is a
requisite component of the normal insulin signaling pathway that controls de
novo lipogenesis in lean non-steatotic livers. Following high-carbohydrate
feeding, influx of glucose and secretion of insulin induce hepatic de novo
lipogenesis in normal animals. However, liver-specific Akt2 null mice failed to
induce de novo lipogenesis in response to high-carbohydrate feeding. These
data demonstrate that Akt2 is required for the insulin-dependent regulation of
hepatic lipid metabolism both in normal livers and during insulin resistance.
These studies contribute to our understanding of insulin’s control of metabolism,
and may potentially aid in the development of therapeutics for diseases that are
increasing in prevalence around the world.
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Chapter 1:

General Introduction

1

Preface
Though nutrition is essential to our survival, it has become the leading cause of
death in the developed world. Cardiovascular disease and other diseases of overnutrition dominate the health care systems of high- and middle-income countries,
accounting for over 20 percent of mortality (WHO, 2008). Meanwhile, the incidence of
these diseases is increasing in low-income countries, even while diseases associated
with malnutrition are still prevalent. Physiologic processes evolved to maximize energy
storage in a world where sustenance was scarce are now resulting in obesity and Type 2
Diabetes Mellitus (T2DM) in the face of surplus.
Among its numerous functions, the mammalian liver serves both as a repository
for stored nutrients and an organ that senses, integrates and controls the metabolic state
of the organism. As a metabolic tissue, the liver responds to multiple inputs, including
hormones, neuronal impulses and nutrients. Understanding how the liver processes
these diverse inputs becomes even more challenging when one considers pathological
states associated with over-nutrition. Hepatic insulin signaling serves to coordinate
energy allocation and storage upon food ingestion. During times of nutritional
abundance, insulin signals to the liver to halt catabolism and to stimulate anabolism,
resulting in the conversion of substrate into triglyceride for local storage as well as
export. However, when this point of regulation goes awry due to the insulin resistance of
T2DM, and it becomes difficult to distinguish protective from maladaptive processes.
Hepatic insulin resistance can simultaneously result in the dysregulation of both
catabolism, leading to the excessive output of glucose, and anabolism, driving the
accumulation of lipid in the liver. Thus an understanding of hepatic insulin signaling and
its regulation of metabolism are required for the development of therapies to combat the
most common pathologies facing the world.
2

The regulation of whole-body metabolism by insulin
Introduction to insulin’s control of anabolism
Insulin signaling is necessary for the regulation of growth and metabolism, and
the signaling components of this pathway are conserved across species. In mammals,
the metabolic role of insulin has been defined predominantly in terms of glucose and
lipid homeostasis. Nutrient influx after a meal stimulates secretion of insulin from the βcells of the pancreas, promoting nutrient uptake in peripheral metabolic tissues and
suppressing energy production by the liver (Saltiel, 2001). This process is tightly
regulated so that nutrient intake and storage are perfectly balanced. Insulin promotes
the uptake of dietary glucose into muscle and adipose by stimulating the translocation of
the glucose transporter, Glut4, to the cell surface (Nelson and Cox, 2008). The uptake
of dietary lipids by peripheral tissues is also regulated by insulin, which stimulates the
production of lipoprotein lipase (LPL) by endothelial cells proximal to peripheral tissues.
LPL hydrolyzes triglycerides into fatty acids, which are permeable to the cell membrane
and can be taken up into adipocytes to be re-esterified and stored or into muscle cells to
be oxidized for energy (Ginsberg et al., 2005). Simultaneously, in order to prevent
release of those stored fatty acids back into the circulation, insulin blocks lipolysis in
adipocytes by inhibiting hormone-sensitive lipase (HSL).
However, while insulin stimulates the storage of nutrients by its effects in the
periphery, a major site of insulin’s action on metabolism is the liver. Insulin blocks
hepatic glucose production, which is high during fasting, by inhibiting gluconeogenes
and glycogenolysis (Saltiel, 2001). Additionally, insulin switches the liver from oxidation
of fatty acids to synthesis of fatty acids from excess dietary nutrients. Insulin controls
these processes in the liver by a variety of signaling pathways, involving a complex
network of intracellular mediators that control cytoplasmic and transcriptional targets,
3

which will be described in greater detail in a later section. Overall, hepatic insulin
signaling is essential to the maintenance of energy homeostasis through its regulation of
glucose and lipid metabolism.

Impairments in insulin’s control of metabolism occurs in Type 2 Diabetes Mellitus
(T2DM)
T2DM results from a combination of impaired insulin secretion and action: insulin
resistance results in reduced insulin action, leading to the need for increased insulin
secretion from the pancreas, further contributing to resistance. The onset of T2DM
theoretically occurs when insulin secretion can no longer compensate for increasing
insulin resistance (Ahren, 2005). When this occurs, carbohydrate and lipid metabolism
are no longer properly regulated, resulting in hyperglycemia and dyslipidemia. While the
underlying cause of insulin resistance has not been defined, it is evident that there is an
inherit defect in insulin signaling. The curve for glucose disposal in response to
increasing doses of insulin is not only shifted to the right in diabetic patients, indicating a
reduced responsiveness to insulin, but the maximum rate of disposal is decreased,
indicating that resistance cannot be overcome by merely increasing insulin levels
(Kolterman et al., 1981). Therefore, as exogenous insulin is not a cure, a better
understanding of the causes of insulin resistance is required for the development of
therapeutics for T2DM.
Insulin was originally discovered in the 1920s as the active compound secreted
by the pancreas that could reverse the effects of Type 1 Diabetes Mellitus, resulting from
auto-immune destruction of pancreatic β-cells (Nelson and Cox, 2008). Prior to the
discovery of insulin, Type 1 diabetic patients were profoundly hyperglycemic and unable
to store any glucose in the absence of insulin, resulting in glycosuria and ketosis from
4

high levels of fatty acid oxidation, all of which were reversed with insulin treatment. As
the most noticeable and profound effect of insulin treatment was control of
hyperglycemia in Type 1 diabetics, the study of insulin’s role in the regulation of glucose
metabolism has dominated. As such, most of the treatment in Type 2 diabetic patients
has focused on control of glucose homeostasis. However, in a seminal essay, McGarry
argued persuasively that the view T2DM as a disease of glucose metabolism is purely
historical, and that the lipid abnormalities are equally intrinsic to the pathophysiology
(McGarry, 1992). Though glucose levels remain a major focus in the control of type 2
diabetics, cardiovascular disease remains the leading cause of death in these patients,
and determining the causes of these lipid abnormalities is the key to understanding
much of the pathology associated with this disease.

Insulin’s control of hepatic glucose metabolism
Insulin promotes glycogen synthesis and inhibits gluconeogenesis in the liver
During the transition from fasting to the fed state, insulin stimulates glycogen
synthesis while simultaneously inhibiting hepatic gluconeogenesis and glycogen
breakdown, resulting in suppression of hepatic glucose production (reviewed in Saltiel,
2001). Net glycogenesis occurs via posttranslational activation of synthesis and
inhibition of breakdown, whereas termination of gluconeogenesis depends on the
transcriptional suppression of gluconeogenic genes. Glycogen is synthesized by
glycogen synthase, which is inhibited by phosphorylation by glycogen synthase kinase-3
(GSK3) and other kinases, such as protein kinase A (PKA); alternatively, glycogen is
degraded by glycogen phophorylase, which is stimulated by phosphorylation by
phosphorylase kinase (Nelson and Cox, 2008). Insulin signaling results in the
phophorylation and inhibition of GSK3 and activation of protein phosphatase 1 (PP1),
5

promoting the dephosphorylation and subsequent activation of glycogen synthase.
Concurrently, PP1 dephosphorylates glycogen phosphorylase, resulting in reduced
activity (Nelson and Cox, 2008). However, most of the regulation of glycogen cycling
has been described in muscle, and it is unclear whether regulation in the liver proceeds
in exactly the same manner. Regardless, combined influx of glucose and insulin to the
liver results in increased glycogen synthase flux and decreased glycogen phosphorylase
flux, leading to the net storage of glycogen (Petersen et al., 1998).
During fasting, gluconeogenesis is amped up by the expression of critical genes
such as those encoding the enzymes phosphoenolpyruvate carboxykinase (PEPCK) and
glucose 6-phosphatase (G6Pase). PEPCK catalyzes an irreversible reaction at the start
of gluconeogenesis and G6Pase catalyzes the dephosphorylation of newly-made
glucose so that it can be released into the bloodstream (Nelson and Cox, 2008). Upon
feeding when glucose and insulin levels rise, the expression of these two genes is
rapidly turned off in response to the activation of insulin signaling and diminishing levels
of intracellular cyclic AMP from decreasing glucagon signaling (Granner and Pilkis,
1990). The insulin signaling cascade controlling this suppression proceeds
predominately through inhibition of forkhead box O1 (FoxO1) and peroxisome
proliferator-activated receptor-γ coactivator-1α (PGC-1α), two proteins required in the
induction of PEPCK and G6Pase expression (reviewed in Gross et al., 2008).
However, while insulin regulates the expression of genes associated with
gluconeogenesis, recent studies have questioned how this directly relates to metabolic
fluxes. While PEPCK mRNA levels are decreased to 50% by insulin during
hyperinsulinemic euglycemic clamp, mice with just 10% residual expression of PEPCK
are viable and only exhibit a 40% reduction in gluconeogenesis (Burgess et al., 2007;
Sun et al., 2002). Additionally, Burgess and colleagues reported that flux through the
6

TCA cycle better correlates with gluconeogenic flux than does hepatic PEPCK protein
content, arguing that insulin’s suppression of hepatic glucose production extends beyond
its conventional suppression of gluconeogenic gene expression (Burgess et al., 2007).
Emerging evidence suggests that insulin may instead act by rapidly turning off hepatic
glucose production from glycogenolysis by switching from glycogen breakdown to
synthesis (Ramnanan et al., 2010).

Hyperglycemia
Though insulin’s control of hepatic glucose metabolism is likely more complex
than its influence on gluconeogenic gene expression, the outcome in T2DM is obvious:
an insulin-resistant liver fails to suppress hepatic glucose output (reviewed in Saltiel,
2001). The persistence of hepatic glucose output following a meal compounds
diminished glucose uptake into muscle and adipose tissue, resulting in postprandial
hyperglycemia. Gluconeogenesis is inappropriately increased in states of insulin
resistance due to lack of insulin signaling: disruption of hepatic insulin signaling at the
level of the insulin receptor results in increased PEPCK and G6Pase expression and an
inability of insulin to suppress hepatic glucose output (Michael et al., 2000).

Insulin’s control of hepatic lipid metabolism
Insulin promotes de novo lipogenesis while inhibiting fatty acid oxidation and very low
density lipoprotein (VLDL) export
Following food intake, insulin stimulates the liver to switch from fatty acid
oxidation to fatty acid synthesis. When carbohydrate flux into the liver is high after a
meal, insulin promotes the synthesis of fatty acids from excess substrates, called de
novo lipogenesis. These fatty acids, along with dietary fatty acids, are esterified into
7

triglycerides and eventually exported in very low density lipoproteins (VLDL) for storage
and utilization by peripheral tissues. Insulin regulates de novo lipogenesis through the
upregulation of the genes encoding lipogenic enzymes, as described below in more
detail. As fatty acid synthesis proceeds, accumulation of malonyl-CoA, a precursor of
fatty acids synthesis, directly inhibits carnitine palmitoyltransferase-1 (CPT1), a
transporter that shuttles fatty acids into the mitochondria, the rate-limiting step of fatty
acid oxidation (Nelson and Cox, 2008). Simultaneously, insulin turns off β-oxidation of
fatty acids though its inhibition of PGC-1α, a master regulator of fatty acid oxidation
(reviewed in Lin et al., 2005).
While insulin stimulates lipogenesis and thus increases lipid substrates for VLDL
particles, it also appears to acutely decrease VLDL secretion (reviewed in Sparks and
Sparks, 1994). Insulin inhibits the release of VLDL in perfused rat liver and in vivo in
rats injected with glucose to stimulate insulin production (Chirieac et al., 2000; Sparks et
al., 1989). VLDL assembly requires the presence of both of its substrates, hepatic lipids
and apolipoprotein B (apoB), and insulin likely functions by inhibiting the latter. Most
regulation of apoB is thought to occur post-translationally, as increased fatty acid
delivery to the liver by infusion in mice causes an increase in apoB secretion but not an
increase in apoB mRNA levels (Zhang et al., 2004b). Insulin may work to suppress
VLDL secretion directly by increasing degradation of apoB: in primary rat hepatocytes,
the inhibition of apoB secretion by insulin correlates with an increase in intracellular
degradation of apoB (Sparks and Sparks, 1994). Correspondingly, mice lacking the
hepatic expression of the insulin receptor have increased apoB levels in their serum
(Biddinger et al., 2008). Though the precise mechanism is unclear, insulin’s effect on
apoB degradation may be mediated through phosphoinositide 3-kinase (PI3K) signaling
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as inhibition of PI3K by wortmannin results in increased VLDL production and secretion
in vivo (Chirieac et al., 2006).

Dyslipidemia
Type 2 diabetic patients have characteristic lipid abnormalities, called diabetic
dyslipidemia; this is a triad of increased levels of triglycerides in VLDL, high or normal
levels of low density lipoprotein (LDL) cholesterol, and low levels of high density
lipoprotein (HDL) cholesterol is known to be highly atherogenic (Taskinen, 2003). The
presence of insulin resistance and diabetic dyslipidemia is one of the major risk factors
in the development of atherosclerosis and other cardiovascular disease (Isomaa et al.,
2001; Reilly and Rader, 2003). While high serum cholesterol levels have been
recognized as a major risk factor for cardiovascular disease and LDL has been the major
target of lipid-lowering therapy, hypertriglyceridemia is emerging as another major risk
factor. Though these particles are not thought to be directly atherogenic, increased
VLDL levels can lead to the generation of small, dense LDL through the action of
cholesteryl ester transfer protein (CEPT) (Ginsberg et al., 2005). These small, dense
cholesterol ester-depleted LDL particles are highly atherogenic, and low levels of HDL
cholesterol can also result from this CEPT-mediated process. Thus, elevated serum
triglycerides are considered to be an independent risk factor for heart disease, though
the pathogenesis remains unclear.
Hypertriglyceridemia is thought to be caused in the insulin-resistant state by
VLDL overproduction in the liver (Taskinen, 2003). There are three major sources of
triglyceride for hepatic VLDL, all of which have been shown to be upregulated in insulinresistant states: fatty acid flux from adipose to the liver, hepatic uptake of VLDL
remnants, and de novo lipogenesis (reviewed in Ginsberg et al., 2005). Studies using a
9

fructose-fed hamster model of insulin resistance and dyslipidemia showed that VLDL
overproduction may result from decreased apoB degradation normally induced by insulin
(Taghibiglou et al., 2000). When hepatic insulin signaling is improved pharmacologically
in this model, apoB degradation increases, and VLDL secretion decreases (Carpentier et
al., 2002). However, which process actually drives hypertriglyceridemia present in
T2DM remains unclear: leptin-deficient obese ob/ob mice have massively increased
rates of de novo lipogenesis but do not exhibit increased VLDL triglyceride or apoB
levels (Li et al., 1997; Wiegman et al., 2003). Regardless, insulin still fails to effectively
inhibit VLDL secretion in ob/ob livers under hyperinsulinemic euglycemic clamp
conditions, and this may be the point of dysregulation that leads to hypertriglyceridemia
in this model (Wiegman et al., 2003). Alternatively, triglyceride secretion from perfused
liver from Zucker Diabetic Fatty (ZDF) rats is 5 times greater than that from lean rats,
and their secreted VLDL particles had increased apoB content (Azain et al., 1985).
Therefore the precise pathogenesis underlying VLDL oversecretion in T2DM remains
unclear.

Hepatic steatosis
Another lipid abnormality associated with insulin resistance is the accumulation
of lipid, mostly triglycerides, in the liver, called hepatic steatosis. Hepatic steatosis is
thought to be relatively benign, but can progress to inflammatory steatohepatitis, fibrosis,
and cirrhosis. This entire spectrum is termed non-alcoholic fatty liver disease (NAFLD),
and is likely present in 14% to 24% of the general population (reviewed in Browning and
Horton, 2004). However, when obese individuals are considered, the prevalence rises
to between 57% and 74% (Angulo, 2002). Thus, as the prevalence of obesity and T2DM
increase, so will the number of people with hepatic steatosis and other NAFLDs. While it
10

is unclear what mediates the progression of hepatic steatosis to more serious disease,
increasing prevalence of NAFLD will result in increasing numbers of patients with endstage liver disease: NAFLD is already becoming a dominant indication for liver transplant
(Browning and Horton, 2004).
The underlying pathogenesis of hepatic steatosis remains undefined, though it is
clearly associated with states of hepatic insulin resistance. There are increased sources
of fatty acids for esterification into triglycerides in insulin-resistant livers (reviewed in
Ginsberg et al., 2005). Insulin is less able to block lipolysis in adipose tissue through its
inhibition of HSL, resulting in increased hydrolysis of triglycerides and increased nonesterified fatty acid (NEFA) levels for the liver to take up from the serum (Adeli et al.,
2001). Insulin promotes de novo lipogenesis in a normal liver; thus, in the presence of
insulin resistance, hepatic lipid synthesis should be impaired. Unexpectedly, insulin’s
promotion of lipogenesis is maintained and even enhanced by hyperinsulinemia
occurring in T2DM. Furthermore, hyperglycemia may enhance pathological lipid
accumulation in T2DM as the excess glucose provides increased substrate for de novo
lipogenesis. Additionally, fatty acid oxidation is decreased in insulin-resistant livers,
though whether this is due to inhibition by de novo lipogenesis or secondary to
mitochondrial overload and oxidative stress is unclear (Angulo, 2002; Browning and
Horton, 2004; Parekh and Anania, 2007). Regardless, ketogenesis is decreased by
40% in ZDF rats and malonyl-CoA, an precursor of lipogenesis and inhibitor of fatty
acids oxidation, is increased (Azain et al., 1985).

Selective insulin resistance: insulin signaling is simultaneously defective to
glucose metabolism and enhanced to lipid metabolism

11

Hepatic insulin resistance has been classically defined as an inability of insulin to
suppress hepatic glucose output, as measured by hyperinsulinemic euglycemic clamp.
Since insulin signaling normally induces de novo lipogenesis in the liver, this pathway
should be impaired as well in states of insulin resistance. However, the existence of
hepatic steatosis refutes this assumption and, unlike insulin signaling to glucose
homeostasis, insulin’s promotion of lipogenesis is preserved, driving synthesis and
contributing to the accumulation of triglyceride in the liver. This phenomenon has been
termed selective insulin resistance where the insulin signaling pathways inhibiting
glucose metabolism are impaired while those stimulating lipid metabolism are preserved
(Brown and Goldstein, 2008).
It is this phenomenon that drives the devastating co-existence of hyperglycemia
and hypertriglyceridemia in T2DM. As pointed out by Brown and Goldstein, mice lacking
the insulin receptor in the liver, so-called “pure hepatic insulin-resistant” mice, ironically
exhibit a less severe condition consisting of hyperglycemia but hypotriglyceridemia
(Brown and Goldstein, 2008). Therefore, there must be a bifurcation of insulin signaling
below the level of the insulin receptor into two distinct pathways: one that suppresses
glucose metabolism and is lost in insulin-resistant states and one that stimulates lipid
synthesis and is retained in insulin-resistant states. It is apparent that glucose
metabolism is controlled distally by FoxO1 and lipid metabolism by sterol regulatory
element-binding protein-1c (SREBP1c), but the point at which signaling diverges is
unknown.

De novo lipogenesis: a site of dysregulation in insulin resistance
Mechanism and control of fatty acid synthesis
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Acetyl-CoA is formed in the mitochondria from pyruvate by pyruvate
dehydrogenase and can enter the citric acid cycle for eventual oxidation and generation
of energy (Nelson and Cox, 2008). However, following a meal, more acetyl-CoA is
produced in the liver than needs to be oxidized for energy production: this excess acetylCoA is converted into fatty acids by de novo lipogenesis. The primary source of
substrate for fatty acid synthesis in the liver is glucose, but fructose, galactose, lactate,
pyruvate and amino acids also contribute to the pool of acetyl-CoA (Hillgartner et al.,
1995).

In the cytosol, acetyl-CoA carboxylase (ACC) converts acetyl-CoA into malonyl-

CoA, the major source of carbon for fatty acid synthesis. This step is also the major site
of regulation of de novo lipogenesis. Acetyl-CoA must be exported from the
mitochondria as citrate and converted back into acetyl-CoA by ATP citrate lyase (ACL),
an enzyme activated by insulin (Nelson and Cox, 2008). Citrate allosterically activates
ACC while simultaneously inhibiting flux through glycolysis; conversely, ACC is
allosterically inhibited by the end product of fatty acid synthesis, palmitoyl-CoA. ACC is
also inhibited by phosphorylation induced by glucagon signaling and other pathways that
inhibit fatty acid synthesis, such as AMP-activated protein kinase (AMPK) (Hillgartner et
al., 1995).
The 2-carbon units provided by malonyl-CoA are joined and reduced sequentially
by fatty acid synthase (FAS), eventually forming the saturated 16-carbon fatty acid
palmitate. Palmitate is the major product of de novo lipogenesis, but also serves as a
substrate for elongases and desaturases, such as stearoyl-CoA desaturase-1 (SCD1),
for the generation of longer chain and unsaturated fatty acids. In the liver, most fatty
acids are joined to a glycerol backbone by acyltransferases to generate triglycerides for
storage. Accumulating malonyl-CoA shuts off β-oxidation by inhibiting CPT1 so that
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futile cycling of fatty acid synthesis and breakdown does not occur (Nelson and Cox,
2008).
The transcription of multiple lipogenic enzymes, including FAS, SCD1, ACC,
ACL, glycerol phosphate acyltransferase (GPAT), glucokinase (GCK), and liver pyruvate
kinase (L-PK), are upregulated in response to feeding. These simultaneous increases in
expression are designed to increase the concentration of lipogenic enzymes thus
allowing increased flux through lipogenesis in the presence of excess carbohydrates
(reviewed in Postic and Girard, 2008). Inhibition or deletion of many of these target
genes themselves, including SCD1, ACC, and GPAT can also prevent animals from
developing hepatic steatosis due to leptin-deficiency or diet-induced obesity (DIO) by
either decreasing lipogenesis or increasing flux of fatty acids into β-oxidation (Cohen et
al., 2002; Gutierrez-Juarez et al., 2006; Harada et al., 2007; Jiang et al., 2005; Mao et
al., 2006; Miyazaki et al., 2007; Neschen et al., 2005; Ntambi et al., 2002; Savage et al.,
2006). The influences of both insulin and glucose on lipogenic gene expression are
controlled by two distinct transcription factors: insulin via SREBP1c and glucose via
carbohydrate response element-binding protein (ChREBP) (Dentin et al., 2004; Koo et
al., 2001). These two factors coordinately stimulate lipogenic gene expression in
response to both the nutrient influx and increased insulin secretion that occur during
feeding.

De novo lipogenesis is inappropriately elevated in livers of patients with hepatic steatosis
Rates of hepatic de novo lipogenesis are fairly low in normal lean individuals, as
measured by contribution to the fatty acids in hepatically-derived VLDL. Under postabsorptive conditions in humans, only approximately 4% of triglycerides secreted into
the serum come from de novo lipogenesis, while 50% can be attributed to NEFA re14

esterification (Diraison and Beylot, 1998). De novo synthesis of fatty acids increases
following food intake, rising from approximately 5% of fatty acids in VLDL to
approximately 23% post-prandially at the peak, occurring just over 4 hours after meals
(Timlin and Parks, 2005). Diets rich in carbohydrates can further stimulate de novo
lipogenesis in normal individuals, and have been reported to result in a 10-fold increase
(Schwarz et al., 1995). However, even under these conditions, de novo lipogenesis only
accounts for the synthesis of 5 grams of fatty acids per day (Schwarz et al., 1995).
Though de novo lipogenesis may be low in lean individuals, it still contributes
significantly to hepatic steatosis in the presence of obesity and insulin resistance.
Individuals with existing hepatic steatosis should have very low rates of de novo
lipogenesis as there are already ample stores of triglycerides in their livers. However,
lipogenesis is inappropriately elevated in the livers of patients with hepatic steatosis,
accounting for approximately 25-30% of the total hepatic triglyceride content and a
three-fold increased contribution to VLDL triglyceride secretion (Diraison et al., 2002;
Diraison et al., 2003; Donnelly et al., 2005; Forcheron et al., 2002). Normal individuals
exhibit a cycling of their rates of hepatic de novo lipogenesis, corresponding to food
intake and elevations in serum insulin levels (Timlin and Parks, 2005). However,
Donnelly et al. reported that in individuals with NAFLD, de novo lipogenesis is elevated
even during fasting and exhibits no diurnal variation (Donnelly et al., 2005).
Triglycerides secreted from the perfused livers of ZDF rats contain 5-fold higher levels of
de novo synthesized fatty acids compared with lean rats (Azain et al., 1985). Even
following the consumption of a low-carbohydrate high-fat diet, which is known to
decrease lipogenesis in lean individuals, hyperinsulinemic obese individuals have 3- to
5-fold higher rates of lipogenesis than lean or obese but normoinsulinemic individuals
(Hillgartner et al., 1995; Schwarz et al., 2003). Similar results have been reported in
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ZDF rats, which exhibit high rates of de novo lipongenesis that are not suppressed by
high-fat feeding as observed in lean rats (Lee et al., 2000).

The control of lipogenic gene expression by two transcription factors: SREBP1c
and ChREBP
Much research has been directed towards determining the transcriptional control
of de novo lipogenesis by insulin and glucose via SREBP1c and ChREBP, respectively
(Koo et al., 2001; Postic et al., 2007; Postic and Girard, 2008). Though each
transcription factor is required for the maximal accumulation of hepatic triglyceride during
insulin resistance in mice, the relative roles of these two transcription factors in the
development of hepatic steatosis and under more physiological conditions remains
unclear (Dentin et al., 2006; Postic and Girard, 2008; Yahagi et al., 2002).

Sterol regulatory element-binding protein-1c (SREBP1c)
The SREBP family members are synthesized as precursor molecules in the
endoplasmic reticulum and proteolytically cleaved to release active amino-terminal
transcript factors that translocate to the nucleus (reviewed in Horton, 2002). There are
two SREBP1 isoforms generated by alternative splicing: SREBP1a is more active than
SREBP1c in cultured cells and activates genes for both triglyceride and cholesterol
synthesis, while SREBP1c only activates triglyceride synthetic genes (Shimano et al.,
1996; Shimano et al., 1997a). Transgenic mice overexpressing the active nuclear
transcription factor fragment of SREBP1a (nSREBP1a) have fattier livers, increased
hepatic cholesterol and triglyceride levels, and increased lipogenic gene expression
compared with mice overexpressing nSREBP1c (Shimano et al., 1996; Shimano et al.,
1997a; Shimomura et al., 1997). However, though SREBP1a is more active and the
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more highly expressed variant in cultured cell lines, SREBP1c is expressed at 9-fold
higher levels in the liver (Shimomura et al., 1997). Alternatively, the other SREBP
isoform, SREBP2 preferentially activates genes of cholesterol synthesis, as transgenic
nSREBP2 mice have hepatic steatosis due to massive cholesterol accumulation without
a significant increase in hepatic triglyceride content (Horton et al., 1998b).
Insulin increases SREBP1c mRNA levels, resulting in a parallel increase of
lipogenic target genes, and, conversely, SREBP1c expression is low in rats with insulindeficiency caused by streptozotocin treatment (Foretz et al., 1999; Shimomura et al.,
1999b). nSREBP1c protein and lipogenic mRNAs are low in fasted animals, but
refeeding with a high-carbohydrate/low-fat diet results in a 4-fold increase in both
compared with pre-fasted fed conditions, whereas nSREBP2 protein and cholesterol
synthetic genes only return to non-fasted levels (Horton et al., 1998a). Transgenic mice
overexpressing the active nuclear transcription factor fragment of SREBP1c
(nSREBP1c) in liver have hepatic steatosis, a 4-fold increase in fatty acid synthesis and
increased lipogenic gene expression, which remains high even under fasting conditions
(Horton et al., 1998a; Shimano et al., 1997a; Shimomura et al., 1999a; Shimomura et al.,
1998). Adenoviral overexpression of nSREBP1c in streptozotocin-induced diabetic mice
also induces lipogenic gene expression and increases hepatic triglyceride content
(Becard et al., 2001).
The majority of SREBP1-/- mice die prior to birth, but those that do survive have
decreased lipogenic gene expression during refeeding or prolonged high-carbohydrate
feeding (Shimano et al., 1997b; Shimano et al., 1999). SREBP1c-/- mice do not
experience embryonic lethality like the SREBP1-/- mice, but exhibit a similar reduction in
lipogenic gene expression and serum triglycerides, under both fasted and refed
conditions (Liang et al., 2002). Both models also have decreased serum triglycerides at
17

12 hours after refeeding, but only SREBP1c-/- mice have a significant reduction in
hepatic triglycerides, and only after high-carbohydrate refeeding. Interestingly,
cholesterol biosynthetic genes were increased in both mouse models, likely due to the
compensatory upregulation of SREBP2 that occurs with loss of SREBP1 or SREBP1c
(Liang et al., 2002; Shimano et al., 1999). Leptin-deficient obese ob/ob mice have
increased mRNA and nuclear protein levels of SREBP1c and increased expression of its
lipogenic targets, which correlate with the increased rates of de novo lipogenesis and
hepatic triglyceride content of these animals (Shimomura et al., 1999a). Hepatic
steatosis and lipogenic gene expression are markedly reduced in ob/ob mice lacking
SREBP1 without causing a reduction in obesity or insulin resistance (Yahagi et al.,
2002).
Though SREBP1c expression is important with regards to lipogenesis and
hepatic steatosis, the post-translational regulation of SREBP1c is also influential.
Following high-carbohydrate feeding, nSREBP1c protein increases to a much greater
extent than either SREBP1 mRNA or full-length protein (Horton et al., 1998a).
Lipodystrophic mice exhibit increased hepatic lipogenesis, lipogenic gene expression
and nSREBP1c protein in liver without exhibiting an increase in SREBP1c mRNA
(Shimomura et al., 1999a). Liver-specific deletion of either SREBP cleavage-activating
protein (SCAP) or Site-1 protease, two proteins required for the processing of precursor
SREBP1c into active nSREBP1c, results in decreased hepatic lipid synthesis and
decreased hepatic and serum triglyceride levels (Matsuda et al., 2001; Yang et al.,
2001). Liver-specific deletion of SCAP also results in decreased expression of
SREBP1c target genes (Kuriyama et al., 2005). As these proteins are also required for
the processing of SREBP1a and SREBP2, hepatic cholesterol biosynthesis and content,
and serum cholesterol are decreased as well in these mice.
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Carbohydrate response element-binding protein (ChREBP)
Though SREBP1c is an important regulator of lipogenic gene expression, it is
clearly not the sole influence. Liver-specific deletion of SCAP in mice eliminates most of
the active nSREBP1c protein, yet some lipogenic gene expression does remain
(Matsuda et al., 2001). Certain lipogenic genes (FAS and ACC) show less of a reduction
than others (GPAT) in SREBP1-/- and SREBP1c-/- mice following high-carbohydrate
refeeding (Liang et al., 2002; Shimano et al., 1999). In addition, the maximal
upregulation of many lipogenic genes in primary hepatocytes requires glucose as well as
insulin stimulation, and other lipogenic genes, such as L-PK, respond to increases in
glucose rather than SREBP1c activation (Kawaguchi et al., 2001; Koo et al., 2001; Koo
and Towle, 2000; Stoeckman and Towle, 2002; Yamashita et al., 2001). These
observations eventually lead to the definition of the transcription factor, ChREBP that
responds to increased intracellular glucose levels and, in tandem with the stimulation of
SREBP1c by insulin, results in the upregulation of lipogenic genes (Dentin et al., 2004;
Kawaguchi et al., 2001; Koo et al., 2001; Yamashita et al., 2001). ChREBP-/- mice have
decreased basal and high-carbohydrate diet-stimulated hepatic expression of FAS, ACL,
ACC and L-PK, the latter being a specific target of ChREBP, as well as having
decreased lipogenesis and hepatic triglycerides on high-carbohydrate diet (Iizuka et al.,
2004). These mice have normal hepatic triglyceride levels on chow diet as both lipid
oxidation and synthesis are decreased, but exhibit decreased fat stores, and an inability
to store and metabolize fatty acids, resulting in increased hepatic glycogen storage and
dependence on carbohydrate metabolism (Burgess et al., 2008; Iizuka et al., 2004). As
with SREBP1c, ChREBP is upregulated in the livers of ob/ob mice, and lipogenic gene
expression and hepatic steatosis is reduced in ob/ob mice lacking ChREBP either
globally or specifically in the liver. However, unlike SREBP1-/- mice on an ob/ob
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background, ChREBP deficiency improves the insulin resistance and glucose
intolerance of ob/ob mice, revealing different roles for these transcription factors beyond
the stimulation of lipogenic gene expression (Dentin et al., 2006; Iizuka et al., 2006;
Yahagi et al., 2002).

The insulin/PI3K signaling pathway
Overview of the insulin signaling cascade
Insulin signaling influences cellular processes through two major branches:
signaling through phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein
kinase (MAPK). Much of insulin’s effects on metabolism have been attributed to
signaling through PI3K, while MAPK is thought to mediate insulin’s effects on growth and
differentiation; the latter will not be discussed further in this overview. The major
signaling components of the PI3K pathway are shown in Figure 1-1. Insulin signaling is
initiated when insulin binds to its receptor present on the membrane surface of the cell
(reviewed in Nelson and Cox, 2008; Taniguchi et al., 2006a). The insulin receptor is a
receptor tyrosine kinase, which, upon binding of insulin, is autophosphorylated and
activated. Once activated, the receptor can phosphorylate tyrosine residues on the
insulin receptor substrate (IRS) molecules, leading to their activation. IRS proteins can
bind and activate molecules with SH2 domains, including PI3K, a lipid kinase. PI3K
phosphorylates the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2)
converting it into 3,4,5-tiisphosphate (PIP3); PIP3 can be reverted back to PIP2 by the
phosphatase PTEN (Nelson and Cox, 2008). PIP3 binds and co-localizes the 3phosphoinositide-dependent protein kinase 1 (PDK1) and its targets, Akt and atypical
protein kinase C (aPKC) at the cell membrane. These two kinases are phosphorylated
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and activated, eventually leading to many of insulin’s effects on glucose, lipid, and
protein metabolism (Taniguchi et al., 2006a).

Akt is a major mediator of the metabolic actions of insulin
The serine-threonine kinase Akt exists as three highly related isoforms, Akt1-3,
each encoded by a distinct gene. Based on studies of mice with interruptions in each
locus, Akt2 is the major isoform mediating insulin’s effects on glucose metabolism,
whereas Akt1 and Akt3 are more important to growth (Chen et al., 2001; Cho et al.,
2001a; Cho et al., 2001b; Easton et al., 2005; Garofalo et al., 2003). Each isoform
contains a highly similar pleckstrin homology (PH) domain responsible for Akt’s binding
to PIP3, a kinase domain, and carboxyl-terminal regulatory domain (reviewed in Hanada
et al., 2004). There are two known activating phosphorylations that all Akt isoforms can
undergo: PDK1 phosphorylates threonine-308 within the kinase domain and mammalian
target of rapamycin complex 2 (mTORC2) phosphorylates serine-473 within the
regulatory domain (Alessi et al., 1997; Hresko and Mueckler, 2005; Sarbassov et al.,
2005; Stephens et al., 1998). Phosphorylation at both of these sites is thought to
required for the full activation of Akt (Hanada et al., 2004). Akt exerts its effects through
the activation of mTOR complex 1 (mTORC1) and the inhibition of GSK3, FoxO1, and
PGC-1α. Akt is central to the hepatic actions of insulin on glucose output: the prevalent
model is that activated Akt phosphorylates and inhibits the transcription factor FoxO,
PGC-1α, and others, thereby terminating expression of the rate-controlling enzymes of
gluconeogenesis (Gross et al., 2008; Li et al., 2007). Additionally, Akt phophorylates
and inhibits GSK3, releasing its inhibition on glycogen synthase, with the net effect of
insulin stimulating the production of glycogen (Cross et al., 1995; Roach, 2002). Akt
also positive regulates mTOR signaling and protein synthesis by phophorylating and
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inhibiting tuberous sclerosis complex-2 (TSC2), which in conjunction with tuberous
sclerosis complex-1 (TSC1) negatively regulates mTORC1 (Taniguchi et al., 2006a).

Insight into insulin’s control of lipid metabolism from insulin signaling mutants
Insulin Receptor
While the signal transduction pathways through which insulin controls lipid
metabolism have not been fully defined, the study of rodents with mutations in the
components of the insulin signaling cascade has aided in this process. Mice lacking the
insulin receptor in liver (LIRKO mice) have no hepatic insulin signaling and as a result
exhibit severe glucose intolerance due to an inability to suppress hepatic glucose output
in response to insulin (Michael et al., 2000). Though they are able to maintain normal
hepatic triglyceride levels on a chow diet, these mice have decreased SREBP1c, SCD1,
FAS, GCK, and L-PK expression and well as dramatically decreased nSREBP1c protein
levels (Biddinger et al., 2008; Michael et al., 2000). Decreased lipogenic gene
expression coupled with increased secretion and decreased clearance of VLDL results
in triglyceride-deficient cholesterol-rich VLDL particles. Though serum triglyceride levels
are low and serum cholesterol levels are normal in chow-fed LIRKO mice, they do have
a significantly higher propensity for developing severe atherosclerosis on an atherogenic
diet, likely due to their abnormal lipoprotein profile (Biddinger et al., 2008). Similarly,
mice with severely impaired insulin signaling (L1 mice) on a Ldlr-/- background exhibit
decreased serum triglyceride levels along with decreased lipogenic gene expression
when fed an atherogenic diet; however, these mice have reduced VLDL and serum
cholesterol levels and are actually protected from the development of atherosclerosis
unlike the LIRKO mice (Han et al., 2009). The differing results observed in these two
models is likely due to residual hepatic insulin signaling in the L1 mice as opposed to the
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complete absence of hepatic insulin signaling in the LIRKO mice. The dyslipidemia and
decreased lipogenic gene expression are partially reversed by expression of
constitutively active Akt in both models and by expression of dominant-negative GSK3 in
the latter, but it is unclear if this was a physiological action of these proteins or a result of
overexpression in the context of complete or almost complete insulin receptor deficiency
(Biddinger et al., 2008; Han et al., 2009).

Insulin Receptor Substrate (IRS)
Once activated, the insulin receptor phosphorylates IRS proteins, and it has been
proposed that the bifurcation of selective insulin signaling in the liver may occur at the
level of these molecules, though this idea is controversial. Disruption of either IRS1 or
IRS2 globally results in insulin resistance in both models, and overt diabetes in IRS2-/mice, potentially confounding the interpretation of the role of each protein in hepatic lipid
metabolism in whole-body null animals (Araki et al., 1994; Tamemoto et al., 1994;
Withers et al., 1998). IRS1-/- mice have hypertriglyceridemia likely due to loss of IRS1 in
adipose tissue and IRS2-/- mice have increased SREBP1c, ACL, and FAS expression
and increased hepatic triglyceride content likely caused by leptin resistance (Abe et al.,
1998; Tobe et al., 2001). High doses of leptin decrease the elevation in SREBP1c
expression in IRS2-/- mice and leptin-deficient ob/ob mice exhibit decreased IRS2 and
increased SREBP1c expression (Kerouz et al., 1997; Shimomura et al., 1999a; Tobe et
al., 2001).
Liver-specific IRS2-/- mice have normal serum NEFA and triglyceride levels, in
addition to having normal lipogenic gene expression and hepatic triglyceride content
(Simmgen et al., 2006). However, acute liver-specific knockdown using RNA
interference (RNAi) against IRS2 in adult mice results in increased SREBP1c expression
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and mild fatty liver changes but no increase in hepatic triglyceride content (Taniguchi et
al., 2005). Alternatively, acute liver-specific knockdown of IRS1 by RNAi does not alter
lipogenic gene expression or serum and hepatic triglyceride levels, but does cause an
increase in gluconeogenic gene expression and fasting glucose levels, suggesting that
IRS1 is more important to insulin’s control of glucose metabolism (Taniguchi et al.,
2005). However, there is likely overlap between the IRS proteins as coordinate hepatic
knockdown by RNAi of IRS1 and IRS2 results in a more substantial increase in lipogenic
gene expression, serum and hepatic triglycerides, glucose levels and gluconeogenic
gene expression (Taniguchi et al., 2005).
While Taniguchi et al suggests that IRS1 controls glucose metabolism and IRS2
is more important to lipid metabolism based on acute hepatic knockdown, White and
colleagues have published a series of reports arguing that IRS1 is more critical to
hepatic lipid metabolism. IRS1-associated PI3K activity is highest after refeeding,
coinciding with the activation of SREBP1c and lipogenic gene expression, while IRS2associated PI3K activity is highest during fasting and immediately after refeeding (Horton
et al., 1998a; Kubota et al., 2008). Unlike short-term hepatic knockdown, IRS1/IRS2
liver-specific null mice have normal fasted but decreased refed SREBP1c expression,
highlighting the potential differences resulting from genetic ablation versus adult
knockdown (Dong et al., 2008). These mice lack the normal rise in GCK, FAS, and
SREBP1c levels that occurs during refeeding in addition to having decreased serum
triglycerides. The effects on serum triglycerides are reversed with the presence of one
allele of either IRS1 or IRS2, while the effect on lipogenic gene expression is reversed,
and only partially, with one allele of IRS1 (Guo et al., 2009). Additionally, though both
IRS1/IRS2 liver-specific null mice have impairments in the induction of lipogenic genes
during the fasted to fed transition, these impairments appear to be greater for the most
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part in the absence of IRS1 (Guo et al., 2009). When fed a high fat diet, IRS1/IRS2
liver-specific null mice have decreased hepatic triglycerides, an effect that is also
observed in the IRS1 liver-specific null, but not in the IRS2 liver-specific null (Guo et al.,
2009). Thus there is conflicting evidence for the bifurcation of insulin signaling to
glucose and lipid metabolism at the level of IRS.

Phosphatidylinositol 3-kinase (PI3K)
There is evidence that PI3K may mediate insulin’s effects on both VLDL
secretion and lipogenesis. Acute inhibition of PI3K by wortmannin reverses insulin’s
suppression of hepatic VLDL production, resulting in increased serum VLDL apoB
protein and triglyceride in mice (Chirieac et al., 2006). Adenoviral expression of a
dominant-negative PI3K p85 regulatory subunit results in a marked decrease in
phosphorylation of Akt, decreased SREBP1c and GCK expression, as well as lower
serum triglycerides and NEFA, though the reduction in serum lipids is likely due to
increased hyperinsulinemia driving uptake into adipose tissue (Miyake et al., 2002). A
similar result is found in mice with genetic ablation of all PI3K activity in the liver, which
results in decreased serum triglycerides and NEFA and decreased fasted SREBP1c
expression as well as elevated glucose and insulin levels and increased gluconeogenic
gene expression (Taniguchi et al., 2006b). Insulin-dependent induction of SREBP1c
expression is blocked in rat hepatocytes following inhibition of PI3K with wortmannin (Li
et al., 2010). Additionally, SREBP1c processing is influenced through a PI3K-dependent
mechanism as wortmannin treatment of rat hepatocytes results in decreased nSREBP1c
levels (Hegarty et al., 2005).

Atypical protein kinase C (aPKC)
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Genetic ablation of all PI3K activity in the liver results in decreased serum
triglycerides and fasted SREBP1c expression and decreased insulin-stimulated activity
of its downstream target aPKCs, including PKCλ (Taniguchi et al., 2006b). Adenoviral
overexpression of constitutively active PKCλ dramatically increases fasted SREBP1c
expression in both liver-specific PI3K null and control mice, though the metabolic
ramifications of this manipulation were not reported (Taniguchi et al., 2006b).
Additionally, overexpression of PKCλ in primary rat hepatocytes results in increased
SREBP1c and FAS expression, while overexpression of kinase-inactive PKCλ results in
decreased insulin-stimulated expression (Matsumoto et al., 2003). These findings are
corroborated by the liver-specific PKCλ null mice, which exhibit decreased hepatic
SREBP1c expression and triglyceride content and have blunted induction of SREBP1c,
FAS, and SCD1 expression during refeeding (Matsumoto et al., 2003; Sajan et al.,
2009). Additionally, hepatic adenoviral expression of a kinase-inactive aPKC results in
decreased SREBP1c expression and nSREBP1c levels and decreased serum and
hepatic triglycerides (Sajan et al., 2009). However, in the latter two models, decreased
aPKC activity resulted in a simultaneous decrease in insulin levels, and thus the effects
on triglyceride levels and lipogenic gene expression could be secondary to decreased
insulin levels (Matsumoto et al., 2003; Sajan et al., 2009).

Akt
Akt activates the transcription of SREBP1c and its lipogenic targets in isolated
hepatocytes and a human epithelial cell line (Fleischmann and Iynedjian, 2000;
Porstmann et al., 2005; Ribaux and Iynedjian, 2003). Hepatic overexpression of
constitutively active Akt (myr-Akt) results in hepatic steatosis and hypertriglyceridemia,
with induction of SREBP1c, SCD1, and GCK, a smaller increase in FAS and no change
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in ACC or fatty acid oxidation genes (Ono et al., 2003). However, not all of the effects of
myr-Akt proceed through SREBP1c, as the induction of hepatic triglyceride
accumulation, GCK and FAS expression by myr-Akt in SREBP1 null mice is similar to
that in normal mice, though the degree of hypertriglyceridemia and SCD1 expression is
dramatically reduced (Ono et al., 2003). Additionally, hepatic deficiency of PTEN, a
negative regulator of Akt, also leads to increased lipogenesis, lipogenic gene expression
and VLDL secretion, resulting in hepatic steatosis (Horie et al., 2004; Stiles et al., 2004).
However, it has been argued that the resulting hepatic steatosis could be an off-target
effect of overexpression of Akt, and not indicative of the role of Akt in normal hepatic
lipid metabolism. Genetic ablation of all PI3K activity in the liver results in decreased
fasted SREBP1c expression, an effect that is not reversed with overexpression of myrAkt (Taniguchi et al., 2006b).

Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α)
PGC-1α is a transcription factor that integrates multiple inputs including insulin
signaling to coordinately regulate many aspects of metabolism (reviewed in Lin et al.,
2005). Expression of PGC-1α is highest in the liver during fasting and positively
regulates β-oxidation and perhaps VLDL secretion while potentially inhibiting SREBP1c
expression (Zhang et al., 2004a). Akt directly phosphorylates and inhibits PGC-1α at
Ser570, impairing its ability to activate genes involved in fatty acid oxidation, in
particular, medium-chain acetyl-CoA dehydrogenase (MCAD) (Li et al., 2007).
Additionally, in primary hepatocytes, expression of PGC-1α stimulates palmitate
oxidation and co-expression of myr-Akt significantly blunts this stimulation in cells
expressing PGC-1α but not in those expressing a S570A mutant of PGC-1α. Akt’s
inhibition of PGC-1α serves as a dual regulatory step for the hepatic switch from fasting
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to feeding, simultaneously turning off fatty acid oxidation and gluconeogenesis, the latter
in concert with Akt’s phosphorylation and inhibition of FoxO1 (Li et al., 2007).
Mice lacking PGC-1α either in the whole body or specifically in the liver develop
hepatic steatosis during fasting due to decreased β-oxidation and increased lipogenic
gene expression (Estall et al., 2009; Leone et al., 2005). Additionally, liver-specific
PGC-1α-/- mice display hypertriglyceridemia, correlating with increased apoB levels, as
well as increased hepatic insulin resistance (Estall et al., 2009). Mice lacking the highly
homologous protein PGC-1β also exhibit increased hepatic steatosis when fed a high fat
diet due to decreased β-oxidation (Lelliott et al., 2006; Sonoda et al., 2007).

Mammalian Target of Rapamycin (mTOR)
mTOR is a serine-threonine kinase that promotes insulin/PI3K/Akt’s positive
effects on protein synthesis through activation of S6 Kinase (S6K) and inhibition of the
translation inhibitor eIF4E-binding protein (4E-BP). The activities of both mTOR and
S6K are increased in obese rats, and S6K1 activity is increased in ob/ob mice
(Khamzina et al., 2005; Um et al., 2004). Inhibition of mTOR by rapamycin in isolated
rat hepatocytes results in decreased de novo lipogenesis and esterification of fatty acids
and increased fatty acid oxidation (Brown et al., 2007). Furthermore, rapamycin blocked
the stimulation of SREBP1c expression by insulin in isolated rat hepatocytes and by
fasting/refeeding in rats in vivo (Li et al., 2010). Expression of myr-Akt in vitro activates
SREBP1 processing, SREBP1, FAS and ACL expression and leads to increased de
novo lipogenesis, all of which are prevented by mTOR inhibition with rapamycin
(Porstmann et al., 2008). This is a highly-conserved pathway for nutrient storage as
Drosophila melanogaster deficient in dTOR have decreased lipid levels while those
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deficient in 4E-BP have normal triglyceride stores but deplete them more rapidly and
thus have reduced survival during starvation (Luong et al., 2006; Teleman et al., 2005).
Mice deficient for S6K1 are hyperglycemic due to reduced insulin secretion, but
are small and have reduced fatty acid levels due to increased β-oxidation in adipose
tissue (Pende et al., 2000; Um et al., 2004). However, it is unknown whether S6K plays
a similar role in hepatic β-oxidation and it has been proposed that S6K may not have a
direct role in metabolism but causes negative feedback to the insulin signaling pathway
at the level of IRS1 (Um et al., 2004). This concept has been reinforced by findings in
mice lacking 4E-BP1/4E-BP2 that exhibit hepatic steatosis, increased S6K activity in
liver, muscle, and adipose, and increased adiposity due to a combination of decreased
energy expenditure and lipolysis and an increase in re-esterfication in adipose tissue on
high fat diet (Le Bacquer et al., 2007).

Forkhead box O1 (FoxO1)
FoxO1 is a transcription factor that is negatively regulated by insulin signaling
through phosphorylation by Akt (Brunet et al., 1999). In the absence of insulin signaling,
FoxO1 is active and elevates serum triglycerides through increasing VLDL secretion and
decreasing triglyceride clearance. Overexpression of normal or constitutively active
FoxO1 in liver either genetically or by adenovirus increases serum triglycerides during
fasting or following an oral lipid load (Altomonte et al., 2004; Kamagate et al., 2008).
This work by Dong and colleagues attributes the increase in serum triglycerides to
increased VLDL production and decreased clearance of triglycerides from the
bloodstream. FoxO1 directly activates the expression of microsomal triglyceride transfer
protein (MTP), a protein that transfers lipids to growing VLDL particles in the liver;
inhibition of MTP in vivo results in decreased serum triglyceride but increased hepatic
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triglyceride levels (Kamagate et al., 2008; Liao et al., 2003). Mice expressing a
constitutively active FoxO1 transgene have increased MTP expression, VLDL production
and serum triglyceride levels (Kamagate et al., 2008). Adenoviral expression of FoxO1
in the liver also results in increased hepatic expression of apoC-III, the apolipoprotein
that inhibits the enzyme responsible for the hydrolysis of circulating triglycerides,
lipoprotein lipase, and thus inhibits clearance of VLDL triglycerides (Altomonte et al.,
2004). Conversely, RNAi knockdown of FoxO1 in the liver increases hepatic triglyceride
levels but decreases VLDL production, suggesting that the absence of FoxO1 can
secondarily cause hepatic steatosis by impairing triglyceride secretion from the liver
(Kamagate et al., 2008).
FoxO1 also has an influence on lipogenic and β-oxidative gene expression,
however it is unclear whether this is a primary action of FoxO1. RNAi knockdown of
FoxO1 in the liver decreases FAS and ACC expression, while hepatic expression of
constitutively active FoxO1 by adenovirus results in increased lipogenic gene and
decreased β-oxidative gene expression (Kamagate et al., 2008; Matsumoto et al., 2006).
However, hepatic steatosis occurs in both cases, attributed to decreased VLDL secretion
in the absence of FoxO1 and to increased lipid synthesis and decreased oxidation in the
presence of constitutively active FoxO1 (Kamagate et al., 2008; Matsumoto et al., 2006).
Interestingly, the latter mice also exhibit a compensatory increase in IRS2 protein levels
and phosphorylation of Akt, so the hepatic steatosis resulting from constitutively active
FoxO1 expression may be secondary to the upregulation of another Akt-dependent
pathway. This same group reported that FoxO1 deletion fails to reverse the blunted
refeeding-stimulated expression of SREBP1c or decrease in serum triglyceride levels in
double IRS1/IRS2 null livers, though it is able to partially restore VLDL triglyceride
secretion, arguing that FoxO1 is a component of IRS-dependent VLDL secretion but not
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of IRS-dependent lipogenesis (Dong et al., 2008). However, Zhang et al reported the
opposite in their transgenic mice expressing constitutively active FoxO1 in liver, which
have decreased hepatic expression of SREBP1c and its lipogenic targets, decreased
lipogenesis following feeding and decreased serum triglyceride levels during fasting and
feeding (Zhang et al., 2006). Though these mice do not exhibit differential activation of
other insulin signaling pathways, they are markedly glucose-intolerant and insulinresistant (Zhang et al., 2006). Thus, it is unclear whether a directly action of FoxO1 is to
modulate the expression of lipogenic genes

Glycogen synthase kinase 3 (GSK3)
As its name indicates, GSK3 phosphorylates and inhibits glycogen synthase in
the absence of insulin signaling; upon nutrient influx, GSK3 is inhibited via
phosphorylation by Akt, mediating insulin’s stimulation of glycogen production (Cross et
al., 1995; reviewed in Roach, 2002). Though it mediates insulin’s action on glycogen
synthesis, a role with regards to lipid synthesis is less established. A series of reports by
Ericsson and colleagues have shown that GSK3 can directly phosphorylate SREBP1,
which promotes the ubiquitination and degradation of SREBP1 protein in vitro
(Bengoechea-Alonso and Ericsson, 2009; Punga et al., 2006; Sundqvist et al., 2005).
Additionally, expression of constitutively active GSK3 blocks the accumulation of
nSREBP protein that occurs in cells expressing myr-Akt (Porstmann et al., 2008). This
implicates a role for GSK3 in the downregulation of lipogenesis during fasting, a process
that would then be turned off by insulin during feeding; however, the relevance of this
pathway has yet to be shown in vivo.

Forkhead box A2 (Foxa2)
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Foxa2 is a transcription factor and may serve as a potential pathway through
which insulin regulates lipid metabolism during the fasting to feeding transition. Stoffel
and colleagues have published that adenoviral overexpression of constitutively active
Foxa2 in either lean or obese mice leads to increased VLDL secretion and increased βoxidation, as assessed by gene expression and calorimetry, resulting in decreased
hepatic triglyceride accumulation (Wolfrum et al., 2004; Wolfrum and Stoffel, 2006).
Mice lacking one allele of Foxa2 exhibit decreased hepatic ketogenesis and increased
serum triglyceride and fatty acid levels, an effect that is enhanced by high fat dietfeeding (Wolfrum et al., 2004). Activity of Foxa2 is highest in fasted low-insulin states,
but whether this and its effects on lipid metabolism are due to lack of insulin regulation or
coactivation with PGC-1β remains unclear (Wolfrum et al., 2004; Wolfrum and Stoffel,
2006; Zhang et al., 2005). Additionally, whether Foxa2 is negatively regulated by insulin
through phosphorylation by Akt and nuclear exclusion during refeeding remains
contested, as does its role in the regulation of hepatic lipid metabolism (Wolfrum et al.,
2004; Zhang et al., 2005).

Concluding remarks
While the underlying pathogenesis of hepatic steatosis remains elusive, its
development is clearly associated with insulin resistance. The characterization of the
insulin signaling transduction pathways that control hepatic lipid metabolism is essential
to revealing novel therapeutic targets for the treatment of dyslipidemia and hepatic
steatosis associated with T2DM. These signaling pathways appear to be distinct from
those controlling hepatic glucose metabolism and are preserved in insulin-resistant
states, leading to the proposal of selective insulin resistance in the liver. Specifically,
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insulin’s stimulation of de novo lipogenesis is preserved in T2DM, and as such,
individuals with hepatic steatosis have inappropriately elevated rates of lipogenesis.
Much insulin’s regulation of lipogenesis is thought to proceed through the
transcription factor SREBP1c, which activates the broad transcription of genes
expressing lipogenic enzymes. SREBP1c expression has been shown to be decreased
in the absence of many components of the insulin signaling pathway, including the
insulin receptor, IRS, PI3K, and aPKCs. However the consequences of this decrease on
the rate of de novo lipogenesis are rarely investigated in vivo. Certainly, animals are
protected against the development of hepatic steatosis in the absence of SREBP1c,
corresponding to a decrease in de novo lipogenesis, but this has never been
recapitulated in an animal deficient in a component of the insulin signaling pathway.
Additionally, it is conceivable that not all regulation of de novo lipogenesis by insulin
proceeds through SREBP1c expression: there are likely SREBP1c-independent controls
of lipid synthesis, and SREBP1c mRNA levels may not always be an accurate measure
of de novo lipogenesis. Additionally, it is unclear if other lipid metabolic processes
beyond lipogenesis, such as VLDL secretion and β-oxidation, are controlled by the same
pathway and if they contribute to hepatic lipid accumulation in insulin-resistant states.
At the outset of this thesis, we wanted to determine the downstream signaling
pathway that insulin utilizes to promote hepatic lipid accumulation and, in particular, the
induction of SREBP1c and de novo lipogenesis, a question for which a consensus
answer had yet to emerge. Here we present an in vivo model that is inherently defective
in insulin signaling due to loss of hepatic Akt2, and utilize these mice to evaluate the role
of Akt2 in lipid synthesis and accumulation. Akt2 is the predominant isoform expressed
in insulin target tissues, such as liver, muscle and adipose tissue, and Akt2-/- mice exhibit
glucose intolerance and a mild diabetic phenotype (Cho et al., 2001a; Garofalo et al.,
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2003). In the experiments described below, we establish a role for Akt2 in the
development of hepatic steatosis in two models of insulin resistance, and in the elevation
of de novo lipogenesis in one of these models. Additionally, we show that hepatic Akt2
is required for the induction of lipogenesis that occurs in lean animals during feeding.
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Figure 1-1: The insulin/PI3K signaling pathway
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Chapter 2:

Akt2 is required for increased de novo lipogenesis and the
development of hepatic steatosis in the ob/ob mouse.
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Introduction
The study of lipid metabolism has relied upon the use of rodent models to
characterize both normal and pathological processes. One of the most commonly used
models of obesity, hepatic steaotsis, dyslipidemia, and T2DM is the ob/ob mouse. First
described in 1950 by Ingalls et al. as a naturally occurring recessive mutation, the ob/ob
mouse was utilized for decades prior to the characterization of the point mutation in the
gene encoding leptin (Lepob/ob) that caused the mouse’s phenotype (Bray and York,
1979; Halaas et al., 1995; Ingalls et al., 1950). Leptin is a hormone secreted by
adipocytes that acts predominantly on the brain to reduce food intake and increase
energy expenditure, in addition to having other influences on metabolism (reviewed in
Ahima and Osei, 2004). Serum leptin levels correlate with body mass index in both
humans and rodents, and administration of leptin to Lepob/ob mice and humans results in
weight loss and reversal of the increased food intake and decreased energy expenditure
seen in leptin deficiency (Farooqi et al., 1999; Halaas et al., 1995). However, the use of
leptin as a general therapy for weight loss in humans has not been successful, though it
has been employed to treat congenital lipodystrophy and severe insulin resistance
syndromes (Cochran et al., 2004; Petersen et al., 2002; Shimomura et al., 1999c).
ob/ob mice are insulin-resistant, largely due to their increased adiposity, and exhibit
increasing serum insulin levels throughout their life beginning around one month of age
(reviewed in Bray and York, 1979). However, the severity of the insulin resistance and
development of diabetes is background strain-dependent (Haluzik et al., 2004).
One of the most striking characteristics of the ob/ob mouse is the extreme
hepatic steatosis that develops at an early age, likely due to a combination of increased
de novo lipogenesis and esterification of elevated serum NEFA, as well as decreased
fatty acid oxidation (reviewed in Bray and York, 1979). Leptin administration to ob/ob
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mice results in decreased expression of lipogenic and cholesterol biosynthetic genes,
and increased expression of fatty acid oxidation genes (Liang and Tall, 2001). Despite
having elevated serum triglyceride levels, hepatic VLDL production and secretion are not
drastically changed in ob/ob mice, indicating that these animals likely have impairments
in clearance of VLDL from the circulation (Li et al., 1997; Wiegman et al., 2003).
However, when subjected to hyperinsulinemic euglycemic clamp, ob/ob mice exhibit
decreased suppression of VLDL production by insulin (Wiegman et al., 2003).
Most closely correlating with the increase in hepatic triglyceride accumulation in
ob/ob mice is a dramatic increase in de novo lipogenesis in the liver, which is increased
by between 10- to 23-fold per organ in ob/ob versus lean mice (Shimomura et al., 1999a;
Wiegman et al., 2003). This increase in de novo lipogenesis is accompanied by
increased mRNA and nuclear protein levels of SREBP1c, increased expression of
ChREBP and upregulation of their lipogenic target genes (Dentin et al., 2006; Iizuka et
al., 2006; Shimomura et al., 1999a; Yahagi et al., 2002). These two factors play an
inciting role in the development of hepatic steatosis, as hepatic triglyceride levels and
lipogenic gene expression are reduced in ob/ob mice lacking SREBP1 or ChREBP
(Dentin et al., 2006; Iizuka et al., 2006; Yahagi et al., 2002). This is likely due to their
influences on lipogenic gene expression and not on modulation of insulin sensitivity as
deletion of ChREBP improves insulin resistance and glucose intolerance while loss of
SREBP1 has no effect on insulin sensitivity. Deletion of other lipid metabolic genes,
such as PPARγ, Cidec/Fsp27, and SCD1, in ob/ob animals can also improve the hepatic
steatosis with varying affects on the diabetic phenotype (Cohen et al., 2002; Flowers et
al., 2007; Matsusue et al., 2003; Matsusue et al., 2008).
In this chapter, we describe the role of hepatic Akt2 in the development of
hepatic steatosis of the ob/ob mouse. We find that hepatic Akt2 is absolutely required
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for the accumulation of hepatic triglycerides, corresponding to a requirement for the
increase in lipogenic gene expression and de novo lipogenesis. However, while loss of
hepatic Akt2 does not significantly alter the diabetic phenotype of the ob/ob mouse,
Lepob/ob Akt2-/- mice exhibit severe glucose intolerance and insulin resistance.

Results
Germline Akt2 deficiency prevents hepatic steatosis in ob/ob mice.
While the role of Akt2 in glucose homeostasis has been established, its influence
on lipid metabolism in vivo is controversial. The first model we used to resolve this was
the ob/ob mouse, which we initially crossed with Akt2-/- mice. The Lepob/ob Akt2+/+ mice
were substantially heavier than Lep+/+ Akt2+/+ littermates at 12 weeks of age and had
large, lipid-laden livers. However, deletion of both alleles of Akt2 led to a dramatic
reduction of both body and liver weight in ob/ob mice, with loss of one allele of Akt2
resulting in an intermediate decrease (Figure 2-1A and 2-1B). Triglyceride accumulation
in the livers of ob/ob mice under both fed and fasted conditions was completely
prevented by loss of both alleles of Akt2, and, as above, mice heterozygous for Akt2
demonstrated intermediate protection from hepatic steatosis (Figure 2-1C and 2-1D).
Accumulation of hepatic triglyceride in ob/ob mice is associated with an increase
in de novo lipogenesis (Shimomura et al., 1999a; Wiegman et al., 2003). Therefore, we
measured hepatic fatty acid synthesis and incorporation into triglycerides using
deuterated water as a biosynthetic tracer. Lepob/ob Akt2+/+ mice demonstrated greater de
novo lipogenesis compared with Lep+/+Akt2+/+ mice, but this was reduced in both Lepob/ob
Akt2+/- and Lepob/ob Akt2-/- mice (Figure 2-1E). Serum triglycerides were increased in
both Lepob/ob Akt2+/- and Lepob/ob Akt2-/- relative to Lepob/ob Akt2+/+ mice, while cholesterol
levels were increased in all Lepob/ob mice compared with Lep+/+ mice and modestly
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decreased with loss of Akt2 under fed conditions (Figure 2-2A and 2-2B). Non-esterified
free fatty acids (NEFA) were unchanged or increased in Lepob/ob Akt2-/- compared with
Lepob/ob Akt2+/+ mice while serum ketones were not changed in any group (Figure 2-2C
and 2-2D).

Germline Akt2 deficiency results in severe diabetes in ob/ob mice.
Many mouse models exhibit improved hepatic insulin sensitivity in conjunction
with improvements in hepatic steatosis, possibly confounding the interpretation of which
preceded the other. Therefore, we wanted to characterize the state of glucose
homeostasis and insulin sensitivity of the Lepob/ob Akt2-/- mice. Deletion of Akt2
exacerbated the already impaired glucose homeostasis of the ob/ob mice, as indicated
by an elevation in blood glucose levels both under fasted conditions and during an oral
glucose tolerance test (OGTT) (Figure 2-3A and 2-3B). Lepob/ob Akt2+/+ mice exhibited
hyperinsulinemia to compensate for insulin resistance at both fasting and 15 minutes
post oral glucose, and Lepob/ob Akt2-/- mice had a further increase in fasted serum insulin
levels (Figure 2-3C). Interestingly, hyperglycemia was not worsened in the Lepob/ob
Akt2+/- mice, suggesting that redistribution of hepatic lipid to other organs was not the
cause of the aggravated insulin resistance. Additionally, Lepob/ob Akt2-/- mice failed to
decrease their blood glucose levels during insulin tolerance tests (ITT), even at a high
dose of insulin that induced glucose-lowering effects in Lepob/ob Akt2+/+ and Lepob/ob Akt2+/mice (Figure 2-3D and 2-3E). To determine whether the insulin resistance observed in
these mice was due to hepatic or peripheral insulin resistance, Lepob/ob Akt2+/+ and
Lepob/ob Akt2-/- mice were subjected to hyperinsulinemic euglycemic clamp (Figure 2-4A).
As Lepob/ob Akt2-/- mice had reduced body weight, slightly younger Lepob/ob Akt2+/+ mice
were used to better weight-match the groups. A very high level of infused insulin
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(250mU/kg/min) was employed to reduce Lepob/ob Akt2-/- mice to euglycemia. At this
dose of insulin, Lepob/ob Akt2+/+ mice required a high glucose infusion rate (GIR) in order
to maintain euglycemia, while Lepob/ob Akt2+/+ mice had a markedly reduced GIR,
confirming that these mice were extremely insulin-resistant (Figure 2-4A). Hepatic
glucose production (HGP) was increased under both basal and clamped conditions in
Lepob/ob Akt2+/+ mice, while rate of disposal (Rd) of glucose into the periphery was
unchanged (Figure 2-4A).
As body weight was dramatically reduced in ob/ob mice with loss of Akt2 (Figure
2-1A), we wanted to determine whether this was due a reduction in fat mass, lean mass,
or both. Body composition was determined using the assimilation of injected D2O from
the lipogenesis assay (Figure 2-1E) into the body water compartment as described
previously (McCabe et al., 2006). Lepob/ob mice had increased fat mass by both weight
and percentage, and had slightly decreased lean mass by weight compared with Lep+/+
mice (Figure 2-4B). Loss of Akt2 on a ob/ob background resulted in both decreased fat
and lean mass by weight, as well as a decrease in the percentage of body fat, indicating
that these mice have an impaired ability to store fat even though they have a normal Rd
by clamp (Figure 2-4A and 2-4B). However, Lepob/ob Akt2+/- mice mice had decreased fat
mass by weight and percentage, but exhibited normal lean mass by weight compared
with Lepob/ob Akt2+/+ mice (Figure 2-4B).

Generation of ob/ob liver-specific Akt2 null mice.
In the experiments described above, the non-cell autonomous effects of germline
deletion of Akt2 confound interpretation of changes in hepatic lipid content and
metabolism. To clarify this, we generated mice with liver-specific deletion of Akt2. Mice
containing an allele of Akt2 in which exons 3 and 4 are flanked by loxP sires (Akt2lox/lox)
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were crossed with mice expressing Cre recombinase under the control of the albumin
promoter with an alpha-fetoprotein enhancer (AFP). Progeny were crossed with ob/ob
mice, and offspring were assessed for deletion of Akt2 selectively in the liver. As shown
in Figure 2-5, AFP;Akt2lox/lox and Lepob/ob AFP;Akt2lox/lox mice lacked hepatic Akt2 protein,
while showing no compensatory changes in the levels of Akt1 or decrease in Akt2
protein in other tissues. While AFP;Akt2lox/lox mice exhibited no difference in body weight
compared to Akt2lox/lox mice, Lepob/ob AFP;Akt2lox/lox mice weighed less than both Lepob/ob
Akt2lox/lox and Lepob/ob AFP;Akt2+/+ mice (Figure 2-6A and 2-9A). This decrease in body
weight was due to proportional reductions in both lean and fat mass, such that relative
body composition remained unchanged (Figure 2-7A). The decreased body weight
could not be attributed to changes in food intake or energy expenditure, which were
indistinguishable in ob/ob mice with or without hepatic Akt2 (Figure 2-7B and 2-7C).

Loss of hepatic Akt2 reduces hepatic triglyceride levels, de novo lipogenesis and
lipogenic gene expression in the ob/ob mouse.
Hepatic deletion of Akt2 resulted in decreased liver weight in the ob/ob mouse,
due at least in part to a reduction in triglyceride content under both fed and fasted
conditions (Figure 2-6B, 2-6C and 2-6D). None of these changes could be attributed to
the effect of AFP Cre alone (Figure 2-9B, 2-9C, and 2-9D). The decrease in hepatic
triglycerides does not solely reflect the decreased body weight in Lepob/ob AFP;Akt2lox/lox
mice, as even compared to weight-matched controls, Lepob/ob AFP;Akt2lox/lox mice
exhibited reduced hepatic triglyceride content under fed conditions (Lepob/ob Akt2lox/lox:
56.7 ± 3.34 mg/g TG, 34.9 ± 1.6 g body weight; , Lepob/ob AFP;Akt2lox/lox:12.3 ± 1.43
mg/g TG, 38.7 ± 1.1 g body weight). Fasted serum triglyceride levels were decreased in
Lepob/ob AFP;Akt2lox/lox mice compared with Lepob/ob Akt2lox/lox mice, while fed values were
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unchanged (Figure 2-8A). Serum cholesterol was decreased in Lepob/ob mice upon liverspecific deletion of Akt2, but serum NEFA and ketones were unaffected; fasted serum
ketones were decreased in all ob/ob mice (Figure 2-8B, 2-8C, and 2-8D). The content
and distribution of long-chain fatty acyl-CoA were not significantly different among any of
the genotypes, though there was a trend towards a decrease in the two
monounsaturated fatty acids (MUFA) palmitoleate (C16:1) and oleate (C18:1) in Lepob/ob
AFP;Akt2lox/lox compared with Lepob/ob Akt2lox/lox livers (Figure 2-6E). De novo lipogenesis
was elevated in the Lepob/ob Akt2lox/lox mice, and loss of hepatic Akt2 reversed this effect,
as was previously observed with whole-body loss of Akt2 (Figure 2-6F). These results
demonstrate that Akt2 is required in the liver for the increases in both hepatic de novo
lipogenesis and triglyceride accumulation in ob/ob mice.
The augmented de novo lipogenesis in the ob/ob mouse is associated with an
increase in lipogenic gene expression, in particular SREBP-1c and its transcriptional
targets (Shimomura et al., 1999a). In the present studies, we confirmed the predicted
increases in the mRNAs for SREBP-1c, SCD1, FAS, ACC, ACL, GPAT, and GCK in
Lepob/ob Akt2lox/lox livers, and moreover found that all of these increases were prevented
by loss of hepatic Akt2 (Figure 2-10). Expression of ChREBP was unchanged, but its
target L-PK was increased in Lepob/ob Akt2lox/lox mice and normalized in livers from
Lepob/obAFP;Akt2lox/lox mice. PPARγ and Cidec/Fsp27, gene products required for
development of hepatic steatosis in ob/ob mice, were induced in Lepob/ob Akt2lox/lox livers
and this was prevented by loss of hepatic Akt2 (Figure 2-10) (Matsusue et al., 2008).
Lepob/obAkt2lox/lox mice exhibited a slight increase in the expression of PGC-1α,
which was further enhanced in Lepob/ob AFP;Akt2lox/lox mice (Figure 2-10). However,
expression of medium-chain acetyl-CoA dehydrogenase (MCAD), a transcriptional target
of PGC-1α and rate-determining enzyme in fatty acid oxidation, was not altered in
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Lepob/ob AFP;Akt2lox/lox compared with Lepob/ob Akt2lox/lox livers (Schreiber et al., 2003).
Additionally, the expression of CPT1, another PGC-1α target, was actually decreased in
Lepob/ob AFP;Akt2lox/lox livers, while the expression of the mitochondrial gene cytochrome
c oxidase subunit 7a (Cox7a) was not different between Lepob/ob Akt2lox/lox and Lepob/ob
AFP;Akt2lox/lox mice (Figure 2-10) (Song et al., 2004).
While fatty acid oxidation did not appear to be altered, at least by gene
expression, in Lepob/ob AFP;Akt2lox/lox mice (Figure 2-10), we wanted to determine if
triglyceride secretion was dramatically altered and therefore contributing the reduction in
hepatic triglyceride accumulation. Mice were injected with poloxamer 407 (P-407), a
detergent that inhibits lipoprotein lipase and triglyceride uptake in the periphery, and
serum triglycerides were monitored to determine if there was greater export of
triglycerides from livers lacking Akt2 (Millar et al., 2005). VLDL production secretion was
not dramatically altered in ob/ob mice, as has been previously reported, and loss of
hepatic Akt2 in ob/ob mice did not alter triglyceride levels (Figure 2-11) (Li et al., 1997;
Wiegman et al., 2003).

Acute excision of hepatic Akt2 results in a reversal of hepatic steatosis in ob/ob mice.
While genetic loss of hepatic Akt2 prevents the accumulation of hepatic
triglycerides in ob/ob mice, this could be due to a requirement of Akt2 either during liver
development or for the initiation of hepatic steatosis. Thus, we wanted to see if acute
deletion of Akt2 could reverse existing hepatic steatosis. Male Lepob/ob Akt2lox/lox mice
were injected with adeno-associated virus (AAV) expressing GFP (AAV-GFP) or Cre
(AAV-Cre) at approximately 10 weeks of age, an age at which ob/ob mice have already
developed hepatic steatosis, and sacrificed two week later under fed conditions. During
this time, Lepob/ob Akt2lox/lox mice injected with AAV-GFP exhibited a 14% increase in
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body weight, while those injected with AAV-Cre only gained approximately 4% (Figure 212A). AAV-Cre-injected mice had a significant reduction in liver weight and hepatic
triglyceride content to levels similar to those of Lepob/ob AFP;Akt2lox/lox mice (Figure 2-12B
and 2-12C compared with 2-6B and 2-6C). Serum triglycerides, NEFA, and ketones
were unchanged in mice injected with AAV-GFP versus AAV-Cre, but serum cholesterol
was decreased in those injected with AAV-Cre, again following the same pattern as
Lepob/ob AFP;Akt2lox/lox mice (Figure 2-12D to 2-12G compared with 2-8). These results
indicate that the ongoing presence of Akt2 is required to maintain hepatic steatosis.

Loss of hepatic Akt2 causes hepatic insulin resistance in lean mice, but does not worsen
glucose homeostasis or insulin tolerance in ob/ob mice.
As whole-body Akt2-/- mice exhibit hepatic and peripheral insulin resistance, we
wanted to determine if hepatic loss of Akt2 would lead to hepatic insulin resistance (Cho
et al., 2001a). Akt2lox/lox and AFP;Akt2lox/lox male mice were subjected to
hyperinsulinemic euglycemic clamp, and AFP;Akt2lox/lox mice had significantly lower GIR
than their Akt2lox/lox littermates, indicating that loss of hepatic Akt2 does indeed to lead to
insulin resistance (Figure 2-13A). While basal HGP was normal in AFP;Akt2lox/lox mice, it
was elevated under clamped conditions, showing that insulin’s suppression of hepatic
glucose production is impaired in the absence of hepatic Akt2. Additionally, loss of
hepatic Akt2 also causes peripheral insulin resistance as Rd was reduced in
AFP;Akt2lox/lox mice (Figure 2-13A).
Since loss of hepatic Akt2 leads to insulin resistance in lean mice, it is possible
that loss of Akt2 in the liver of ob/ob mice was leading to the severe diabetes seen in
Lepob/ob Akt2-/- mice. Lepob/ob AFP;Akt2lox/lox mice had slightly increased fasted serum
glucose levels compared with Lepob/ob Akt2lox/lox mice, and did exhibit slightly impaired
45

glucose tolerance by OGTT, but this was not nearly as severe as the glucose intolerance
of the Lepob/ob Akt2+/+ mice (Figure 2-13B and 2-13C). As observed above, Lepob/ob
Akt2lox/lox mice exhibited hyperinsulinemia to compensate for insulin resistance during
fasting and 15 minutes post oral glucose, and there was no difference due to loss of
hepatic Akt2 (Figure 2-13D). ITTs were performed, and at a dose of 1 Unit of insulin per
kilogram of body weight (1U/kg) in 10-week old mice, Lepob/ob AFP;Akt2lox/lox mice had
elevated glucose levels compared with Lepob/ob Akt2lox/lox mice, though neither group
responded to insulin injection by lowering their blood glucose levels (Figure 2-13E).
However, when an ITT was performed using 2U/kg insulin in 8-week old mice, both
Lepob/ob Akt2lox/lox and Lepob/ob AFP;Akt2lox/lox mice exhibited a glucose-lowering response
to insulin, even though basal glucose levels were lower initially in the younger mice
(Figure 2-13F). Consistent with the results of the clamp, AFP;Akt2lox/lox mice did exhibit
impaired insulin tolerance compared to Akt2lox/lox mice at both doses of insulin (Figure 213E and 2-13F). None of the effects observed could be attributed to the effects of AFP
Cre alone (Figure 2-14A, 2-14B, and 2-14C).

Loss of hepatic Akt2 decreases insulin signaling in lean mice, but does not change
downstream protein phosphorylation in ob/ob livers.
In order to gain insight into the pathways that could be mediating Akt2’s effect on
hepatic lipid metabolism, we performed Western blots on liver extracts from Akt2lox/lox
and AFP;Akt2lox/lox following intraperitoneal (IP) injection of saline or insulin (Figure 215A). Phosphorylation of Akt at residues S473 and T308 was increased in Akt2lox/lox
mice injected with insulin, and this increase was blunted in the absence of Akt2. The
same pattern held true for the phosphorylation of Proline-Rich Akt Substrate of 40kDa
(PRAS), GSK3β and phospho-tuberous sclerosis complex-2 (TSC2), while
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phosphorylation of FoxO1 did not appear to be decreased in the absence of hepatic
Akt2. Interestingly, phosphorylation of these Akt targets was increased under basal
fasted conditions in AFP;Akt2lox/loxmice, suggesting relief of a negative feedback loop in
the absence of Akt2 (Figure 2-15A). We also wanted to determine if loss of Akt2 had
significant effects on hepatic insulin signaling in ob/ob mice (Figure 2-15B). In order to
assess insulin signaling in both experimental groups in the presence of comparable
levels of insulin and glucose, Lepob/ob Akt2lox/lox and Lepob/ob AFP;Akt2loxlox mice were
submitted to a hyperinsulinemic euglycemic clamp and liver extracts were prepared.
Insulin signaling was significantly impaired in the insulin-resistant ob/ob mice, such that
phosphorylation of Akt and its targets was significantly below stimulated conditions in
Akt2lox/lox animals; moreover, loss of hepatic Akt2 did not reduce protein phosphorylation
further (Figure 2-15B).

Discussion
In order to determine if Akt2 was involved in the development of pathological lipid
accumulation, we crossed Akt2-/- mice to ob/ob mice. These mice are frequently used as
a model of obesity and hepatic steatosis, and have decreased energy expenditure and
hyperphagy, leading to excessive nutrient intake, increased adiposity, hyperglycemia,
hyperinsulinemia, and insulin resistance (Bray and York, 1979). In addition to increased
substrate for hepatic triglycerides from esterification of dietary and adipose fatty acids,
these mice also have increased lipogenic gene expression and increased rates of
lipogenesis, all likely contributing to excess lipid accumulation (Shimomura et al., 1999a;
Wiegman et al., 2003). In the absence of Akt2, ob/ob mice failed to develop hepatic
steatosis or exhibit increased de novo lipogenesis (Figure 2-1). However, as the Lepob/ob
Akt2-/- mice were smaller and substantially more diabetic than Lepob/ob mice, we moved
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to liver-specific Akt2 null mice with the intent to determine the role of hepatic Akt2
without potential complications from the loss of Akt2 in extrahepatic tissues. Similar to
ob/ob mice with whole-body loss of Akt2, Lepob/ob AFP;Akt2lox/lox mice had a dramatic
reduction in both de novo lipogenesis and hepatic triglyceride accumulation (Figure 2-6).
Emphasizing the importance of Akt2 for the development of hepatic steatosis, there was
an intermediate decrease in hepatic triglycerides in the Lepob/ob Akt2+/- mouse,
suggesting that Akt2 is not only required for this process but is rate-limiting. In addition,
acute excision of hepatic Akt2 from the livers of Lepob/ob Akt2lox/lox mice by AAV-Cre
reversed existing steatosis, indicating that the ongoing presence of Akt2 is required for
this process.
As for the mechanism of decreased lipogenesis in the Lepob/ob AFP;Akt2lox/lox
mice, our data suggest that Akt2 is required for the upregulation of lipogenic gene
expression in the ob/ob mouse. It has been reported that insulin increases SREBP1c
expression through Akt in cell lines and primary hepatocytes, though Akt never been
shown to do so in vivo (Fleischmann and Iynedjian, 2000; Porstmann et al., 2005). In
the absence of Akt2, the expression of SREBP1c, and its targets, SCD-1, FAS, ACC,
ACL, GPAT, and GCK, failed to increase in the ob/ob liver (Figure 2-10). Interestingly,
while we did not observe any changes in ChREBP expression in Lepob/ob AFP;Akt2lox/lox
mice, the induction of L-PK expression was blocked in ob/ob mice with loss of hepatic
Akt2, suggesting an influence on lipogenesis beyond the control of SREBP1c expression
in these mice.
While the decrease in de novo lipogenesis correlates with the reversal of hepatic
steatosis in Lepob/ob AFP;Akt2lox/lox mice, it does not exclude a role for Akt2 in the
regulation of another aspect of lipid metabolism. PGC-1α regulates fatty acid oxidation
in the liver, and our lab has previously reported that Akt phosphorylates and inactivates
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PGC-1α, thus impairing its ability to promote fatty acid oxidation, establishing a
connection between Akt and β-oxidation (Li et al., 2007). Indeed, PGC-1α was
significantly upregulated in Lepob/ob AFP;Akt2lox/lox livers (Figure 2-10); however,
expression of MCAD and CPT1, transcriptional targets of PGC-1α, was not increased in
Lepob/ob AFP; Akt2lox/lox compared with Lepob/ob Akt2lox/lox livers (Schreiber et al., 2003;
Song et al., 2004). Additionally, serum ketones and RER were not changed in these
mice (Figure 2-7C and 2-8D).
Another potential pathway that could contribute to decreased hepatic triglyceride
accumulation is triglyceride export from the liver. Lepob/ob Akt2-/- mice had elevated
serum triglyceride levels, suggesting that increased in triglyceride export could decrease
hepatic triglycerides by shunting them into the serum (Figure 2-2A). However in Lepob/ob
AFP;Akt2lox/lox mice, fed serum triglyceride levels did not differ from Lepob/ob Akt2lox/lox
mice, and fasted serum triglycerides were actually lower (Figure 2-8A). Furthermore, a
triglyceride export assay using P-407 showed similar serum triglyceride levels in ob/ob
mice with and without hepatic Akt2 (Figure 2-11). These observations suggest that
increased triglyceride export does not play a role in reducing hepatic triglyceride
accumulation in the absence of Akt2 in the liver. It is possible the increase in serum
triglycerides observed in the Lepob/ob Akt2-/- mice is due to loss of Akt2 in an extrahepatic
tissue, such as adipose tissue, or, alternatively, secondary to worsened glucose
homeostasis.
As shown in Figure 2-3 and 2-4, deletion of Akt2 on an ob/ob background
resulted in fasting hyperglycemia, glucose intolerance and insulin resistance
considerably more severe than that in mice lacking either Akt2 or leptin. Hepatic
glucose production was increased under both basal and clamped conditions in Lepob/ob
Akt2-/- mice, while Rd of glucose into the periphery was unchanged, indicating that the
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insulin resistance resulting from loss of Akt2 on an ob/ob background is more
pronounced in the liver. However, deletion of hepatic Akt2 from ob/ob mice did not
further contribute to diabetes as measured by OGTT and ITT, showing that the absence
of hepatic Akt2 alone is not driving the severity of the diabetes in Lepob/ob Akt2-/- mice
(Figure 2-13). Some of the difference may be due to genetic background as the wholebody Akt2 null mice are C57BL/6J and the liver-specific Akt2 null mice are mixed; it has
been shown that the severity of the insulin resistance and development of diabetes in
ob/ob mice is strain-dependent (Haluzik et al., 2004). Nevertheless, hepatic Akt2 is
required for normal insulin sensitivity in a lean liver as AFP;Akt2lox/lox mice have
decreased GIR and suppression of HGP by clamp (Figure 2-13A).
Likely reflective of their severe diabetes and resulting inability to normally store
nutrients, Lepob/ob Akt2-/- mice exhibited a decrease in both lean and fat mass by weight
(Figure 2-4B). These mice almost certainly have glycosuria, which likely contributes to
caloric loss and reduction in body size in these mice. However, the reduction in
adiposity does not appear to be due entirely to the severely diabetic and catabolic state
of these animals as Lepob/ob Akt2+/- mice exhibited an intermediate reduction in adiposity
without a decrease in lean mass. However, whether this specific reduction in adiposity
is due to heterozygote loss of Akt2 in a single tissue, specifically adipose tissue, or in the
whole animal is unknown. Surprisingly, Lepob/ob AFP;Akt2lox/lox mice also exhibited a
reduction in body weight compared with Lepob/ob Akt2lox/lox mice, but this reduction was
due to an overall decrease in body size as both lean and fat mass were reduced
proportionally and food intake was unaffected (Figure 2-7). This non-autonomous effect
on body size does not appear to be developmental, as mature Lepob/ob Akt2lox/lox mice
gain less weight following acute excision of hepatic Akt2 (Figure 2-12).
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Chapter 2 Figures
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Figure 2-1: Deletion of Akt2 in ob/ob mice results in decreased hepatic
triglycerides and de novo lipogenesis.
A,B. Body weight (A) and liver weight (B) of 12-week old fed male mice.
C,D. Hepatic triglyceride (TG) levels of 12-week old fed (C) and overnight fasted (D)
male mice.
E. De novo lipogenesis: 12 week-old male mice were injected with D2O after a 5 hour
fast, sacrificed after 3 hours, and liver was removed and analyzed for palmitate by
GC/MS.
All values are expressed as mean ± SEM. n=5-6; *p<0.05 vs Lep+/+;Akt2+/+ and **p<0.05
vs Lepob/ob;Akt2+/+ by one-way ANOVA using Newman-Keuls post-test.
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Figure 2-2: Serum measurements of Lepob/ob Akt2-/- mice.
Serum triglycerides (TG) (A), cholesterol (CH) (B), non-esterified fatty acids (NEFA) (C),
and ketones (D) from 12 week-old fed (left) and overnight fasted (right) male mice.
All values are expressed as mean ± SEM. n=6; *p<0.05 vs Lep+/+;Akt2+/+ and **p<0.05
vs Lepob/ob;Akt2+/+ by one-way ANOVA using Newman-Keuls post-test.
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Figure 2-3: Lepob/ob Akt2-/- mice are severely diabetic.
A-C. Fasted blood glucose levels (A) at start of 1g/kg oral glucose tolerance test (OGTT)
(B) and insulin levels (C) at the start and 15 minutes post glucose load in 8-week old
overnight fasted male mice. n=5-6.
D,E. Insulin tolerance tests (ITT) in 5-hour fasted male mice: 1 unit insulin/kg
intraperitoneally (IP) at 10 weeks of age (D) and 2 units insulin/kg subcutaneously
(subcu) at 8 weeks of age (E). n=3-9.
All values are expressed as mean ± SEM; *p<0.05 vs Lep+/+;Akt2+/+ and **p<0.05 vs
Lepob/ob;Akt2+/+ by one-way ANOVA using Newman-Keuls post-test.
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Figure 2-4: Lepob/ob Akt2-/- mice exhibit severe hepatic insulin resistance and
decreased adiposity.
A. Hyperinsulinemic euglycemic clamp of 250mU insulin/kg/min on approximately 8week old male mice. Glucose infusion rate (GIR), basal and clamped hepatic glucose
production (HGP) and rate of disposal (Rd) are shown. n=4; *p<0.01 by Student’s t-test.
B. Body composition of 12 week-old male mice calculated from D2O injections expressed
as mass by gram (left) and percentage of body weight (right). n=5-6; *p<0.05 vs
Lep+/+;Akt2+/+ and **p<0.05 vs Lepob/ob;Akt2+/+ for by one-way ANOVA using NewmanKeuls post-test.
All values are expressed as mean ± SEM.
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Figure 2-5: AFP;Akt2lox/lox mice lack Akt2 in the liver without change in Akt1.
A. Western blot of Akt1, Akt2, and actin from hepatic lysates from Akt2lox/lox,
AFP;Akt2lox/lox, Lepob/ob Akt2lox/lox, Lepob/ob AFP;Akt2lox/lox, germline Akt2-/- and Akt1-/- mice.
Each lane represents an individual mouse, and all samples were run on the same gel.
B. Western blot of Akt2 and tubulin from tissue lysates as indicated from Akt2lox/lox,
AFP;Akt2lox/lox, and whole-body Akt2-/- mice. Each lane represents an individual mouse.
Abbreviations: Mus (muscle), WAT (white adipose tissue), Panc (pancreas), Kid
(kidney), Spn (spleen). The arrow indicates Akt2; in some tissues there is a slightly more
mobile non-specific band.
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Figure 2-6: Lepob/ob AFP;Akt2lox/lox mice have decreased hepatic triglyceride levels,
which correlate with a decrease in de novo lipogenesis.
A,B. Body weight (A) and liver weight (B) of 12-week old fed male mice. n=6-8.
C,D. Hepatic triglyceride (TG) levels of 12-week old fed (C) and overnight fasted (D)
male mice. n=6-9.
E. Hepatic long-chain fatty acid CoA (LLCoA) concentrations from 12 week-old overnight
fasted male mice. n=3-4.
F. De novo lipogenesis measured as in Figure 2-1. n=5-6.
All values are expressed as mean ± SEM. *p<0.05 vs Lep+/+;Akt2lox/lox and **p<0.05 vs
Lepob/ob;Akt2lox/lox by one-way ANOVA using Newman-Keuls post-test.
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Figure 2-7: Lepob/ob AFP;Akt2lox/lox mice have decreased body weight and a
proportional decrease in body fat content without detectable changes in energy
expenditure or food intake.
A. Body composition of 12 week-old male mice.
B. 24-hour food intake of 12 week-old male mice.
C. 24-hour respiratory exchange ratio (RER) of 12 week-old male mice.
All values are expressed as mean ± SEM. n=5; *p<0.05 vs Lep+/+;Akt2lox/lox and **p<0.05
vs Lepob/ob;Akt2lox/lox by one-way ANOVA using Newman-Keuls post-test.
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Figure 2-8: Serum measurements of Lepob/ob AFP;Akt2lox/lox mice.
Serum triglycerides (TG) (A), cholesterol (CH) (B), non-esterified fatty acids (NEFA) (C),
and ketones (D) from 12 week-old fed (left) and overnight fasted (right) male mice.
All values are expressed as mean ± SEM. n=6-9; *p<0.05 vs Lep+/+;Akt2lox/lox and
**p<0.05 vs Lepob/ob;Akt2lox/lox by one-way ANOVA using Newman-Keuls post-test.
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Figure 2-9: AFP Cre alone does not affect body weight, liver weight, hepatic
triglycerides or serum measurements in ob/ob mice.
All mice are 12-week old male Lepob/ob mice.
A,B. Body weight (A) and liver weight (B).
Hepatic triglycerides (TG) (C), serum triglycerides (D), serum cholesterol (CH) (E),
serum non-esterified fatty acids (NEFA) (F), and serum ketones (G) in fed and overnight
fasted mice as indicated.
All values are expressed as mean ± SEM. n=5-7; no points are significantly different to
any others within conditions (p<0.05 by one-way ANOVA using Newman-Keuls posttest).
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Figure 2-10: Hepatic gene expression in Lepob/ob AFP;Akt2lox/lox mice.
Hepatic gene expression as measured by Real-Time PCR of 12 week-old fed male mice.
Data are presented as mRNA expression relative to that of TATA binding-protein and
normalized to expression in Akt2lox/lox, which is set to 1.0 using the ddCt method.
All values are expressed as mean ± SEM. n=6; *p<0.05 vs Lep+/+;Akt2lox/lox and **p<0.05
vs Lepob/ob;Akt2lox/lox by one-way ANOVA using Newman-Keuls post-test.

Abbreviations: sterol regulatory element binding protein-1c (SREBP1c), stearoyl-CoA
desaturase-1 (SCD1), fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), ATP
citrate lyase (ACL), glycerol phosphate acyltransferase (GPAT), glucokinase (GCK),
carbohydrate regulatory-element binding protein (ChREBP), pyruvate kinase, liver
isoform (L-PK), peroxisome proliferator-activated receptor- γ (PPARγ ), peroxisome
proliferators-activated receptor-coactivator 1α (PGC-1α), carnitine palmitoyltransferase I
(CPT1), medium-chain acetyl-CoA dehydrogenase (MCAD), and cytochrome c oxidase
subunit 7a (Cox7a).
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Figure 2-11: Loss of hepatic Akt2 does not dramatically alter triglyceride secretion
in lean or ob/ob mice.
12-week old male mice were intraperitoneally (IP) injected with 100µl 10% poloxamer
407 (P-407) per 10 grams body weight after a 5-hour fast and serum triglycerides were
measured by tail bleed at 0, 1, 2, and 4 hours after injection.
Area under the curve calculated using Graphpad Prism.
All values are expressed as mean ± SEM. n=6-9; no points are significantly different to
others (p<0.05 by one-way ANOVA using Newman-Keuls post-test).
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Figure 2-12: Acute excision of Akt2 reverses hepatic steatosis in ob/ob mice.
Male Lepob/ob Akt2lox/lox mice were injected retro-orbitally with AAV-GFP or AAV-Cre at
approximately 10 weeks of age, and were sacrificed under fed conditions 2 weeks later.
A. Body weight at time of injection and at time of sacrifice (left) and percentage change
in body weight (BW) from the time of injection to sacrifice (right).
B,C. Liver weight (B) and hepatic triglycerides (TG).
D-G. Serum triglycerides (TG) (D), cholesterol (CH) (E), non-esterified fatty acids
(NEFA) (F), and ketones (G).
All values are expressed as mean ± SEM. n=4; *p<0.01 by Student’s t-test.

74

75

Figure 2-13: Loss of hepatic Akt2 causes hepatic insulin resistance in lean mice,
but does not further worsen diabetes of ob/ob mice.
A. Hyperinsulinemic euglycemic clamp of 2.5mU insulin/kg/min on 8-week old male
mice. Glucose infusion rate (GIR), basal and clamped hepatic glucose production (HGP)
and rate of disposal (Rd) shown. n=4; *p<0.01 by Student’s t-test.
B-D. Fasted blood glucose levels (B) at start of 1g/kg oral glucose tolerance test (OGTT)
(C) and insulin levels (D) at the start and 15 minutes post glucose load in 8-week old
overnight fasted male mice. n=6-9; *p<0.05 vs Lep+/+;Akt2lox/lox and **p<0.05 vs
Lepob/ob;Akt2lox/lox by one-way ANOVA using Newman-Keuls post-test.
E-F. Insulin tolerance test (ITT) in 5-hour fasted male mice: 1 unit insulin/kg
intraperitoneally (IP) at 10 weeks of age (E) and 2 units insulin/kg subcutaneously
(subcu) at 8 weeks of age (F). n=4-9; *p<0.05 vs Lep+/+;Akt2lox/lox and **p<0.05 vs
Lepob/ob;Akt2lox/lox by one-way ANOVA using Newman-Keuls post-test.
All values are expressed as mean ± SEM.
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Figure 2-14: AFP Cre alone has no effect on GTT or ITT in lean or ob/ob mice.
A, B. Fasted blood glucose levels (A) at start of 1g/kg oral glucose tolerance test (OGTT)
(B) in 8-week old overnight fasted male mice.
C. 1 unit insulin/kg intraperitoneally (IP) insulin tolerance test (ITT) in 10-week old 5-hour
fasted male mice.
All values are expressed as mean ± SEM. n=5-9; no points are significantly different to
any others (p<0.05 by one-way ANOVA using Newman-Keuls post-test).

78

79

Figure 2-15: Hepatic insulin signaling is blunted by loss of Akt2 in the liver in lean
mice, but not in ob/ob mice.
A. Western blot of phospho-Akt (p473 and p308) and downstream signaling targets in
hepatic lysates from Akt2lox/lox and AFP;Akt2lox/lox mice. 8-week old male mice were
fasted overnight and injected IP with either saline or 1U/kg insulin, then sacrificed after
20 minutes.
B. Western blot of phospho-Akt (p473 and p308) and downstream signaling targets in
hepatic lysates from 8-10 week old male Lepob/ob;Akt2lox/lox and Lepob/ob AFP;Akt2lox/lox
mice under hyperinsulinemic euglycemic clamp conditions. Akt2lox/lox mice injected with
saline or insulin as in A are included for comparison.
Each lane represents an individual mouse. Loading controls are included when the
phospho-protein and total protein were run on different gels, though the same protein
extracts were used. The arrow indicates Akt2 as there is a slightly more mobile nonspecific band.
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Chapter 3:

Akt2 is required for the development of hepatic steatosis
resulting from diet-induced obesity.
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Introduction
We have shown that hepatic Akt2 is required for the development of hepatic
steatosis and increased de novo lipogenesis that occurs in the ob/ob mouse (Chapter 2).
However, though the ob/ob mouse is a robust model of obesity and hepatic steatosis,
these mice lack leptin, which itself plays a role in metabolism. Thus we wanted to test
the generality of the requirement of Akt2 for hepatic steatosis in another insulin-resistant
model of obesity, diet-induced obesity (DIO). High-fat diets (HFD) are commonly used
to induce obesity and diabetes in mice, and may be more physiologically similar to
human obesity than genetic manipulations (reviewed in Collins et al., 2004). The use of
HFD is advantageous as the onset of obesity and insulin resistance is gradual and often
less severe than genetic causes of obesity. However, these effects are strongly
influenced by genetic background and may not be solely dependent on excess energy
intake (Rebuffe-Scrive et al., 1993; West et al., 1992). In addition, the majority of dietary
fat in a HFD comes from a single source unlike human diets, and the particular type of
fat used in the diet influences the severity of resulting insulin resistance (Buettner et al.,
2006).
The Surwit HFD, originally defined in the 1980s by Richard Surwit, is both high in
fat and sucrose, and rapidly induces obesity and insulin resistance in C57BL/6J mice
(Surwit et al., 1988). The combination of high fat, high simple carbohydrate and low fiber
resembles the type of diet that is likely a major factor in the growing prevalence of
human obesity. Surwit HFD is extremely palatable to mice, resulting in hyperphagia and
increased calorie intake (Surwit et al., 1995; Surwit et al., 1988). However, C57BL/6J
mice still gain weight and exhibit hyperglycemia after 3 months on Surwit HFD when
restricted to the same caloric intake as the control group (Petro et al., 2004). Both the
obesity and diabetes can be reverse if the animals are taken off the diet and switched to
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one low in fat and sucrose (Parekh et al., 1998). However, all of these effects are
heavily influenced by background strain, emphasizing how complex inherited traits
interact with environmental conditions. While C57BL/6J mice are very susceptible to
DIO and diabetes on Surwit HFD, other strains, in particular A/J mice, are resistant
(Black et al., 1998; Parekh et al., 1998; Surwit et al., 1995). This dependency on strain
holds true with other high fat diets as well (West et al., 1992).
In this chapter, we describe the role of hepatic Akt2 in the development of
hepatic steatosis resulting from DIO. For these studies, we used a Surwit HFD
containing 58% kcal from fat (mostly coconut oil) and 25.5% kcal from carbohydrates
(approximately half from sucrose) and a lard-based HFD containing 60% kcal from fat
and 20% kcal from carbohydrates (approximately one-third from sucrose). HFDs
containing either coconut oil or lard have been shown to increase the hepatic expression
of SREBP1c and its lipogeneic target genes in rats (Buettner et al., 2006). We find that
hepatic Akt2 is required for the accumulation of hepatic triglycerides in DIO, but this
does not correspond to a decrease in de novo lipogenesis or lipogenic gene expression.
Furthermore, lipogenic gene expression does not correlate with lipogenesis in mice fed
either HFD, and mice fed lard HFD actually have decreased de novo lipogenesis while
exhibiting hepatic steatosis. However, while loss of hepatic Akt2 does not significantly
alter the diabetic phenotype of the Surwit HFD-fed mouse, Akt2-/- mice on Surwit HFD
fail to gain weight but are more insulin-resistant compared with Akt2+/+ mice.

Results
Germline Akt2 deletion decreases hepatic lipid accumulation resulting from Surwit HFD.
Male Akt2+/+ and Akt2-/- mice were started on a Surwit HFD at approximately 5
weeks of age, and maintained on the diet for one or 4 months; chow-fed age-matched
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male mice served as controls (for composition of Surwit HFD, see Table 6-3 in Materials
and Methods). Mice on Surwit HFD steadily gained weight over time, but this increase
was blunted in Akt2-/- mice, so that the weights of the two groups bifurcated during their
second month on the diet (Figure 3-1A). This was not due to differences in food intake,
as Akt2-/- mice actually ate more than their Akt2+/+ littermates, or to significantly altered
energy expenditure, as measured after 4 months on Surwit HFD (Figure 3-1B and 3-1C).
The decrease in body weight of the Akt2-/- mice after 4 months on Surwit HFD could be
attributed to a significant decrease in fat mass while maintaining normal lean mass by
weight (Figure 3-1D).
After 4 months on Surwit diet, Akt2+/+ mice gained more weight than their chowfed counterparts, while Akt2-/- mice on HFD weighed the same as those on chow (Figure
3-2A). Though liver weight was not significantly different between any of the groups
(Figure 3-2B), the increase in fed hepatic triglycerides observed in Akt2+/+ mice after 4
months on the diet was abrogated with loss of Akt2 (Figures 3-2C and 3-2D).
Interestingly, Akt2-/- mice on Surwit HFD for 4 months had significantly reduced fasted
hepatic triglycerides compared with chow-fed Akt2-/- mice (Figure 3-2D). Germline
deletion of Akt2 did not change serum triglyceride levels on Surwit HFD, but did lead to a
decrease in fed serum cholesterol, fasted serum NEFA and serum ketones after 4
months on the diet (Figure 3-3A, 3-3B, 3-3C and 3-3D).

Akt2-/- mice are more insulin-resistant but maintain normal glucose tolerance by
increasing insulin levels on Surwit HFD.
Akt2-/- mice display hepatic and peripheral insulin resistance, and have impaired
glucose tolerance and hyperinsulinemia at a young age (Cho et al., 2001a). Thus, we
wanted to see if the stress of a Surwit HFD would increase these glucose metabolic
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impairments. Akt2-/- mice on chow did display fasting hyperglycemia, hyperinsulinemia
and glucose intolerance compared with Akt2+/+ mice at 2 months of age (one month on
diet), but these differences were largely resolved by 5 months of age (4 months on diet)
(Figures 3-4A to 3-4E). Similarly, after 4 months on Surwit HFD, Akt2-/- mice exhibited
normal glucose tolerance compared with Akt2+/+ mice, and actually had normal fasting
glucose levels while Akt2+/+ mice were hyperglycemic (Figures 3-4A, 3-4D). Akt2-/- mice
on Surwit HFD eventually exhibited improved glucose tolerance compared with Akt2+/+
mice on Surwit HFD likely due to increased compensation by the pancreatic β-cells (see
Addendum). These effects did not appear to be the result of improved insulin sensitivity
on Surwit HFD as fasted and post-glucose load insulin levels were higher in Akt2-/versus Akt2+/+ mice both after one and 4 months on Surwit HFD (Figures 3-4C and 34E).
To determine if Akt2-/- mice are more insulin-resistant than Akt2+/+ mice on Surwit
HFD, these mice were subjected to hyperinsulinemic euglycemic clamp; age-matched
chow-fed Akt2-/- mice were also included to determine the contribution of HFD-feeding.
After 6 weeks on Surwit HFD, Akt2-/- mice required a significantly lower GIR to maintain
euglycemia than their Akt2+/+ counterparts, confirming that though they had similar
glucose tolerance, they were more insulin-resistant (Figure 3-4F). While basal HGP was
similar, clamped HGP was increased in Akt2-/- mice on HFD compared with both Akt2+/+
mice on HFD and Akt2-/- mice on chow, indicating that both Surwit HFD-feeding and loss
of Akt2 leads to hepatic insulin resistance. Rd was also significantly decreased in Akt2-/versus Akt2+/+ mice on Surwit HFD, showing that Akt2-/- mice had peripheral insulin
resistance despite gaining less fat mass on HFD. However, as GIR and Rd were similar
in Akt2-/- mice on Surwit HFD and chow, this increase in peripheral insulin resistance
was likely due to loss of Akt2 in peripheral tissue Figure 3-4F).
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AFP;Akt2lox/lox mice display decreased hepatic triglycerides on Surwit HFD without
significant changes in de novo lipogenesis or lipogenic gene expression.
As in the previous ob/ob experiments, we wanted to determine if the requirement
for Akt2 in hepatic triglyceride accumulation resulting from Surwit HFD was cellautonomous. Starting at approximately 5 weeks of age, we fed male AFP;Akt2lox/lox mice
Surwit HFD for one or 4 months and used chow-fed age-matched male mice as controls.
During this period, there were no differences in the weight gained on Surwit HFD
between Akt2lox/lox mice and AFP;Akt2lox/lox mice or in liver weight between any of the
groups (Figure 3-5A, 3-5B, and 3-6A). AFP;Akt2lox/lox mice did not differ from Akt2lox/lox
mice with regards to food intake, energy expenditure, or body composition (Figures 36B, 3-6C, and 3-6D). After one month on Surwit HFD, Akt2lox/lox mice had significantly
increased fed hepatic triglyceride levels compared to their chow-fed counterparts, an
effect that was partially ameliorated by loss of hepatic Akt2 (Figure 3-5C). This
difference could not be attributed to an effect of AFP Cre alone (Figure 3-8). The same
held true after 4 months on Surwit HFD, as the 4-fold increase in fed hepatic
triglycerides in Akt2lox/lox mice was reduced by approximately 25% with loss of hepatic
Akt2. Total long chain fatty acyl-CoA and linoleoyl-CoA (C18:2) were decreased in livers
from mice on Surwit HFD, as the latter is an essential fatty acid and its abundance is
relatively low in coconut oil, the major source of fat in the Surwit diet. However, there
were no differences between mice having or lacking hepatic Akt2 (Figure 3-5D). While
there were no differences in serum triglycerides, fed serum cholesterol was increased
after 4 months and NEFA were increased after both one and 4 months on HFD in mice
with or without Akt2 in the liver (Figure 3-7A to 3-7C and 3-7E to 3-7G).
While there was a significant increase in de novo lipogenesis in livers from mice
on a Surwit HFD, this was not prevented by deletion of Akt2 (Figure 3-5E). Lipogenic
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gene expression paralleled this finding, as there was no decrease in hepatic expression
of SREBP-1c or its targets in AFP;Akt2lox/lox fed Surwit HFD for one month; in fact there
was a slight increase in SREBP1c, FAS, ACC and L-PK expression (Figure 3-9).
However, only SCD1 showed a significant increase in livers from Akt2lox/lox mice on Surwit
HFD compared chow-fed animals. Additionally, there were no changes in the
expression of PGC-1α, CPT-1, MCAD, or Cox7a in the AFP:Akt2lox/lox livers (Figure 3-9).
Though fed and fasted serum ketones were similar at one month, fed levels were slightly
elevated after 4 months in AFP;Akt2lox/lox mice compared with Akt2lox/lox mice on Surwit
HFD (Figure 3-7D and 3-7H). Nonetheless, β-oxidation in Surwit HFD-fed mice did not
appear to be significantly altered by loss of hepatic Akt2 as RER was unchanged (Figure
3-6C). As neither de novo lipogenesis nor fatty acid oxidation appeared to be changed
in AFP;Akt2lox/lox mice on Surwit HFD, we wanted to determine if triglyceride secretion
could be responsible for the reduction in hepatic triglyceride accumulation. However,
triglyceride secretion from the liver did not appear to be altered in mice fed Surwit HFD
for 4 months or lacking hepatic Akt2 as measured by serum triglyceride accumulation
following P-407 injection (Figure 3-10).

Loss of hepatic Akt2 does not impair glucose tolerance or insulin sensitivity on Surwit
HFD.
As described in Chapter 2, loss of hepatic Akt2 results in both hepatic and
peripheral insulin resistance in lean mice but does not seem to further progress the
diabetic phenotype of the ob/ob mouse (Figure 2-12). Thus, we wondered if loss of
hepatic Akt2 in mice on Surwit HFD would have an effect on glucose tolerance and
insulin resistance. Male mice were subjected to GTT after 4 months on Surwit HFD;
age-matched chow-fed male mice were used as controls. Though mice on Surwit HFD
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did not exhibit fasting hyperglycemia, they did have impaired glucose tolerance; loss of
hepatic Akt2 did not have an effect (Figure 3-11A and 3-11B). Chow-fed AFP;Akt2lox/lox
mice trended towards increased fasting insulin levels, and there was a trend for Surwit
HFD insulin levels at fasting and 15 minutes post-glucose load to be increased above
Akt2lox/lox chow levels; however, none of these differences were significant (Figure 311C). In order to measure insulin sensitivity, Akt2lox/lox and AFP;Akt2lox/lox mice were
subjected to hyperinsulinemic euglycemic clamp after 4 months on Surwit HFD. There
were no differences in GIR, HGP or Rd between the 2 sets of mice, indicating that loss
of hepatic Akt2 does not lead to further insulin resistance in Surwit HFD-fed animals
(Figure 3-11D).

Loss of hepatic Akt2 does not change downstream protein phosphorylation in insulinresistant Surwit HFD-fed livers.
In order to gain insight into the pathways that could be mediating the decrease in
hepatic triglycerides observed in AFP;Akt2lox/lox mice fed Surwit HFD, we wanted to
determine if loss of Akt2 had significant effects on hepatic insulin signaling in HFD-fed
mice by Western blots (Figure 3-12). As glucose and insulin levels did not differ
between Akt2lox/lox and AFP;Akt2lox/lox after one month on a Surwit HFD, liver extracts
were made from these animals under fed conditions. Unfortunately, insulin signaling
was significantly impaired due to the insulin resistance caused by HFD-feeding, such
that phosphorylation of Akt and its targets was significantly below stimulated conditions
in Akt2lox/lox animals; moreover, loss of hepatic Akt2 did not reduce protein
phosphorylation further (Figure 3-12).

AFP;Akt2lox/lox mice display decreased hepatic steatosis with lard HFD-feeding.
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Given the differences in phenotype between mice deficient for leptin and those
fed a Surwit HFD, we tested the generality of the requirement for Akt2 in hepatic
steatosis by feeding male AFP;Akt2lox/lox mice another commonly used HFD, one
enriched in fat from lard (60% kcal from fat) with a mixture of both starch and sucrose
(20% kcal from carbohydrates) (for composition of lard HFD, see Table 6-4 in Materials
and Methods). After one month on the lard HFD, there was an increase in hepatic
triglycerides in Akt2lox/lox mice, which was ameliorated by loss of hepatic Akt2 (Figure 313A). However, this increase in hepatic triglyceride caused by lard HFD-feeding did not
correlate with an increase in de novo lipogenesis; in fact, lipogenesis was significantly
reduced in lard HFD-fed animals and loss of hepatic Akt2 did not reduce it further
(Figure 3-13B). This differs dramatically from Surwit HFD-fed animals, which exhibited
an increase in de novo lipogenesis after both one and 4 months on HFD (Figure 3-5E).
However, in both HFDs, there was a lack of correlation between de novo lipogenesis
and hepatic lipogenic gene expression. While there was an increase in lipogenesis but
no change in gene expression during Surwit HFD, there was a significant increase in
SREBP-1c expression in the livers of Akt2lox/lox mice after one month on lard HFD even
though lipogenesis was actually decreased (Figure 3-13C). This increase was
significantly reduced in AFP;Akt2lox/lox mice, though other lipogenic genes were not
changed in lard HFD-fed animals. Nonetheless, these data again show clearly that
hepatic Akt2 is required for hepatic lipid accumulation ensuing from HFD-feeding.
As AFP;Akt2lox/lox mice did not exhibit increased hepatic triglyceride accumulation
after one month on lard HFD, we wanted to determine if acute excision of hepatic Akt2
could reverse existing triglyceride accumulation from lard HFD. Therefore we fed male
Akt2lox/lox mice lard HFD for one month; one group of age-matched Akt2lox/lox mice were
maintained on chow as a control. After one month, one group of lard HFD-fed mice
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were sacrificed while the others were injected with either AAV-GFP or AAV-Cre and kept
on lard HFD for another month; chow-fed mice were injected with AAV-GFP and all
AAV-injected mice were sacrificed one month later. There was a significant increase in
the body weight of mice on lard HFD after two versus one month or compared with
chow-fed animals; there was no effect of loss of hepatic Akt2 (Figure 3-14A). Mice
injected with AAV-GFP on lard HFD for 2 months had increased liver weight compared
with those fed lard HFD for one month, though their liver weight was decreased
compared with chow-fed control mice (Figure 3-14B). Mice injected with AAV-Cre had
decreased liver weight compared to those injected with AAV-GFP after 2 months of lard
HFD, but exhibited similar liver weights to mice after one month of lard HFD (Figure 314B). Akt2lox/lox mice with AAV-GFP had hepatic steatosis after 2 months on lard HFD
compared with chow-fed mice, and there was an increase in triglyceride accumulation
from one month to two months on the HFD (Figure 3-14C). Akt2lox/lox mice injected with
AAV-Cre had significantly reduced hepatic triglycerides after 2 month on lard HFD, but
had levels similar to those in mice after one month on lard HFD (Figure 3-14C). This
indicated that acute loss of Akt2 could ameliorate hepatic triglyceride accumulation but
could not completely prevent hepatic steatosis. Serum triglycerides did not vary, but
serum cholesterol was increased in all mice fed lard HFD and was partially decreased
with loss of hepatic Akt2 (Figure 3-14D and 3-14E).

Discussion
As leptin signaling itself can influence metabolism, we wanted to determine if the
effect of Akt2 on lipid metabolism depended on the absence of leptin; therefore, we
choose two DIO models to test the role of Akt2 in another insulin-resistant context. In
animals fed a Surwit HFD, loss of hepatic Akt2 significantly decreased hepatic
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triglyceride accumulation, though it did not result in a complete reversal as in ob/ob
mice. Surprisingly, it appears that Akt2 is required for lipid accumulation on Surwit HFD
through a completely different mechanism than in the ob/ob mice as the increase in
lipogenesis on Surwit HFD was not attenuated by loss of hepatic Akt2 (Figure 3-5).
However, unlike ob/ob mice, the increase in lipogenesis did not correspond to an
increase in hepatic SREBP1c or lipogenic gene expression, with the exception of SCD1,
suggesting that Surwit HFD induces an increase in lipogenesis that is independent of
lipogenic gene expression (Figure 3-9). Furthermore, some gene expression, such as
SREBP1c, FAS, ACC, and L-PK was actually increased in AFP;Akt2lox/lox compared with
Akt2lox/lox mice on Surwit HFD, suggesting that the decrease in lipid accumulation due to
loss of Akt2 stimulated a compensatory upregulation of lipogenic genes.
To confirm these findings in another HFD model, we fed mice a lard-based HFD,
and once again found that loss of hepatic Akt2 significantly decreased hepatic
triglyceride accumulation and that this did not correlate with changes in lipogenesis
(Figure 3-13). However, unlike mice fed Surwit HFD, those fed lard HFD actually
exhibited decreased de novo lipogenesis and loss of hepatic Akt2 did not decrease this
further. Despite having decreased lipogenesis, Akt2lox/lox animals on lard HFD had
increased hepatic SREBP1c expression that was reversed with loss of hepatic Akt2,
though there were not significant changes in the expression of the other lipogenic genes
that were measured (Figure 3-13).
A general question in the development of hepatic steatosis is why would a liver
with existing triglyceride accumulation synthesize additional lipid (Tamura and
Shimomura, 2005). For example, hyperinsulinemic obese humans have higher rates of
de novo lipogenesis on HFD than normoinsulinemic lean individuals (Schwarz et al.,
2003). Additionally, HFD-feeding in mice, where animals consume a relative surplus of
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dietary lipids, has been reported to induce hepatic lipogenic gene expression and even
lipogenesis (Buettner et al., 2006; Oosterveer et al., 2009). One report attributes
increased hepatic fatty acid synthesis predominantly to chain elongation and
desaturation of exogenous fatty acids rather than actual de novo synthesis, as palmitate
(C16:0) synthesis was unchanged, but oleate (C18:1) synthesis was increased in
C57BL/6J mice fed HFD (Oosterveer et al., 2009). Though de novo lipogenesis was not
increased in these mice, hepatic expression of SREBP1c, SCD1, FAS, ACC1, and
GPAT were all elevated. While we observed an increase in SREBP1c expression in our
lard HFD-fed mice, we did not see an increase in any other lipogenic mRNAs, and
actually saw a decrease in the synthesis of palmitate (Figure 3-13). Conversely, mice
fed Surwit HFD did exhibit increased palmitate synthesis in the absence of lipogenic
gene upregulation. It is unclear if this difference results from the differences in the
source of fat of each of the diets (coconut oil vs lard) or if the increase in sucrose content
of the Surwit HFD is influencing de novo lipogenesis independently of dietary fat.
Nonetheless, as loss of hepatic Akt2 does ameliorate hepatic steatosis in both models of
DIO and does not act through de novo synthesis of fatty acids, exogenous fatty acid
elongation and desaturation are potential mechanisms through which Akt2 could
function.
While it is not possible to completely rule out lipogenesis as a cause for
decreased hepatic triglyceride accumulation on either HFD, it appears that Akt2 acts
through another mechanism to regulate lipid metabolism in HFD-fed mice. Other
possibilities through which loss of Akt2 could lead to decreased hepatic triglyceride
levels include increased β-oxidation and increased triglyceride export. However, there
were no changes in any of the hepatic oxidative genes measured between Akt2lox/lox and
AFP;Akt2lox/lox mice on Surwit HFD (Figure 3-9). Fed serum ketones were slightly
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increased in AFP;Akt2lox/lox versus Akt2lox/lox mice on Surwit HFD for 4 months, though
this is unlikely to represent a significant increase in β-oxidation as RER was
indistinguishable in these two groups (Figure 3-6C, 3-7D, and 3-7H). Similarly,
triglyceride export did not appear to be changed in the absence of hepatic Akt2 as serum
triglycerides were not different in fed or fasted conditions or during the P-407 assay
(Figure 3-7A, 3-7E and 3-10).
Interestingly, acute loss of Akt2 in lard HFD-fed animals prevented some hepatic
triglyceride accumulation but could not reverse existing hepatic steatosis as it did in
ob/ob mice. Though this result shows that the requirement for Akt2 in DIO is not
restricted to liver development, it is further evidence that Akt2 regulates different lipid
metabolic processes in ob/ob and HFD livers. Acute loss of Akt2 did not completely
ameliorate triglyceride accumulation after 2 months of lard HFD (Figure 3-14); one
explanation for this finding is that hepatic Akt2 could be required for a lipid metabolic
process that contributes to hepatic steatosis but is not the sole cause. Surwit HFDinduced hepatic steatosis appears to be only partial regulated by Akt2 as AFP;Akt2lox/lox
mice after 4 months of Surwit HFD still had increased hepatic triglycerides over chow-fed
animals (Figure 3-5), and this may also be the case for lard HFD. Alternatively, Akt2permissive hepatic steatosis could be cumulative and not dynamically influenced by Akt2
once it has developed. Regardless, Akt2 is certainly required for the full development of
hepatic steatosis that results from DIO, though it is unclear how Akt2 influences hepatic
lipid metabolism in this model.
Interestingly, the phenotype of Akt2-/- mice on Surwit HFD varied greatly from that
of AFP;Akt2lox/lox mice on HFD, illustrating the importance of Akt2 in extrahepatic tissues.
Akt2-/- mice gained significantly less weight on Surwit HFD compared with their Akt2+/+
counterparts, and this was predominately due to their failure to gain fat mass (Figure 394

1). These mice also had a reduction in serum NEFA during fasting, likely a result of their
reduced fat mass (Figure 3-3C). However, though they have reduced adiposity, Akt2-/mice still have increased hepatic and peripheral insulin resistance compared with Akt2+/+
mice, suggesting that the prevention of lipid accumulation does not improve insulin
sensitivity in this model (Figure 3-4F). While GIR, basal HGP and Rd were similar in
Akt2-/- mice on Surwit HFD and chow, clamped HGP was elevated in Surwit HFD-fed
mice (Figure 3-4F). This indicates that the most profound effect after 6 weeks of HFD is
on the liver of the Akt2-/- mouse and that most of the peripheral insulin resistance is likely
due to loss of Akt2 iteself in muscle or adipose tissue. Though liver-specific Akt2 null
animals exhibited hepatic insulin resistance compared with their wildtype littermates on
chow (Figure 2-13A), after 4 months on Surwit HFD, there were no differences (Figure 311D). It is unclear whether these differences resolved over time, could be due to strain
differences or whether loss of hepatic Akt2 is not additive with the stress of DIO to
insulin resistance. The latter is consistent with the Western blots of insulin signaling that
show that DIO blunted insulin signaling, and that loss of hepatic Akt2 had a negligible
effect on this already decreased state (Figure 3-12).
In light of similar insulin sensitivity in Akt2lox/lox and AFP;Akt2lox/lox mice on Surwit
HFD, it is not surprising that these mice exhibited similar glucose tolerance after 4
months on HFD (Figure 3-11). Unexpectedly, Akt2-/- and Akt2+/+ mice also exhibited
similar glucose tolerance after 4 months, even though Akt2-/- mice were more insulin
resistant and showed impaired glucose tolerance after one month on Surwit HFD
compared with Akt2+/+ animals (Figure 3-4). This maintenance of GTT by Akt2-/- mice
appears to be the result of increased insulin secretion, as these mice exhibited much
higher serum insulin levels during GTT: thus, this elevation was an appropriate
compensation for their increased insulin resistance. However, serum insulin levels in
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Akt2-/- mice on Surwit HFD continued to increase over time so that these mice actually
over-compensated and had improved glucose tolerance over their Akt2+/+ counterparts
on HFD: this appears to be the result of greatly increased β-cell mass (see Addendum).
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Chapter 3 Figures
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Figure 3-1: Akt2-/- mice gain less weight and fat mass on Surwit HFD.
Male Akt2+/+ and Akt2-/- littermates were started on Surwit HFD at approximately 5 weeks
of age.
A. Body weights following start of HFD.
B. 24-hour food intake of mice after 4 months on Surwit HFD.
C. 24-hour respiratory exchange ratio (RER) of mice after 4 months on Surwit HFD.
D. Body composition of mice after 4 months on Surwit HFD.
All values are expressed as mean ± SEM. n=6; *p<0.01 by Student’s t-test.
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Figure 3-2: Akt2-/- mice have decreased hepatic triglyceride levels after 4 months
on Surwit HFD.
Male Akt2+/+ and Akt2-/- littermates were started on Surwit HFD at approximately 5 weeks
of age and sacrificed after either 1 or 4 months along with age-matched chow controls.
Body weight (A), liver weight (B); hepatic triglyceride (TG) levels of fed (C) and overnight
fasted (D) mice.
All values are expressed as mean ± SEM. n=5-9; *p<0.05 by one-way ANOVA using
Newman-Keuls post-test.
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Figure 3-3: Serum measurements of Akt2-/- mice on Surwit HFD.
Data from male Akt2+/+ and Akt2-/- littermates started on Surwit HFD at approximately 5
weeks of age and sacrificed after 1 or 4 months on diet along with age-match chow
controls.
Serum triglycerides (TG) (A), cholesterol (CH) (B), non-esterified fatty acids (NEFA) (C),
and ketones (D) from fed (left) and overnight fasted (right) mice.
All values are expressed as mean ± SEM. n=5-9; *p<0.05 vs Akt2+/+ chow and **p<0.05
vs Akt2+/+ HFD by one-way ANOVA using Newman-Keuls post-test.
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Figure 3-4: Akt2-/- mice are insulin-resistant but maintain normal glucose tolerance
by increasing insulin levels on Surwit HFD.
Data from male Akt2+/+ and Akt2-/- littermates started on Surwit HFD or maintained on
chow at approximately 5 weeks of age.
A-E. Fasted blood glucose levels (A) at start of glucose tolerance test (GTT) after 1
month (B) and 4 months (D) on Surwit HFD; insulin levels at the start and 15 minutes
post glucose load (C and E). n=6-13.
F. Hyperinsulinemic euglycemic clamp of 5mU insulin/kg/min on 11-week old male mice
started on Surwit HFD at 5 weeks of age along with age-match chow controls. Glucose
infusion rate (GIR), basal and clamped hepatic glucose production (HGP) and rate of
disposal (Rd) shown. n=4-5.
All values are expressed as mean ± SEM; *p<0.05 by one-way ANOVA using NewmanKeuls post-test.
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Figure 3-5: AFP;Akt2lox/lox mice on Surwit HFD have decreased hepatic triglyceride
levels, but do not exhibit changes in de novo lipogenesis.
Male mice were started on Surwit HFD at approximately 5 weeks of age and sacrificed
after either 1 or 4 months along with age-matched chow controls.
Body weight (A), liver weight (B); hepatic triglyceride (TG) levels of fed mice (C). n=5-9;
*p<0.05 by one-way ANOVA using Newman-Keuls post-test.
D. Hepatic long-chain fatty acyl CoA (LLCoA) concentrations from overnight fasted male
mice after 1 month on Surwit HFD. n=4. *p<0.05 vs Akt2lox/lox chow by two-way ANOVA
using Bonferroni post-test.
E. De novo lipogenesis: Male mice after 1 or 4 months on Surwit HFD or maintained on
normal chow were injected with D2O after a 5 hour fast, sacrificed after 3 hours, and liver
was removed and analyzed for palmitate by GC/MS. n=5; *p<0.05 by one-way ANOVA
using Newman-Keuls post-test.
All values are expressed as mean ± SEM.
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Figure 3-6: AFP;Akt2lox/lox mice on Surwit HFD have normal body weight, body
composition and energy expenditure.
Male mice were started on Surwit HFD at approximately 5 weeks of age.
A. Body weights following start of HFD. n=7-11.
B. 24-hour food intake of mice after 4 months on Surwit HFD. n=6.
C. 24-hour respiratory exchange ratio (RER) of mice after 4 months on Surwit HFD. n=6.
D. Body composition of mice after 4 months on Surwit HFD. n=6.
All values are expressed as mean ± SEM; no points are significantly different to any
others (p<0.05 by one-way ANOVA using Newman-Keuls post-test).
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Figure 3-7: Serum measurements of AFP;Akt2lox/lox mice on Surwit HFD.
A-D. Data from male mice started on Surwit HFD at approximately 5 weeks of age and
sacrificed after 1 or 4 months on diet along with age-match chow controls under fed
conditions. Serum triglycerides (TG) (A), cholesterol (CH) (B), non-esterified fatty acids
(NEFA) (C), and ketones (D).
E-H. Data from male mice started on Surwit HFD at approximately 5 weeks of age and
sacrificed after 1 month on diet along with age-match chow controls after an overnight
fast. Serum triglycerides (E), cholesterol (F), NEFA (G), and ketones (H).
All values are expressed as mean ± SEM. n=4-9; *p<0.05 vs Akt2lox/lox chow and
**p<0.05 vs Akt2lox/lox HFD by one-way ANOVA using Newman-Keuls post-test.
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Figure 3-8: AFP Cre alone does not affect body weight, liver weight, hepatic
triglycerides or serum measurements in mice fed Surwit HFD for one month.
Data from male mice started on Surwit HFD at approximately 5 weeks of age and
sacrificed after one month on diet along with age-match chow controls under fed
conditions. Body weight (A) and liver weight (B), hepatic triglycerides (TG) (C), serum
triglycerides (D), serum cholesterol (CH) (E), serum non-esterified fatty acids (NEFA)
(F), and serum ketones (G).
All values are expressed as mean ± SEM. n=3-5; *p<0.05 for both genotypes on chow
vs both genotypes on Surwit HFD by one-way ANOVA using Newman-Keuls post-test.
No values Akt2+/+ vs AFP;Akt2+/+ on a given diet are significantly different (p<0.05 by
one-way ANOVA using Newman-Keuls post-test).
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Figure 3-9: Hepatic gene expression in AFP;Akt2lox/lox mice on Surwit HFD.
Hepatic gene expression as measured by Real-Time PCR of male mice after 1 month on
Surwit HFD along with age-matched chow-fed controls sacrificed under fed conditions.
Data are presented as mRNA expression relative to that of TATA-binding protein and
normalized to expression in Akt2lox/lox chow-fed, which is set to 1.0 using the ddCT
method.
All values are expressed as mean ± SEM. n=6; *p<0.05 vs Akt2lox/lox chow and **p<0.05
vs Akt2lox/lox HFD by one-way ANOVA using Newman-Keuls post-test.

Abbreviations: sterol regulatory element binding protein-1c (SREBP1c), stearoyl-CoA
desaturase-1 (SCD1), fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), ATP
citrate lyase (ACL), glycerol phosphate acyltransferase (GPAT), glucokinase (GCK),
carbohydrate regulatory-element binding protein (ChREBP), pyruvate kinase, liver
isoform (L-PK), peroxisome proliferator-activated receptor- γ (PPARγ ), peroxisome
proliferators-activated receptor-coactivator 1α (PGC-1α), carnitine palmitoyltransferase I
(CPT1), medium-chain acetyl-CoA dehydrogenase (MCAD), and cytochrome c oxidase
subunit 7a (Cox7a).
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Figure 3-10: Loss of hepatic Akt2 does not dramatically alter triglyceride secretion
on Surwit HFD.
Male mice were started on Surwit HFD at 5 weeks of age, and after 4 months on diet
were intraperitoneally (IP) injected with 100µl 10% poloxamer 407 (P-407) per 10 grams
body weight after a 5-hour fast and serum triglycerides were measured by tail bleed at 0,
1, 2, and 4 hours after injection.
Area under the curve calculated using Graphpad Prism.
All values are expressed as mean ± SEM. n=3-6; no points are significantly different to
others (p<0.05 by one-way ANOVA using Newman-Keuls post-test).
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Figure 3-11: AFP;Akt2lox/lox mice have normal glucose tolerance and insulin
sensitivity on Surwit HFD.
Data from male mice started on Surwit HFD or maintained on chow at approximately 5
weeks of age.
A-C. Fasted blood glucose levels (A) at start of glucose tolerance test (GTT) (B) after 1
month on Surwit HFD, and insulin levels at the start and 15 minutes post glucose load
(C). n=5-6.
D. Hyperinsulinemic euglycemic clamp of 2.5mU insulin/kg/min on 22-week old male
mice started on Surwit HFD at 5 weeks of age. Glucose infusion rate (GIR), basal and
clamped hepatic glucose production (HGP) and rate of disposal (Rd) shown. n=4.
All values are expressed as mean ± SEM; no points are significantly different to any
others (p<0.05 by one-way ANOVA using Newman-Keuls post-test).
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Figure 3-12: Hepatic insulin signaling is not blunted by loss of Akt2 in the liver of
Surwit HFD-fed mice.
Western blot of phospho-Akt (p473 and p308) and downstream signaling targets in
hepatic lysates from Akt2lox/lox and AFP;Akt2lox/lox mice on Surwit HFD for 1 month under
fed conditions. Akt2lox/lox mice injected with saline or insulin as in Figure 2-15A are
included for comparison. All samples were run on the same gel and imaged at the same
exposure, but were cropped to exclude lanes in the middle, as denoted by the vertical
line. Each lane represents an individual mouse. Loading controls are included when
blots from different gels were used for phospho-protein and total protein, though the
same protein extracts were used. The arrow indicates Akt2 as there is a slightly more
mobile non-specific band.
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Figure 3-13: AFP;Akt2lox/lox mice on lard HFD have decreased hepatic triglyceride
levels and SREBP-1c expression, but no alterations in de novo lipogenesis.
Male mice were started on HFD at approximately 6 weeks of age and sacrificed after 1
month on lard HFD under fed conditions along with age-matched chow-fed controls.
A. Hepatic triglycerides (TG).
B. De novo lipogenesis: Male mice after 1 month on lard HFD or maintained on normal
chow were injected with D2O after a 5 hour fast, sacrificed after 3 hours, and liver was
removed and analyzed for palmitate by GC/MS. Data from chow-fed mice are the same
as Figure 3-5E, as these experiments were run concurrently.
C. Hepatic gene expression as measured by Real-Time PCR. Data are presented as
mRNA expression relative to that of TATA-binding protein and normalized to expression
in Akt2lox/lox chow-fed, which is set to 1.0 using the ddCT method.
All values are expressed as mean ± SEM. n=5-6; *p<0.05 vs Akt2lox/lox chow and
**p<0.05 vs Akt2lox/lox HFD and ***p<0.05 for bracketed group by one-way ANOVA using
Newman-Keuls post-test.
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Figure 3-14: Acute excision of hepatic Akt2 decreases hepatic triglyceride
accumulation on lard HFD.
Male mice were started on lard HFD at approximately 5 weeks of age or maintained on
chow. One group of mice was sacrificed after one month on lard HFD under fed
conditions; all others were injected retro-orbitally with AAV-GFP or AAV-Cre. Chow-fed
mice were injected with AAV-GFP; half of the remaining mice on lard HFD were injected
with AAV-GFP and the other half with AAV-Cre. AAV-injected mice were then sacrificed
one month later under fed conditions.
A-C. Body weight (A) and liver weight expressed as grams weight (B) and as a ratio to
body weight (LW/BW) (C).
D. Hepatic triglycerides (TG) expressed as concentration per gram liver (left) and total
(right).
E,F. Serum triglycerides (E) and cholesterol (CH) (F).
All values are expressed as mean ± SEM. n=4-5; all points are significantly different
(p<0.05 by one-way ANOVA using Newman-Keuls post-test) to all others except for
those marked non-significant (NS).
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Chapter 4:

Akt2 is required for the induction of de novo lipogenesis during
refeeding in lean animals
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Introduction
We have shown that Akt2 is required for the development of hepatic steatosis in
two different models of insulin-resistance, the ob/ob mouse and DIO. Additionally, Akt2
is indispensible for the elevated rate of de novo lipogenesis that occurs in the ob/ob
mouse. However, the question still remains if Akt2 plays a role in normal lipid
metabolism, specific the induction of de novo lipogenesis that occurs in lean animals
without insulin resistance. In order to test the requirement for Akt2 in the regulation of
lipogenesis in a lean liver, we wanted to establish a paradigm where lipogenesis would
be stimulated acutely in an insulin-dependent manner. De novo lipogenesis is normally
induced by the intake of food, when increased flux through glycolysis increases the
amount of acetyl-CoA available for fatty acid synthesis. In addition, post-prandial
hyperinsulinemia promotes lipogenesis, which peaks approximately 4 hours after meals
in humans correlating with peak serum insulin concentrations (Timlin and Parks, 2005).
It has been long observed that high-carbohydrate diets (HCD) in particular lead
to increased rates of de novo lipogenesis. Three to five days of high-carbohydrate
consumption in humans results in up to a 10-fold increase in lipogenesis (Chong et al.,
2008; Schwarz et al., 2003; Schwarz et al., 1995). Both lean and hyperinsulinemic
obese individuals exhibit increased de novo palmitate synthesis following one to two
weeks of diets high in simple carbohydrates and low in fat (Hudgins et al., 1996; Hudgins
et al., 2000). Associated with this increase in lipogenesis is an increase in VLDL
secretion and serum triglyceride levels. This is especially problematic for disease
control in Type 2 diabetics, as long-term HCD consumption results in elevations of
fasting plasma triglyceride, glucose and insulin levels in these patients (Garg et al.,
1994). It has been proposed that HCDs also suppress hepatic fatty acid oxidation,
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which, along with increased fatty acid synthesis, contributes to increased triglyceride
secretion from the liver (Mittendorfer and Sidossis, 2001).
HCD consumption likely leads to increased rates of de novo lipogenesis at least
in part through stimulation of gene expression: fasting followed by refeeding with a HCD
leads to exponential increases in lipogenic gene expression in both humans and rodents
(Horton et al., 1998a; Iritani et al., 1992). Lipogenic gene expression is coordinately
upregulated in HCD-feeding by the combination of glucose through ChREBP and insulin
through SREBP1c (Dentin et al., 2004; Koo et al., 2001) (and reviewed in Postic and
Girard, 2008). SREBP1c mRNA and nuclear protein levels are very low during fasting in
mice as are its lipogenic target genes; upon refeeding with a HCD, the expression of
these genes rises dramatically and even increases 5- to 10- fold above fed levels
(Horton et al., 1998a). In the absence of SREBP1c or ChREBP, the increase in
lipogenic gene expression in response to fasting/refeeding is blunted (Iizuka et al., 2004;
Liang et al., 2002; Shimano et al., 1999).
In this chapter, we show that hepatic Akt2 is required for the induction of de novo
lipogenesis that occurs with HCD refeeding. This correlates with decreased expression
of some lipogenic genes, but expression is not universally impaired in the absence of
Akt2; specifically SREBP1c expression is not reduced by loss of hepatic Akt2. These
studies also reveal additional roles for Akt2 in hepatic metabolism as liver-specific Akt2
null mice have reduced liver weight and serum triglycerides following refeeding.

Results
HCD refeeding induces SREBP1c and lipogenic gene expression.
In order to first establish the validity of a fasting/refeeding protocol in normal
mice, 8-week old C57BL/6J male mice were fasted overnight and sacrificed after various
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points following refeeding with a HCD (for HCD composition, see Table 6-5 in Materials
and Methods). Mice fasted overnight had low body weights, which were increased at the
earliest time point (1.5 hours) following refeeding (Figure 4-1A). Upon refeeding, liver
weight, both by mass and as expressed as a ratio to body weight, increased linearly over
time (Figure 4-1B and 4-1C). Neither protein nor triglyceride content could account for
this increase. Total protein content remained constant, whereas protein concentration
per gram liver decreased with refeeding, presumably due to increasing liver weight over
that time period (Figure 4-1D and 4-1E). However, hepatic triglycerides remained
unchanged through the experiment, both in concentration and total (Figure 4-1F and 41G). The observed increase in liver weight was likely due at least partially to
replenishing glycogen stores (see below).
Serum triglycerides did not significantly vary during the transition from fasting to
feeding until 6 hours after refeeding, when levels spiked before returning to basal (Figure
4-2A). A similar sort of peak was observed for serum cholesterol, though this occurred
much earlier, at just 1.5 hours after refeeding (Figure 4-2B). However, after this early
peak, serum cholesterol was decreased after 12 hours of refeeding compared with
fasting (Figure 4-2B). Both serum NEFA and ketones were elevated under fasting
conditions, and decreased dramatically upon refeeding for the duration of the time points
measured (Figure 4-2C and 4-2D).
SREBP1c expression was very low under fasting conditions, and increased
dramatically upon refeeding as has been previously reported (Horton et al., 1998a)
(Figure 4-3). Expression was maximal by 3 hours and persisted through 12 hours after
refeeding. FAS expression also increased with refeeding but in a delayed pattern
compared with SREBP1c, not increasing above fasting until after 6 hours, and not
reaching maximal expression until 9 hours after refeeding (Figure 4-3). This lag in
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expression was consistent with the time needed for additional round of transcription
following SREBP1c activation and subsequent stimulation of its lipogenic targets,
including FAS. However, mRNA levels of SCD1, another target gene of SREBP1c, did
not change with refeeding, as has been previously reported; these reports, however, did
not observe as robust an increase as with FAS (Horton et al., 1998a; Liang et al., 2002;
Shimano et al., 1999). GCK mRNA also increased with refeeding, but its expression
pattern was different from those of SREBP1c and FAS, reaching its highest level at 3
hours after refeeding and then decreasing over the rest of the time course (Figure 4-3).

AFP;Akt2lox/lox mice have smaller livers upon refeeding.
Having shown that our fasting/refeeding protocol was a robust stimulus of
SREBP1c expression in wildtype mice, we wanted to subject the liver-specific Akt2 null
mice to this protocol. 8-week old mixed background Akt2lox/lox and AFP;Akt2lox/lox male
littermates were used for all of the experiment described. Body weight did not differ
during the refeeding time course in either group (Figure 4-4A). Blood glucose and
serum insulin levels increased dramatically upon refeeding and were not affected by loss
of hepatic Akt2 (Figure 4-4D and 4-4E). These levels remained elevated during the
duration of the time course, indicating that the mice were likely feeding at various times,
and not only acutely upon refeeding. AFP;Akt2lox/lox mice were able to maintain normal
glucose levels during refeeding despite exhibiting insulin resistance by hyperinsulinemic
euglycemic clamp (Figure 2-12A), indicating that glucose metabolism in AFP;Akt2lox/lox
mice was not significantly impaired under fasting/refeeding conditions.
However, while Akt2lox/lox mice had steadily increasing liver weight during
refeeding, AFP;Akt2lox/lox mice did not exhibit any change in liver weight (Figure 4-4B).
The liver weight to body weight ratio was slightly elevated in AFP;Akt2lox/lox mice 12
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hours after refeeding, but it was significantly reduced compared with Akt2lox/lox mice
(Figure 4-4C). As observed in the original C57BL/6J time course experiment, hepatic
triglycerides did not change either in concentration or in total, while hepatic protein
concentrations decreased with refeeding though total levels remained constant in
Akt2lox/lox mice (Figure 4-1, 4-5A to 4-5D). Glycogen, and its associated water weight, is
likely responsible for the increase in liver weight that occurs with refeeding, as glycogen,
both concentration and total, increased from non-detectable levels at fasting over the
course of refeeding, correlating with the increase in liver weight in Akt2lox/lox mice (Figure
4-5E and 4-5F). Total glycogen levels were decreased at 6 and 12 hours after refeeding
in AFP;Akt2lox/lox mice compared with Akt2lox/lox mice, though glycogen concentrations
were not significantly altered at these points (Figure 4-5E and 4-5F). Additionally, there
was a trend towards decreased total levels of hepatic triglyceride and protein in
AFP;Akt2lox/lox mice at 12 hours after refeeding, though their concentrations were not
altered from those in Akt2lox/lox mice (Figure 4-5A to 4-5D).
Similar to those in the C57BL/6J time course experiment, serum triglycerides
increased upon refeeding in Akt2lox/lox mice, though this occurred earlier at 1.5 hours
after refeeding, before decreasing to a lower level at 12 hours (Figure 4-6A). This
increase was not present in the absence of hepatic Akt2, as AFP;Akt2lox/lox mice
exhibited fairly constant serum triglyceride levels during refeeding (Figure 4-6A). Serum
cholesterol levels were not altered over time in either genotype (Figure 4-6B). Serum
NEFA and ketones decreased similarly in both groups upon refeeding, though
AFP;Akt2lox/lox mice exhibited a slight decrease in fasting NEFA levels compared with
Akt2lox/lox mice (Figure 4-6C and 4-6D).
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AFP;Akt2lox/lox mice have decreased de novo lipogenesis and reductions of some
lipogenic gene expression during refeeding, without changes in SREBP1c expression.
We have shown that our fasting/refeeding protocol is a potent stimulus of
SREBP1c and lipogenic gene expression (Figure 4-3); thus, it should also cause an
increase in de novo lipogenesis. Indeed, Akt2lox/lox mice refed HCD for 6 or 12 hours
exhibited significantly elevated de novo lipogenesis compared with mice that were fasted
(Figure 4-7A and 4-7B). While lipogenesis in AFP;Akt2lox/lox mice was similar to that in
Akt2lox/lox mice under fasted conditions, it was significantly decreased upon 6 or 12 hours
of refeeding (Figure 4-7A and 4-7B). Interestingly, refeeding did not stimulate an
increase in lipogenesis in AFP;Akt2lox/lox mice, as fasted and 6 hour refed levels were not
significantly different (Figure 4-7A). AFP Cre alone did not affect lipogenesis as
AFP;Akt2+/+ mice exhibited identical levels of lipogenesis to Akt2lox/lox mice at 6 hours
after refeeding (Figure 4-7A).
Consistent with our findings in C57BL/6J mice, SREBP1c, FAS, and GCK
expression increased with refeeding, as did that of ACL, ACC, GPAT, in Akt2lox/lox livers;
loss of hepatic Akt2 resulted in the blunted expression of FAS and ACL (Figure 4-8).
GCK mRNA peaked at 1.5 and 3 hours after refeeding and decreased at later time
points in Akt2lox/lox mice, and this peak was significantly decreased in AFP;Akt2lox/lox mice,
though levels at 6 and 12 hours were similar. However, SREBP1c mRNA increased
normally in AFP;Akt2lox/lox livers, as did ACC and GPAT mRNA (Figure 4-8). Expression
of the ChREBP target, L-PK, was also normal in AFP;Akt2lox/lox mice, increasing during
refeeding similarly to Akt2lox/lox mice. Expression of G6Pase was initially suppressed at 3
hours of refeeding, but then recovered at later time points; loss of hepatic Akt2 had no
effect on this pattern of expression (Figure 4-8).
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Discussion
In this chapter, we established a role for hepatic Akt2 in the control of normal de
novo lipogenesis in lean animals. As the rate of lipogenesis is very low in lean animals
under most conditions, we utilized a situation where lipogenesis would be maximally
induced: fasting and refeeding with HCD. Overnight fasting following by HCD refeeding
resulted in a profound increase in SREBP1c and other lipogenic gene expression
(Figure 4-3 and 4-8). Paralleling this increase in lipogenic gene expression, animals
exhibited an approximately 5-fold increase in de novo lipogenesis after 6 or 12 hours of
HCD refeeding over that of fasted animals, similar to the increase that has been reported
in humans with high carbohydrate consumption (Chong et al., 2008; Schwarz et al.,
2003; Schwarz et al., 1995). Using this model, we showed that though AFP;Akt2lox/lox
mice exhibited normal lipogenesis under fasting conditions, they lacked the induction
upon refeeding (Figure 4-7). Correspondingly, lipogenesis levels at both 6 hours and 12
hours after refeeding were decreased in AFP;Akt2lox/lox mice compared with Akt2lox/lox
mice. Thus, we have determined that Akt2 is required for the normal induction of de
novo lipogenesis in response to high-carbohydrate feeding.
However, it is unclear how Akt2 actually influences lipogenesis in the
fasted/refeed condition. HCD refeeding dramatically induced the expression of
SREBP1c and other lipogenic genes; FAS mRNA in particular was increased 100-fold
over fasted levels (Figure 4-3). The only exception was SCD1, though this gene as has
been previously reported to be upregulated in response to HCD refeeding but to a lesser
degree than other lipogenic genes (Horton et al., 1998a; Liang et al., 2002; Shimano et
al., 1999). While fasted expression levels were similar in Akt2lox/lox and AFP;Akt2lox/lox
mice, loss of hepatic Akt2 blunted the increase in some but not all mRNAs (Figure 4-8).
Those genes whose upregulation was Akt2-dependent were FAS, ACL and GCK; those
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that were Akt2-independent were ACC, GPAT, L-PK, and critically, SREBP1c. Though
SREBP1c expression was decreased in Lepob/ob AFP;Akt2loxlox mice, SREBP1c
upregulation in response to refeeding was unfettered by loss of hepatic Akt2. However,
this does not exclude the possibility that Akt2 could be regulating SREBP1c through
post-transcriptional regulation or enzymatic processing. However, not all SREBP1c
target genes were affected in AFP;Akt2lox/lox mice; therefore, if Akt2 is acting solely
through SREBP1c, either it can regulate the specificity of SREBP1c’s targets or the
expression of some genes can be maintained by other pathways. Additionally, de novo
lipogenesis was increased at 6 hours in Akt2lox/lox mice though FAS, ACC and ACL
expression was not significantly elevated above fasting until this point. Therefore, it is
unclear whether expression of these genes truly drives the increased flux through
lipogenesis during HCD refeeding, or whether the process is mostly substrate-driven.
Accordingly, it is unclear whether the reduction in FAS, ACL and GCK expression in
AFP;Akt2lox/lox mice is sufficient to lower lipogenesis in these mice or whether Akt2 has
another effect, such as modulating enzymatic activity.
Importantly, we also show that though AFP;Akt2lox/lox mice are inherently
defective in lipogenesis, this is not secondary to a decrease in glucose or insulin levels
during refeeding (Figure 4-4D and 4-4E). While this would not be expected as
AFP;Akt2lox/lox mice are insulin resistance by hyperinsulinemic euglycemic clamp (Figure
2-12A), it is essential to exclude this possibility. Unlike the insulin-resistant models
previously used, this demonstrates that there is an impairment in lipid metabolism
coinciding with normal glucose metabolism in AFP;Akt2lox/lox mice. However, though
serum glucose levels were normal in AFP;Akt2lox/lox mice, it is possible that the amount
available for utilization by the liver was not. The rate-limiting step for the entrance of
glucose into the liver is its phosphorylation by GCK. GCK mRNA, unlike the other
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lipogenic mRNAs measured, increased rapidly, peaking at 1.5 and 3 hours after
refeeding (Figure 4-3 and 4-8). This occurred long before SREBP1c expression was
maximal, likely so that the liver could take up increasing levels of glucose from the blood
as it became available after refeeding. This peak was significantly reduced with the loss
of hepatic Akt2, though later expression was maintained (Figure 4-8). However, it
seems unlikely that this resulted in significantly altered glucose uptake into the liver, as
glucose and glycogen concentrations were not altered, though total glycogen content
was decreased at later time points (Figure 4-5 and not shown). Additionally, expression
of L-PK, a transcriptional target of ChREBP, was not blunted with loss of hepatic Akt2,
indicating at least that the stimulation of ChREBP activity by glucose was not decreased.
Interestingly, AFP;Akt2lox/lox mice failed to exhibit the peak in serum triglycerides
that Akt2lox/lox mice did (Figure 4-6A). This peak occurred at 6 hours after refeeding in
C57BL/6J mice and after 1.5 hours in mixed background Akt2lox/lox mice and disappeared
by 12 hours in both groups (Figure 4-2A and 4-6A). It is unknown if this difference was
due to variability in experimental groups or strain differences. Both Akt2lox/lox and
AFP;Akt2lox/lox mice exhibited a constant elevation in glucose and insulin levels following
refeeding, indicating that animals were likely eating a bolus of food initially followed by
continued lighter feeding (Figure 4-4D and 4-4E). This behavior was perhaps
responsible for some of the variability observed as there may be different feeding
behavior among individual animals: in the future, it may be advantageous to feed
animals a single large “meal” instead of ad libitum. Regardless, the most likely source of
the peak in serum triglycerides is dietary: in humans, this peak occurs 2 hours post HCD
consumption while maximum de novo lipogenesis does not occur until 4 hours (Timlin
and Parks, 2005). Additionally, lipolysis in adipose tissue was suppressed with
refeeding, as indicated in our mice by the abrupt fall in serum NEFA; thus, increased
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exogenous fatty acids are likely to be the source of triglycerides in the peak (Figure 46C). AFP;Akt2lox/lox mice did not exhibit an increase in serum triglycerides following
refeeding, indicating that loss of Akt2 in the liver somehow influences the handling of
dietary triglycerides. Non-cell autonomous effects of Akt2 on gut function cannot be
excluded, but a preliminary lipid tolerance test using gavaged olive oil suggested that
there was not a defect in lipid absorption by the gut in AFP;Akt2lox/lox mice (not shown).
Thus, it would be interesting to determine if Akt2 regulates the uptake and reesterification of dietary fatty acids in the liver.
Another finding which appeared to be unrelated to Akt2’s role in lipogenesis, was
the failure of AFP;Akt2lox/lox mice to normally increase their liver weight upon refeeding.
Liver weight was identical in Akt2lox/lox and AFP;Akt2lox/lox mice after an overnight fast,
and we have not previously observed a change in fed liver weight in AFP;Akt2lox/lox mice
on a normal chow diet (Figure 4-4, 2-6B and 3-8B). Therefore, it is unlikely that there is
a developmental aspect to the loss of Akt2 in determining liver size or hepatic cell
number, though it is possible that this difference only becomes apparent with HCDfeeding. The concentrations of glycogen, triglycerides and protein, the 3
macromolecules that make up the bulk of the liver, were unchanged during refeeding
(Figure 4-5). However, total content of glycogen was decreased at 6 and 12 hours after
refeeding, and there was a trend towards decreased triglyceride and protein content at
12 hours. Therefore, it appears that the absence of increasing liver weight in
AFP;Akt2lox/lox mice was due primarily to decreased glycogen content, with a small
contribution by triglyceride and protein content, though it is possible that decreases in all
3 macromolecules were secondary to decreased liver weight by another unknown
cause.
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Chapter 4 Figures

137

Figure 4-1: Liver weight increases with refeeding but not due to increases in
triglycerides or protein.
8-week old male C57BL/6J mice were fasted overnight (4pm to 10am) and refed HCD
for 0, 1.5, 3, 6, 9 or 12 hours prior to sacrifice.
A. Body weight. *p<0.05 by one-way ANOVA using Newman-Keuls post-test.
B, C. Liver weight expressed as grams weight (B) and as a ratio to body weight
(LW/BW) (C). All time points are significantly different (p<0.05 by one-way ANOVA using
Newman-Keuls post-test) to all others except for those marked non-significant (NS).
D. Hepatic protein expressed as concentration per gram liver. All time points are
significantly different (p<0.05 by one-way ANOVA using Newman-Keuls post-test) to all
others except for those marked NS.
E. Total hepatic protein. No time points are significantly different to others (p<0.05 by
one-way ANOVA using Newman-Keuls post-test).
F, G. Hepatic triglycerides (TG) expressed as concentration per gram liver (F) and total
(G). No time points are significantly different to others (p<0.05 by one-way ANOVA
using Newman-Keuls post-test).
All values are expressed as mean ± SEM. n=4-6.
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Figure 4-2: Serum measurements during fasting and refeeding.
8-week old male C57BL/6J mice were fasted overnight (4pm to 10am) and refed HCD
for 0, 1.5, 3, 6, 9 or 12 hours prior to sacrifice.
A. Serum triglycerides (TG). 6-hour time point: *p<0.05 vs all other time points by oneway ANOVA using Newman-Keuls post-test.
B. Serum cholesterol (CH). *p<0.05 for 1.5-hour time point vs all other time points and
two bracketed time points **p<0.05 by one-way ANOVA using Newman-Keuls post-test.
C. Serum non-esterified fatty acids (NEFA). Fasted (0 hour) time point: *p<0.05 vs all
other time points by one-way ANOVA using Newman-Keuls post-test.
D. Serum ketones. Fasted (0 hour) time point: *p<0.05 vs all other time points by oneway ANOVA using Newman-Keuls post-test.
All values are expressed as mean ± SEM. n=4-6.
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Figure 4-3: SREBP1c, FAS, and GCK expression increases with refeeding.
Hepatic gene expression as measured by Real-Time PCR of 8-week old male C57BL/6J
mice fasted overnight (4pm to 10am) and refed HCD for 0, 1.5, 3, 6, 9 or 12 hours prior
to sacrifice. Data are presented as mRNA expression relative to that of TATA-binding
protein and normalized to expression in Fasted (0) time point, which is set to 1.0 using
the ddCT method.
All values are expressed as mean ± SEM. n=4-6; *p<0.05 vs Fasted (0) time point and
**p<0.05 vs 3-hour time point by one-way ANOVA using Newman-Keuls post-test.

Abbreviations: sterol regulatory element binding protein-1c (SREBP1c), fatty acid
synthase (FAS), glucokinase (GCK), and stearoyl-CoA desaturase-1 (SCD1).
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Figure 4-4: AFP;Akt2lox/lox mice gain less liver weight upon refeeding but maintain
normal glucose and insulin levels.
8-week old male mice were fasted overnight (4pm to 10am) and refed HCD for 0, 1.5, 3,
6, or 12 hours prior to sacrifice.
A-C. Body weight (A), liver weight expressed as grams weight (B) and as a ratio to body
weight (LW/BW) (C). *p<0.05 vs Fasted (0) time point of the same genotype and
**p<0.05 of the two bracketed points by one-way ANOVA using Newman-Keuls posttest.
E, F. Blood glucose (E) and seurm insulin (F) at the time of sacrifice. Fasted (0 hour)
time point: *p<0.05 vs all other time points of that same genotype by one-way ANOVA
using Newman-Keuls post-test.
All values are expressed as mean ± SEM. n=5-6.
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Figure 4-5: AFP;Akt2lox/lox mice maintain normal hepatic concentrations of
triglyceride, protein and glycogen but have decreased glycogen content.
8-week old male mice were fasted overnight (4pm to 10am) and refed HCD for 0, 1.5, 3,
6, or 12 hours prior to sacrifice.
A, B. Hepatic triglycerides (TG) expressed as concentration per gram liver (A) and total
(B). No time points are significantly different to others (p<0.05 by one-way ANOVA
using Newman-Keuls post-test).
C. Hepatic protein expressed as concentration per gram liver. Fasted (0 hour) time point:
*p<0.05 vs all other time points of that same genotype by one-way ANOVA using
Newman-Keuls post-test.
D. Total hepatic protein. No time points are significantly different to others (p<0.05 by
one-way ANOVA using Newman-Keuls post-test).
E, F. Hepatic glycogen expressed as concentration per gram liver (E) and total (F).
Fasted (0) levels were undetectable. *p<0.05 by one-way ANOVA using Newman-Keuls
post-test.
All values are expressed as mean ± SEM. n=5-6.
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Figure 4-6: Serum measurements during fasting and refeeding in AFP;Akt2lox/lox
mice.
8-week old male mice were fasted overnight (4pm to 10am) and refed HCD for 0, 1.5, 3,
6, or 12 hours prior to sacrifice.
A, B. Serum triglycerides (TG) (A) and cholesterol (CH) (B).
C, D. Serum non-esterified fatty acids (NEFA) (C) and ketones (D). Fasted (0 hour) time
point: *p<0.05 vs all other time points of that same genotype by one-way ANOVA using
Newman-Keuls post-test.
All values are expressed as mean ± SEM. n=5-6; **p<0.05 of the two bracketed points
by one-way ANOVA using Newman-Keuls post-test.
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Figure 4-7: Refeeding-stimulated de novo lipogenesis is decreased in
AFP;Akt2lox/lox mice.
De novo lipogenesis: 8-week old male mice were injected with D2O at the time points
described below, sacrificed after 3 or 6 hours, and liver was removed and analyzed for
palmitate by GC/MS.
A. Mice were fasted overnight (4pm to 10am), refed HCD (6 hour group) or maintained
fasting (Fasted), injected after 3 hours (1pm), and sacrificed 3 hours later (4pm). n=3-5;
*p<0.05 by one-way ANOVA using Newman-Keuls post-test.
B. Mice were fasted overnight (4pm to 9am), refed HCD (12 hour group), injected after 6
hours (4pm), and sacrificed 6 hours later (9pm). n=5-6; *p<0.01 by Student’s t-test.
All values are expressed as mean ± SEM.
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Figure 4-8: Refeeding-stimulated increases in expression of some, but not all,
lipogenic gene are Akt2-dependent.
Hepatic gene expression as measured by Real-Time PCR of 8-week old male mice were
fasted overnight (4pm to 10am) and refed HCD for 0, 1.5, 3, 6, or 12 hours prior to
sacrifice. Data are presented as mRNA expression relative to that of TATA-binding
protein and normalized to expression in Akt2lox/lox Fasted (0) time point, which is set to
1.0 using the ddCT method.
All values are expressed as mean ± SEM. n=5-6; *p<0.05 vs Fasted (0) time point of the
same genotype and ** p<0.05 by one-way ANOVA using Newman-Keuls post-test.

Abbreviations: sterol regulatory element binding protein-1c (SREBP1c), fatty acid
synthase (FAS), ATP citrate lyase (ACL), acetyl-CoA carboxylase (ACC), glucokinase
(GCK), glycerol phosphate acyltransferase (GPAT), pyruvate kinase, liver isoform (LPK), and glucose-6-phosphatase (G6Pase).

152

153

Chapter 5:

Summary and Speculations
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Akt2 regulates hepatic lipid metabolism
Though insulin is well known to stimulate de novo lipogenesis in liver, the precise
mechanism by which this is accomplished is not well understood. SREBP1c is clearly
an important intermediate in the transcriptional control of lipogenesis, but the pathway by
which insulin activates both processing and expression of SREBP1c remains uncertain
(Raghow et al., 2008). To some extent, the difficulty in investigating this problem relates
to the low rates of de novo lipogenesis in the normal postabsorptive liver, which have
been estimated to contribute as little as 5% of total triglyceride fatty acids in humans
(Diraison et al., 2003). For this reason, it has proven instructive to manipulate the
metabolic state of experimental organisms in order to increase fat accumulation in the
liver. In the present study, we have done so employing both genetic and dietary
strategies and found a strong dependency on the presence of hepatic Akt2 for the
development of steatosis and an absolute requirement for the increase in lipogenesis. In
addition, we have established that Akt2 is required for the induction of de novo
lipogenesis following HCD-feeding in lean animals. Thus, we can conclude that Akt2 is
required definitively for full accretion of hepatic triglyceride during pathological states and
as well as in normal anabolic lipid metabolism.
However, Akt2 does not influence lipid metabolism in the same manner in our
three different models. In the ob/ob mouse, loss of Akt2 prevented any excess hepatic
triglyceride accumulation and acute loss of the kinase reversed existing steatosis. The
absence of hepatic steatosis was associated with decreased de novo lipogenesis, which
appeared to be controlled at the level of SREBP1c expression. On the other hand, loss
of Akt2 in DIO reduced hepatic triglyceride accumulation but did not completely prevent
it, and de novo lipogenesis was unchanged in the absence of the kinase, indicating that
Akt2 is required for another lipid metabolic pathway involved in steatosis. Furthermore,
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Akt2 was required for the induction of de novo lipogenesis following HCD-refeeding in
lean animals, though this did not appear to be due to a requirement for the induction of
SREBP1c expression. Therefore, Akt2 appears to be involved in many facets of the
regulation of hepatic lipid metabolism.

Akt2 is required for increased de novo lipogenesis in the ob/ob mouse, likely
through SREBP1c
The role of Akt as the primary mediator of insulin’s action to increase SREBP1c
and promote lipogenesis has been a point of some controversy. Hepatic overexpression
of constitutively active Akt increases hepatic neutral lipid dramatically by a pathway
partially dependent on SREBP1c (Ono et al., 2003). Similarly, forced activation of
endogenous Akt by liver-specific deletion of the lipid phosphatase PTEN produces
substantial accumulation of hepatic triglyceride and increased lipogenic gene
expression, though this model is complicated by the concomitant activation of other
PI3K-dependent kinases (Stiles et al., 2004). On the other hand, a dominant inhibitory
Akt does not block insulin’s induction of SREBP1c in tissue culture cells and ob/ob mice
have markedly increased SREBP1c mRNA in spite of significantly reduced levels of
phospho-Akt (Matsumoto et al., 2002; Shimomura et al., 2000). aPKC (PKCλ/ζ) proteins
have received considerable attention as obligate mediators of the effects of insulin and
PI3K on anabolic lipid metabolism, and have specifically been advanced as an
alternative to Akt (Matsumoto et al., 2003; Taniguchi et al., 2006b). Matsumoto et al.
showed that mice with liver-specific deletion of PKCλ have decreased SREBP1c
expression and triglyceride content, though reduced serum insulin levels complicated the
interpretation of the in vivo findings in the study (Matsumoto et al., 2003). Kahn and
colleagues undertook a different approach, eliminating both aPKC and Akt activity by
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ablation of all PI3K in the liver, and then selectively introducing constitutively activate
versions of the two kinases by adenovirus-mediated delivery (Taniguchi et al., 2006b).
They found that aPKC, but not Akt, restored SREBP1c mRNA, but the effects on hepatic
lipids were not reported.
The current studies do not address a potential role for aPKC and thus are
compatible with a requirement for this kinase. However, in contrast to Taniguchi et al.,
they strongly support a critical role for Akt2. ob/ob mice lacking hepatic Akt2 exhibited
decreased SREBP1c expression, decreased lipogenesis and greatly improved hepatic
steatosis. Importantly, ob/ob mice heterozygous for Akt2 displayed a reduction in liver
triglyceride content and de novo lipogenesis intermediate between that in mice wildtype
and null for Akt2. This indicates that Akt2 is not only permissive for anabolic lipid
metabolism, but is actually rate-determining. Additionally, acute excision of hepatic Akt2
resulted in a reversal of hepatic steatosis, indicating that Akt2 is required for ongoing
maintenance of lipid accumulation.
Our data suggest that Akt2 is required for the upregulation of lipogenic gene
expression in the ob/ob mouse, and in Akt2’s absence, lipogenic gene expression and
therefore de novo lipogenesis are not increased. Insulin is known to regulate lipogenic
gene expression through stimulating the expression of SREBP1c, and this has been
shown to be Akt-dependent in vitro (Fleischmann and Iynedjian, 2000; Porstmann et al.,
2005). Indeed, we found that the expression of SREBP1c and its lipogenic targets were
decreased in Lepob/obAFP;Akt2lox/lox livers. Upregulation of SREBP1c drives some of the
hepatic lipid accumulation observed in leptin-deficiency as hepatic steatosis is markedly
reduced in ob/ob mice lacking SREBP1, corresponding to a decrease in lipogenic gene
expression, a phenotype similar to our studies in ob/ob mice lacking hepatic Akt2
(Yahagi et al., 2002). However, while the decreased hepatic expression of SREBP1c
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correlates with decreased de novo lipogenesis in Lepob/obAFP;Akt2lox/lox mice, it does not
prove causality between the two.
Interestingly, while we did not observe any changes in ChREBP mRNA in
Lepob/ob AFP;Akt2lox/lox mice, the induction of L-PK expression, a lipogenic gene that is
supposed to be regulated by ChREBP and not SREBP1c, was blocked in ob/ob mice
with loss of hepatic Akt2. In addition, overexpression of constitutively active Akt
promotes hepatic triglyceride accumulation through some SREBP1c-independent
mechanisms, indicating that Akt2’s regulation of de novo lipogenesis may not proceed
solely through SREBP1c (Ono et al., 2003). Liver X receptors (LXR) are transcription
factors activated by oxysterol ligands, and administration of LXR agonists in mice results
in induction of lipogenic gene expression and hepatic steatosis (Schultz et al., 2000).
LXRs are necessary for insulin-stimulated induction of SREBP1c expression in rat
hepatocytes and sufficient to increase hepatic SREBP1c mRNA in vivo (Chen et al.,
2004; Repa et al., 2000). Additionally, LXRs can induce the expression of ChREBP and
L-PK, though this is likely through an increase in ChREBP mRNA and not through
modulation of ChREBP activity (Cha and Repa, 2007; Denechaud et al., 2008). Though
L-PK mRNA was decreased in Lepob/obAFP;Akt2lox/lox mice, ChREBP mRNA was not,
indicating that Akt2 somehow influences ChREBP activity and not expression. To
determine if LXR activity was altered and contributing to the regulation of lipogenic gene
expression in our Lepob/obAFP;Akt2lox/lox mice, we could measure the expression of one of
LXR’s non-lipogenic targets, such as the transporters ABCG5 or ABCG8 (Tontonoz and
Mangelsdorf, 2003).

Akt2 is required for the induction of de novo lipogenesis in lean animals by high
carbohydrate-feeding, likely independent of SREBP1c
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While Akt2 is certainly required in insulin-resistant livers for lipid metabolism and
accumulation, we show that hepatic Akt2 is also required in normal livers for the
induction of de novo lipogenesis by HCD-refeeding. Livers from animals subjected to an
overnight fast had very low levels of lipogenic mRNAs and de novo lipogenesis,
regardless of the presence or absence of Akt2. Upon refeeding with a HCD, both de
novo lipogenesis and lipogenic gene expression increased in Akt2lox/lox mice. Hepatic
Akt2 was required for the induction of de novo lipogenesis above fasted levels and for
the full increase in the expression of some lipogenic genes. However, Akt2 was not
required for the induction of SREBP1c expression and the universal lipogenic gene
program as AFP;Akt2lox/lox mice exhibited normal increases in SREBP1c, ACC, and
GPAT mRNAs. Thus, Akt2 can regulate the rate of de novo lipogenesis in lean animals
in an SREBP1c expression-independent manner.
There are several possible mechanisms through which Akt2 could act to induce
de novo lipogenesis. Akt2 could still induce de novo lipogenesis through the induction of
FAS, ACL, GCK, and possibly other lipogenic enzyme expression though not through
the control of SREBP1c expression. Insulin can control the processing of SREBP1c into
an active transcription factor; nuclear fractionization and Western blotting could be used
to determine if this processing is regulated in an Akt2-dependent manner. Additionally,
Akt2 could either directly or indirectly modulate the translation or activity of key lipogenic
enzymes thereby regulating flux through de novo lipogenesis. Though we have
demonstrated that mRNAs for FAS, ACL and GCK were decreased in the absence of
hepatic Akt2, we need to determine if the protein levels of these enzymes are
correspondingly decreased. Activities of FAS, ACC, ACL, and GCK could be measured
in the absence of Akt2 to assess whether this could be a level of control. If any lipogenic
activity was decreased, add-back of that enzyme by adenoviral expression could be
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performed to reverse the blunted rate of lipogenesis. Further biochemical
characterization of these enzymes could also reveal whether they were Akt2 substrates
and subject to regulation by the kinase.

Akt2 controls lipid accumulation by an unknown lipid metabolic process in dietinduced obesity
One surprising result of these studies is that even though the necessity of Akt2
for steatosis applies to multiple models, in DIO by high-fat feeding, hepatic triglyceride
content was reduced but lipogenesis and lipogenic gene expression were unchanged in
the absence of hepatic Akt2. These results contrast with those in the ob/ob mouse, in
which the protection from steatosis is at least partially mediated through preventing the
stimulation of de novo lipogenesis, though this does not exclude the influence of Akt2 on
another lipid metabolic pathway in the ob/ob mouse. In DIO induced by Surwit HFD, de
novo lipogenesis was elevated compared with chow-fed mice, but lipogenic gene
expression was unchanged, and loss of hepatic Akt2 had no effect on either. In DIO
induced by lard HFD, de novo lipogenesis was reduced compared with chow-fed mice,
though once again lipogenic gene expression was largely unchanged and loss of hepatic
Akt2 did not influence either. The dramatic difference in lipogenesis observed between
the two diets is surprising as the contribution of fat and carbohydrates to caloric content
is similar (58 and 25.5 % kcal in Surwit and 60 and 20 % kcal in lard; see Materials and
Methods). The difference in sucrose content or source of fat is perhaps influencing the
suppression versus the induction of lipogenesis. Regardless, Akt2 does not reduce
hepatic triglyceride content in DIO through its control of de novo lipogenesis.
Additionally, while loss of hepatic Akt2 resulted in a complete prevention of hepatic
triglyceride accumulation in the ob/ob mouse, it only resulted in decreased accumulation
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in DIO, suggesting different underlying causes. Thus, Akt2 likely mediates insulin’s
induction of triglyceride accumulation by stimulating fatty acid synthesis as well as
processes other than de novo lipogenesis.
One obvious candidate mechanism is that loss of Akt2 abrogates the normal
suppression of β-oxidation produced by insulin. For example, insulin suppresses the
PGC-1α-dependent stimulation of fatty acid oxidation, both by reducing hepatocyte
cyclic AMP and by promoting the Akt-dependent inhibition of PGC-1α activity (Li et al.,
2007). However, by several criteria, an increase in β-oxidation is unlikely to explain the
protection from steatosis in DIO or ob/ob mice. First, there were no differences in
expression of hepatic oxidative genes comparing Akt2lox/lox to AFP;Akt2lox/lox mice placed
on a Surwit HFD. Second, though PGC-1α mRNA increased in Lepob/ob AFP;Akt2lox/lox
livers, expression of the critical targets MCAD and CPT1 were not elevated in parallel
(Schreiber et al., 2003; Song et al., 2004). Lastly, RER and serum ketones bodies were
largely indistinguishable in wildtype versus AFP;Akt2lox/lox mice on either an ob/ob
background or Surwit HFD.
Another possible mechanism through which Akt2 could decrease hepatic lipid
accumulation is increased triglyceride export. Insulin can suppress VLDL secretion by
directly increasing apoB degradation in a PI3K-dependent manner (Chirieac et al.,
2000). Han and colleagues reported decreased VLDL levels along with decreased
lipogenic gene expression in mice with severely impaired insulin signaling (L1 mice) on
Ldlr-/- background fed an atherogenic Western diet (Han et al., 2009). VLDL levels were
normalized with hepatic overexpression of constitutively active Akt, suggesting a role for
Akt in the context of almost complete deficiency of the insulin receptor. Lepob/ob Akt2-/mice did exhibit elevated serum triglyceride levels, suggesting that an increase in
triglyceride export could be partially responsible for decreasing hepatic triglycerides by
161

shunting them into the serum. However in Lepob/ob AFP;Akt2lox/lox mice, fed serum
triglyceride levels did not differ from Lepob/ob Akt2lox/lox mice, and fasted serum
triglycerides were actually lower; there was also no difference in AFP;Akt2lox/lox mice on
Surwit HFD. Additionally, a direct measurement of triglyceride export using P-407 in
both ob/ob and DIO mice failed to reveal a requirement for Akt2. These observations
suggest that increased triglyceride export and increased β-oxidation do not play a role in
reducing hepatic triglyceride accumulation in the absence of Akt2 in the liver. However,
we do discuss a potential role for Akt signaling in the control of these two processes
through FoxO1 and PGC-1α below.
Having likely ruled out de novo lipogenesis, VLDL export and β-oxidation as
Akt2-regulated processes that could control hepatic lipid accumulation in DIO, we must
consider other processes, less classically involved in insulin signaling. We measured de
novo lipogenesis as the synthesis of its major product, palmitate, in our mice; however,
increased hepatic fatty acid synthesis could occur through chain elongation and
desaturation of exogenous fatty acids rather than through de novo synthesis. This has
been previously reported to be the case in C57BL/6J mice fed a HFD as palmitate
(C16:0) synthesis was unchanged, but oleate (C18:1) synthesis was increased;
additionally hepatic expression of SREBP1c, SCD1, FAS, ACC1, and GPAT were all
elevated (Oosterveer et al., 2009). However, long-chain fatty acyl-CoAs were not
changed in either Surwit HFD-fed or ob/ob mice lacking hepatic Akt2, suggesting that
Akt2 was not regulating the elongation and saturation of exogenous fatty acids, though
measurement of oleate synthesis could formally rule out this possibility. However, Akt2
could be influencing the handling of exogenous fatty acids, either from the diet or from
adipose tissue. While uptake and re-esterifcation of fatty acids from the serum by the
liver has been considered to be a largely passive process, recent evidence has emerged
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that certain conditions, such as high-fructose feeding, can actually enhance fatty acid reesterification (Parks et al., 2008). AFP;Akt2lox/lox mice have decreased serum
triglycerides following HCD-refeeding at a time when most of the triglycerides in the
serum should be from a dietary source and not from de novo lipogenesis; this suggests
that Akt2-deficient livers may have a defect in their handling of exogenous fatty acids.
We are currently developing an ex vivo liver perfusion system that could be used to
measure uptake and esterification of heavy isotope-labeled fatty acids, thus making it
feasible to question whether Akt2 could control this aspect of hepatic lipid metabolism.

Selective insulin resistance revisited: bifurcation below the level of Akt
A longstanding paradox has been that people with T2DM and obesity or rodents
with equivalent metabolic disorders have systemic insulin resistance in the face of
increased hepatic lipogenesis, a classical insulin response (Petersen et al., 2007).
Though a number of models could explain this, the concept of selective or partial insulin
resistance has received increasing recent attention (Brown and Goldstein, 2008). Both
humans with insulin resistance due to inherited mutations in the insulin receptor and
mice with liver-specific deletion of the insulin receptor exhibit hyperglycemia and
hyperinsulinemia but are protected against steatosis and hypertriglyceridemia (Biddinger
et al., 2008; Semple et al., 2009). This finding is consistent with the idea that in classical
“insulin-resistant” states, not all signaling is blunted, but rather some is preserved, in
particular that to lipid synthesis. While it is likely that the pathways regulating glucose
and lipid metabolism diverge somewhere downstream of the IRS proteins but upstream
of FoxO1 and SREBP1c, respectively, the precise biochemical site is unknown (Dong et
al., 2008; Kubota et al., 2008; Matsumoto et al., 2007). In the studies presented in this
thesis, we have demonstrated that the point of selective insulin resistance likely lies
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downstream of Akt (Figure 5-1A). Additionally, we propose a model for further study in
which Akt mediates both the insulin-resistant arm to glucose output and the insulinsensitive arm to lipid synthesis (Figure 5-1B).

Akt to FoxO1 to glucose output: the insulin-resistant branch
That Akt2 plays a role in glucose homeostasis has been established prior to the
start of this thesis. Earlier reports from our group and another reported that whole-body
Akt2-/- mice are mildly diabetic and exhibit impaired suppression of hepatic glucose
output by insulin (Cho et al., 2001a; Garofalo et al., 2003). We have shown here that
liver-specific Akt2 null mice also failed to suppress hepatic glucose output during
hyperinsulinemic euglycemic clamp, the gold standard measure of insulin resistance with
regards to glucose homeostasis. Akt2-/- mice on an ob/ob background and on Surwit
HFD exhibited increased insulin resistance by clamp compared with their Akt2+/+
counterparts. Akt2-/- mice were able to compensate by increasing their serum insulin
levels, while Lepob/obAkt2-/- mice were unable to do so and succumbed to severe
hyperglycemia. However, AFP;Akt2lox/lox mice on either an ob/ob background or Surwit
HFD did not exhibit worse insulin resistance or glucose intolerance than that of their
Akt2lox/lox counterparts. This clearly demonstrates that Akt2 plays a role in tissues other
than the liver to regulate glucose homeostasis. It also shows that signaling through Akt
in the liver is already likely to be impaired in insulin-resistant states, such that further
loss of hepatic Akt2 does not have an additional effect on glucose homeostasis. Indeed,
Western blotting of both ob/ob and Surwit HFD-fed livers showed substantial
impairments in insulin signaling through Akt.
While Akt2 seems to be specifically required for the regulation of lipid synthesis,
at least in ob/ob and HCD-refed livers, regulation of glucose metabolism is likely shared
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by both Akt2 and Akt1. Though Akt1-/- mice do not exhibit impairments in glucose
homeostasis, compound whole-body Akt1+/- Akt2-/- mice have severe diabetes, indicating
that signaling through Akt1 controls glucose homeostasis at least somewhat in the
absence of Akt2 (Chen et al., 2009; Chen et al., 2001; Cho et al., 2001b). Unpublished
work being done in our group has supported this hypothesis: acute excision of both Akt1
and Akt2 in the liver results in extremely elevated blood glucose levels and complete
dysregulation of the FoxO1 target gene, insulin-like growth factor binding protein-1
(IGFBP1) (unpublished data courtesy of Dr. Mingjian Lu). However, it is unclear whether
the regulation of glucose metabolism is shared by both isoforms equally and only the
amount of hepatic Akt present matters or if there is some level of isoform specificity.
The insulin signaling cascade controlling glucose metabolism is generally thought
to proceed predominately through inhibition of FoxO1 (reviewed in Gross et al., 2008).
Therefore, in the model of selective insulin resistance proposed in this thesis, insulin
signals through Akt and FoxO1 to regulate glucose metabolism and is impaired in
insulin-resistant states; this branch includes signaling through both Akt2 and Akt1
(Figure 5-1B). There is also evidence that FoxO1 mediates insulin’s suppression of
VLDL secretion, through insulin’s suppression of FoxO1’s stimulation. Overexpression
of FoxO1 in liver increases serum triglycerides and conversely, hepatic RNAi knockdown
of FoxO1 decreases VLDL production (Altomonte et al., 2004; Kamagate et al., 2008).
As we did not observe any alterations in VLDL secretion in our Akt2-deficient mice,
residual signaling through Akt1 in the “insulin-resistant” branch could be maintaining
normal control of FoxO1 and VLDL secretion. In addition, Akt phosphorylates and
inhibits PGC-1α, an action which should inhibit fatty acid oxidation (Li et al., 2007);
however, we did not see any gross abnormalities in β-oxidation. Thus this pathway
could also proceed along the “insulin-resistant” branch and receive signaling from Akt1
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in the absence of Akt2. Thus, VLDL secretion and fatty acid oxidation should be
investigated in the liver-specific Akt1/Akt2 double null mice.

Akt2 (to mTOR?) to lipid synthesis: the insulin-sensitive branch
Unlike the glucose arm of insulin/Akt signaling, we propose that insulin signaling
to lipogenesis runs solely through Akt2 and is maintained in insulin-resistant states
(Figure 5-1B). We cannot fully discount a role of Akt1: signaling to lipid synthesis could
require higher hepatic Akt levels than does that to glucose metabolism, and loss of
hepatic Akt2 could decrease signaling through Akt to below what is required. Indeed
Lepob/obAkt2+/- mice exhibited an intermediate decrease in de novo lipogenesis compared
with both Lepob/obAkt2+/+ and Lepob/obAkt2-/- mice. This question could be resolved in
Lepob/obAkt1-/- mice, which should have approximately the same amount of residual Akt
as Lepob/obAkt2+/- mice, and therefore would have a similar rate of de novo lipogenesis.
Having established the presence of Akt2 in the pathway regulating hepatic
lipogenesis, the next step is defining what is downstream. There appear to be both
SREBP1c expression-dependent and –independent influences of Akt2 on de novo
lipogenesis. Since the start of this thesis, mTOR has emerged as a likely downstream
target of insulin signaling for the regulation of SREBP1c expression, though most of the
published studies have relied upon chemical inhibitors of mTOR. Inhibition of mTOR by
rapamycin in isolated rat hepatocytes results in decreased de novo lipogenesis and
blocks insulin-stimulated SREBP1c expression; the latter is also blocked by rapamycin in
fasted/refed rats (Brown et al., 2007; Li et al., 2010). Additionally, rapamycin blocks
myr-Akt-induced SREBP1 processing, SREBP1, FAS and ACL expression and increase
in de novo lipogenesis in vitro (Porstmann et al., 2008). However, further in vivo studies
are required to determine if mTOR is a distal mediator of insulin’s control of SREBP1c
166

and lipogenesis. We have already done preliminary studies in liver-specific Raptor null
mice that are deficient in mTORC1 signaling, and have found that these mice have
decreased SREBP1c, FAS, SCD1, and ACL expression under random fed conditions
(unpublished data in collaboration with Dr. Min Wan). We plan on measuring de novo
lipogenesis in these mice, and hope to use them to further define the pathway through
which insulin/Akt regulates lipogenesis.
The definition of SREBP1c-independent influences of Akt2 signaling on de novo
lipogenesis may prove more difficult. As discussed above, these could include the
regulation of SREBP1c processing, which could be determined by nuclear fractionization
and Western blotting, or modulation of lipogenic enzyme activities. Activities of FAS,
ACC and ACL could be measured in either liver samples or isolated hepatocytes to
assess if the absence of Akt2 has an effect. Additionally, we are planning on injecting
liver-specific Raptor null mice with adenovirus expressing myr-Akt, which induces
massive hepatic steatosis and hypertriglyceridemia (Ono et al., 2003). If Raptordeficiency in the liver results in a complete reversal of the myr-Akt-induced hepatic
steatosis, then it is unlikely that Akt2 has any direct effects on protein processing or
activity. However, if there is still a residual effect of myr-Akt in the absence of Raptor on
the liver, this will give us insight into those pathways that are mTOR- and possibly
SREBP1c-independent.

The role of extrahepatic Akt2
The entire contribution of hepatic Akt2 to metabolism has not been fully
elucidated in the studies described in this thesis. For example, we continually see a
decrease in serum cholesterol in the absence of Akt2: serum cholesterol is reduced in
both Akt2-/- and AFP;Akt2lox/lox mice on an ob/ob background, in Akt2-/- mice on Surwit
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HFD, and in Akt2lox/lox mice on lard HFD following AAV-Cre injection. This is likely due to
a role of hepatic Akt2, yet we have no data as to the mechanism. Additionally, hepatic
Akt2 determines liver weight in response to HCD-refeeding by some unknown influence;
hepatic Akt2 also has a non-autonomous effect on whole-body size of the ob/ob mouse.
All of these observations warrant further investigation beyond the scope of this thesis.
Another question not fully elucidated in these studies is the role of Akt2 in
extrahepatic tissues in the control of metabolism. As mentioned above, whole-body
Akt2-/- mice exhibited a much more severe diabetic phenotype than AFP;Akt2lox/lox mice
did on an ob/ob background. ob/ob mice null for Akt2 also had elevated serum
triglyceride levels, whereas ob/ob mice with liver-specific deletion of Akt2 exhibited
normal or reduced circulating triglycerides. A recent study examining lipid abnormalities
in humans with genetic syndromes of insulin resistance reported increased liver fat
content, lipogenesis, serum triglycerides, and other severe metabolic abnormalities in
several individuals with a dominant-negative mutation in Akt2 (Semple et al., 2009).
This emphasizes the role of non-hepatic tissues in determining glucose and lipid
metabolism and the difficulties in interpreting data in the context of whole-body
metabolism. Perhaps the most striking unexplained observation is the phenotype of
Akt2-/- mice on Surwit HFD: these mice gained significantly less weight on Surwit HFD
compared with their Akt2+/+ counterparts, predominately due to their failure to gain fat
mass. This phenotype cannot be explained by loss of hepatic Akt2 as AFP;Akt2lox/lox
gain normal body weight and fat mass on Surwit HFD. Therefore, while our
understanding of the role of hepatic Akt2 in the regulation of metabolism is advancing,
partially due to the studies described in this thesis, our understanding of the role of Akt2
in other metabolic tissues requires further investigation.
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Figure 5-1: Proposed model of Akt action
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Chapter 6:

Materials and Methods
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Animals
All animals were raised and treated with approval from the University of
Pennsylvania in accordance with NIH guidelines. Male mice were used for all studies.
Mice were reared on normal chow fed ad libitum unless otherwise noted under 12 hour
light:dark cycles (7am:7pm) in a barrier facility. The generation of a conditional allele of
Akt2 and derivation of Akt2 null mice have been described previously (Cho et al.,
2001a). Akt2-/- mice were backcrossed ten generations or more to C57BL/6J mice.
Lepob/+ mice on a C57BL/6J background were purchased from Jackson Laboratories. To
generate Akt2lox/lox mice, mice described by Cho et al prior to loxP mediated
recombination were mated to mice expressing a variant of the Saccharomyces
cerevisiae FLP1 recombinase gene under the direction of the Gt(ROSA)26Sor promoter
(FLPeR) (Jackson Laboratories), thus excising the neomycin selection cassette (Cho et
al., 2001a). The AFP Cre mouse line was generously provided by Dr. Klaus Kaestner
(Zhang et al., 2005). All Akt2lox/lox mice used were of a mixed background, with the
exception of Akt2lox/lox and Lepob/obAkt2lox/lox mice injected with AAVs, which had been
backcrossed ten generations or more to C57BL/6J mice at that point.
Mice were fed specialized diets as noted starting at 5-6 weeks of age:
composition of diets is included below as Tables 6-2 through 6-5. For fasting/refeeding
protocol, mice were first acclimated to high-carbohydrate diet for 2-4 days, fasted
overnight starting at 4pm, and refed at 10am the following morning for the described
intervals prior to sacrifice.

Metabolic measurements and analytical procedures
All blood glucose measurements were made using a glucometer (OneTouch
Ultra, Lifescan). Insulin assays were conducted on blood collected from mice by tail
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bleed into heparinized tubes using an ELISA kit (Ultra Sensitive Rat or Mouse Insulin
ELISA kit, Crystal Chem, Inc.). Serum triglycerides, cholesterol, free fatty acids (NEFA),
and ketone bodies were analyzed from blood collected after sacrifice by cardiac
puncture using colorimetric assay kits (Infinity TG and CH reagents, ThermoDMA, Inc;
NEFA-HR kit, Wako; β-hydroxybutyrate LiquiColor kit, Stanbio Laboratories,
respectively).
Hepatic triglycerides were measured from animals sacrificed by CO2 inhalation,
snap-frozen in liquid nitrogen, and stored at -80ºC until processed. Frozen livers were
weighted and homogenized in lysis buffer (140mM NaCl, 50mM Tris, 0.1% Triton-X)
using a Tissuelyser (Qiagen). Liver homogenates were then incubated at 37ºC with 1%
deoxycholate, and triglycerides measured colorimetrically using Infinity Triglyceride
Reagent (ThermoDMA, Inc). The same homogenates were used to measure hepatic
protein content using a bicinchoninic Acid (BCA) assay (Thermo Scientific). Liver
glycogen was measured using a 6% perchloric acid (PCA) extraction, followed by an
amyloglucosidase digestion; glucose both from liver (pre-digestion) and glycogen (postdigestion) were analyzed using a hexokinase-based assay kit (Glucose (HK) Assay Kit
from Sigma).
Hepatic long-chain fatty acyl-CoAs were isolated as previously described and
measured by using an API 4000 tandem mass spectrometer (Applied Biosystems) in
conjunction with 2 PerkinElmer 200 Series micro pumps and a 200 Series autosampler
(PerkinElmer) (Neschen et al., 2005). This was performed in the laboratory of Gerald
Shulman of Yale School of Medicine.

Adeno-associated virus (AAV) injections

172

In order to acutely excise Akt2, Akt2lox/lox and Lepob/obAkt2lox/lox mice were injected
with AAV2/8 expressing green fluorescent protein (GFP) or Cre recombinase under the
control of the tyroxine-binding globulin (TBG) promoter. Mice were anesthetized using
isoflurane, and injected retro-orbitally with 100µl of virus diluted in phospho-buffered
saline (PBS) so that each mouse received a titer of 1e12 GC/ml. Viruses were produced
by the Penn Vector Core of the Gene Therapy Program at the University of
Pennsylvania.

Glucose tolerance tests (GTT) and insulin tolerance tests (ITT)
For GTT, mice were fasted overnight (approximately 5pm to 9am). 20% dextrose
was injected intraperitoneally or gavaged in a dose of 1g/kg body weight. Blood glucose
was measured from tail bleed at 0, 15, 30, 60 and 120 minutes, and blood was collected
in heparinized tubes for insulin measurement at 0 and 15 minutes. Food was returned to
animals at the end of experiment.
For ITT, mice were fasted for 5 hours (approximately 9am to 2pm). Insulin was
injected intraperitoneally or subcutaneously at 1U/kg or 2U/kg body weight (Humilin,
Lilly). Blood glucose was measured at 0, 15, 30, 60 and 120 minutes post injection by
tail bleed. 20% glucose was on hand to give to if mouse’s blood glucose level dropped
below 20mg/dl. Food was returned to animals at the end of experiment.

De novo lipogenesis assay
The protocols for 2H-Labeling of body water, 2H-Labeling and concentration of
total palmitate, and rate of lipid synthesis were provided by Dr. Stephen Previs of Case
Western Reserve University School of Medicine. GC/MS analysis was performed by Dr.
Previs for all ob/ob mice and by Dr. John Millar of the GC/MS Resource of the Institute of
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Diabetes, Obesity and Metabolism at the University of Pennsylvania School of Medicine
for the fasted/refeeding experiment.

Animal procedure. Male mice were fasted for 5 hours (8am to 1pm), injected with D2O
(400µl per 20g body wt), and sacrificed 3 hours later. Blood was collected by cutting the
aorta/IVC, using the diaphragm as a barrier to the peritoneal cavity. Liver was removed
and snap-frozen in liquid nitrogen.

2

H-Labeling of body water. The 2H-labeling of body water was determined by exchange

with acetone (Yang et al., 1998). Briefly, samples were centrifuged for 1 min at ~ 12,000
g in a microcentrifuge, 40 µl of sample (or standard) was reacted with 2 µl of 10 N NaOH
and 4 µl of a 5% (v/v) solution of acetone in acetonitrile for 24 h at room temperature.
Acetone was then extracted by addition of 600 µl of chloroform followed by addition of ~
0.5 g Na2SO4. Samples were vigorously mixed and a small aliquot of the chloroform was
transferred to a GC-MS vial. Acetone was analyzed using an Agilent 5973N-MSD
equipped with an Agilent 6890 GC system, a DB-17MS capillary column (30 m x 0.25
mm x 0.25 µm) was used in all analyses. The temperature program was as follows:
60ºC initial, increase by 20ºC per min to 100ºC, increase by 50ºC per min to 220ºC and
hold for 1 min. The sample was injected at a split ratio of 40:1 with a helium flow of 1 ml
per min. Acetone eluted at ~ 1.5 min. The mass spectrometer was operated in the
electron impact mode (70 eV). Selective ion monitoring of m/z 58 and 59 was performed
using a dwell time of 10 ms per ion.

2

H-Labeling and concentration of total palmitate. A known quantity of tissue was

hydrolyzed and extracted, after adding a known amount of heptadecanoic acid.
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Palmitate was analyzed as its trimethylsilyl derivative using gas chromatographyelectron impact ionization mass spectrometry. The oven temperature was initially held
for 1 min at 150° C, then increased by 20° C per min to 310° C and maintained for 8 min.
The split ratio was 20:1 with helium flow 1 ml per min. The inlet temperature was set at
270° C and MS transfer line was set at 310° C. Under these conditions, palmitate elutes
at ~ 5.7 min. The 2H-enrichment was determined by using selective ion monitoring
under electron impact ionization of m/z 313 and 314 (M+0 and M+1), 10 ms dwell time
per ion (Brunengraber et al., 2003). The concentration of palmitate was determined by
comparing the corrected abundance of m/z 313 to 314 to that of heptadecanoate (17:0,
m/z 327). To account for possible differences in the ionization efficiency of each fatty
acid, the profile was compared against standards prepared by mixing known quantities
of each fatty acid (Brunengraber et al., 2003).

Rate of lipid synthesis. The percent contribution of newly made palmitate was
determined using the equation:
% newly made palmitate = [total 2H-labeling palmitate / (2H-labeling body water x n)] x
100
where n is the number of exchangeable hydrogens, assumed to equal 22 (Diraison et
al., 1997; Lee et al., 1994a; Lee et al., 1994b). The absolute amount of newly made
palmitate was determined by multiplying the % newly made palmitate by the
concentration of palmitate.

Hyperinsulinemic euglycemic clamps, body composition, food intake, and RER
Hyperinsulinemic euglycemic clamps, body composition (with the exception of
that in Lepob/obAkt2-/- mice), food intake, and RER were performed by the Mouse
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Phenotyping, Physiology and Metabolism Core at the University of Pennsylvania School
of Medicine. Body composition was determined in conscious mice by nuclear MRI
analysis (Echo Medical Systems); food intake and RER were assessed under conditions
of free access to food and water using Comprehensive Laboratory Animal Monitoring
System (CLAMS; Columbus Instruments). Oxygen consumption (VO2) and carbon
dioxide production (VCO2) were measured in CLAMS and used to calculate respiratory
quotient/RER. Body composition of Lepob/obAkt2-/- mice was measured using the 2Hlabeling of body water (determination described above in de novo lipogenesis assay) by
a known amount of injected D2O relative to body weight as a determination of lean mass
as previously described (McCabe et al., 2006).

RNA isolation and gene expression studies
Total RNA was prepared from liver using Trizol reagent (Invitrogen), followed by
chloroform extraction and DNAse treatment (DNA-free kit, Ambion). cDNA was
synthesized with random decamers using the RetroScript Kit (Ambion) and mixed with
Brilliant SYBR Green QPCR Master Mix (Stratagene), and primers as noted in Table 61. Reactions were performed on an Mx3000P Quantitative PCR System (Stratagene).
The relative amounts of specific transcripts were calculated using TATA binding protein
(TBP) mRNA as an invariant control by the comparative CT (ddCT) method, with the
control genotype set to 1.0 (either Lep+/+ Akt2lox/lox or Akt2lox/lox chow-fed).

Western blotting
Mice were sacrificed and tissues snap-frozen in liquid nitrogen and stored at -800
C until being homogenized by Tissuelyser (Qiagen) in lysis buffer containing 140 mM
NaCl, 50 mM Tris, 0.1% Triton-X, 400 mM NaF, 1x Complete protease inhibitor mixture
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(Roche Applied Science) and 1x phosphatase inhibitor mixtures 1 and 2 (Sigma).
Equivalent amounts of protein were subjected to SDS-polyacrylamide gel
electrophoresis (PAGE) followed by transfer to nitrocellulose membranes (Whatman).
Blots were probed for Akt1, pAkt (S473), pAkt (T308), PRAS, pFoxO1 (S256), FoxO1,
pGSK3β (S9), pTSC2 (T1462) (Cell Signaling Technology), pPRAS (T246) (Invitrogen
Corporation), GSK3α/β (Santa Cruz Biotechnology, Inc) Akt2, actin (Abcam, INC) and/or
tubulin (Sigma Chemical Co) followed by horseradish peroxidase-conjugated secondary
antibodies (Santa Cruz Biotechnology, Inc).

Statistics
Data are presented as mean ± SEM. Data were analyzed using one-way
ANOVA using Newman-Keuls post-test, two-way ANOVA using Bonferroni post-test, or
Student’s t-test assuming unequal variance with 2-tailed analysis as described in the
figure legends. Values of p < 0.05 were defined as statistically significant.
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Table 6-1: Real-Time PCR primers

Sterol regulatory-element

AGG CTG TAG GAT

ACG GAG CCA TGG

binding protein 1c (SREBP1c)

GGT GAG TGG

ATT GCA CAT TTG

Stearoyl-CoA desaturase-1

CCG GAG ACC CCT

TAG CCT GTA AAA

(SCD1)

TAG ATC GA

GAT TTC TGC AAA
CC

Fatty acid synthase (FAS)

GCT GCG GAA ACT

AGA GAC GTG TCA

TCA GGA AAT

CTC CTG GAC TT

TGA CAG ACT GAT

TGG AGA GCC CCA

CGC AGA GAA AG

CAC ACA

GCC AGC GGG AGC

CTT TGC AGG TGC

ACA TC

CAC TTC ATC

Glycerol phosphate

CAA CAC CAT CCC

GTG ACC TTC GAT

acyltransferase (GPAT)

CGA CAT C

TAT GCG ATC A

Glucokinase (GCK)

GAA GAC CTG AAG

GTC TAT GTC TTC

AAG GTG ATG AGC

GTG CCT TAC AGG

Carbohydrate regulatory-

CTG GGG ACC TAA

GAA GCC ACC CTA

element binding protein

ACA GGA GC

TAG CTC CC

Pyruvate kinase, liver isoform

CTT GCT CTA CCG

ACC ACA ATC ACC

(L-PK)

TGA GCC TC

AGA TCA CC

Peroxisome proliferator-

GTG CCA GTT TCG

GGC CAG CAT CGT

activated receptor- γ (PPARγ)

ATC CGT AGA

GTA GAT GA

Acetyl-CoA carboxylase (ACC)

ATP citrate lyase (ACL)

(ChREBP)
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Cidec/Fsp27

CAG AAG CCA ACT

TGT AGC AGT GCA

AAG AAG ATC G

GGT CAT AG

Peroxisome proliferators-

GAG AAT GAG GCA

TGC ATG GTT CTG

activated receptorγ-coactivator

AAC TTG CTA GCG

AGT GCT AAG ACC

Carnitine palmitoyltransferase I

GCA GAG GCT CAC

CTT CGT CTG GCT

(CPT1)

CAA GCT GTG

TGA CAT GCG

Medium-chain acetyl-CoA

TAC CCG TTC CCT

CTT CTT CTC TGC

dehydrogenase (MCAD)

CTC ATC AA

TTT GGT CTT

Cytochrome c oxidase subunit

GCT GCT GAG GAC

CCA TTC CCC CGC

7a (Cox7a)

GCA AAA TGA GG

CTT TCA AG

1α (PGC-1α)
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Table 6-2: Composition of normal chow diet (Laboratory Rodent Diet #5001 from
LabDiets)
% kcal
Protein

28.5

Fat

13.5

Carbohydrates

58.0

Ingredients: ground corn, dehulled soybean meal, dried beet pulp, fish meal, ground
oats, brewers dried yeast, cane molasses, dehydrated alfalfa meal, dried why, wheat
germ, porcine animals fat preserved with BHA, porcine meat meal, wheat middlings, salt,
calcium carbonate, DL-methionine, choline chloride, cholecalciferol, vitamin A acetate,
folic acid, menadione dimethylpryimidinol bisulfite, pyridoxine hydrochloride, thiamin
mononitrate, nicotinic acid, calcium pantothenate, dl-alpha tocopheryl acetate, vitamin
B12 supplement, riboflavin, ferrous sulfate, manganeous oxide, zinc oxide, ferrous
carbonate, copper sulfate, zine sulfate, calcium iodate, cobalt carbonate, sodium
selenite.

Diet information reproduced from labdiet.com

180

Table 6-3: Composition of Surwit high fat diet (Research Diets, INC #D12331)
% kcal
Protein

16.4

Fat

58.0

Carbohydrates

25.5

Ingredient

Grams

kcal

Casein

228

912

DL-Methionine

2

0

Maltodextrin 10

170

680

Corn Starch

0

0

Sucrose

175

700

Soybean Oil

25

225

333.5

3001.5

Mineral Mix

40

0

Sodium Bicarbonate

10.5

0

Potassium Citrate

4

0

Vitamin Mix

10

40

Choline Bitartrate

2

0

Coconut Oil,
Hydrogenated

Diet information reproduced from ResearchDiets.com
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Table 6-4: Composition of lard high fat diet (Research Diets, INC #D12492)
% kcal
Protein

20.0

Fat

60.0

Carbohydrates

20.0

Ingredient

Grams

kcal

Casein

200

800

L-Cystine

3

12

Corn Starch

0

0

Maltodextrin 10

125

500

Sucrose

68.8

275.2

Cellulose

50

0

Soybean Oil

25

225

Lard

245

2205

Mineral Mix

10

0

13

0

Calcium Carbonate

5.5

0

Potassium Citrate

16.5

0

Vitamin Mix

10

40

Choline Bitartrate

2

0

Dicalcium
Phosphate

Diet information reproduced from ResearchDiets.com
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Table 6-5: Composition of high carbohydrate diet (Research Diets, INC #D12450B)
% kcal
Protein

20.0

Fat

10.0

Carbohydrates

70.0

Ingredient

Grams

kcal

Casein

200

800

L-Cystine

3

12

Corn Starch

315

1260

Maltodextrin 10

35

140

Sucrose

350

1400

Cellulose

50

0

Soybean Oil

25

225

Lard

20

180

Mineral Mix

10

0

13

0

Calcium Carbonate

5.5

0

Potassium Citrate

16.5

0

Vitamin Mix

10

40

Choline Bitartrate

2

0

Dicalcium
Phosphate

Diet information reproduced from ResearchDiets.com
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Addendum:

Akt2-/- mice have improved glucose tolerance on Surwit HFD due
to increased β-cell compensation
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Figure A-1: Akt2-/- mice have improved glucose tolerance on Surwit HFD by overcompensating for insulin resistance by dramatically increasing insulin secretion.
Akt2+/+ and Akt2-/- male mice were put on a Surwit HFD or maintained on chow at
approximately 5 weeks of age.
A. Glucose tolerance tests (1g/kg IP) were performed every 5 weeks beginning at start
of HFD (week 0).
B. Insulin levels at 0 (left) and 15 (right) minutes post glucose load during GTTs.
All values are expressed as mean ± SEM. n=8-12.
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Figure A-2: Akt2-/- mice on Surwit HFD appear to have dramatically increased βcell mass compared with their Akt2+/+counterparts.
Akt2+/+ and Akt2-/- male mice were put on a Surwit HFD or maintained on chow at
approximately 5 weeks of age for 28 weeks.
A. Composite picture of pancreatic section from Akt2+/+ and Akt2-/- mouse on Surwit
HFD. Sections were fixed in 4% paraformaldehyde, embedded in paraffin, and
immunohistochemistry was performed against insulin.
B. Hematoxylin and eosin stain of pancreatic sections. 100x magnification.
C. Preliminary quantification of β-cell mass from 4 mice (2 Akt2+/+ and 2 Akt2-/-). Each
bar represents the mean ± SEM of mass from 3 pancreatic images (like those shown in
A) of a single mouse. β-cell mass was determined using Metamorph software
(Molecular Devices, INC).
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Figure A-3: Improvement in GTT of Akt2-/- mouse on Surwit HFD is not due to cellautonomous loss of Akt2 in the β-cell.
Akt2lox/lox and Pdx;Akt2lox/lox male mice were put on a Surwit HFD or maintained on chow
at approximately 5 weeks of age.
A-B. Glucose tolerance tests (1g/kg IP) were performed at 10 (A) and 25 (B) weeks after
the start of HFD. Insulin levels were measured at 0 and 15 minutes post glucose load
during GTTs.
All values are expressed as mean ± SEM. n=5-7.

209

210

